Note: Descriptions are shown in the official language in which they were submitted.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
1
ANTI-IL-23P19 ANTIBODIES
Technical Field of the Invention
This invention generally relates to anti-IL-23p19 antibodies for diagnostic
and
therapeutic use. More specifically, humanized anti-IL-23p19 antibodies and
methods
of use for the treatment of various diseases or disorders are disclosed.
Pharmaceutical
compositions and kits comprising such compounds are also disclosed.
Background of the Invention
Higher eukaryotes have evolved an intricate response to pathogens that is
initiated by
the innate immune response and followed by the adaptive immune response.
Together
these two mechanisms not only eradicate pathogens that infect the organism but
also
establish a long term immunological response against future exposures.
Deficiencies
in these responses can result in increased susceptibility to infections and/or
alterations
of the adaptive immune response leading to chronic inflammation and
autoimmunity.
IL-12, a heterodimeric cytokine consisting of a p40 and a p35 protein subunit,
has long
been considered the hallmark cytokine of the innate immune response with major
influence on adaptive immunity. However, data from investigation of this
cytokine's
biological role led to confusing results. For example, while p40-deficient
mice were
resistant to Collagen Induced Arthritis (CIA) and Experimental Autoimmune
Encephalomyelitis (EAE), p35-deficient mice were susceptible to both and even
displayed exacerbated disease. Such conundrums began to be resolved with the
discovery in the late 1990's of a new member of the IL-12 cytokine family with
a
distinct role in the immune response ¨ IL-23.
IL-23 is composed of a common subunit (p40) with IL-12 and a unique p19
subunit.
Despite this shared p40 subunit, the roles for IL-23 and IL-12 are quite
different. IL-12
is important for Th1 responses via promotion of Th1 cell differentiation,
proliferation
and activation. In contrast, IL-23 supports the development and maintenance of
a
recently defined set of CD4+ T helper cells termed Th17 cells due to their
ability to
produce IL-17 and related cytokines. There is mounting evidence that IL-23 is
involved
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
2
in chronic autoimmune inflammation and the modulation of IL-23 activity could
provide
promising therapies against autoimmune diseases.
There is therefore a need for antagonist molecules against IL-23 with
beneficial
pharmacological properties, which can be used as therapeutic agents to treat
diseases, in particular immunological and autoimmune diseases in humans.
Accordingly, one aim of the present invention is to provide anti-IL-23
antagonist
molecules, in particular anti-IL-23 antagonist molecules which have high
binding
affinity to IL-23.
A further aim of the present invention is to provide anti-IL-23 antagonist
molecules,
which have high specificity for IL-23.
A further aim of the present invention is to provide anti-IL-23 antagonists,
which have
high blocking activity for the association of IL-23 and its receptor.
A further aim of the present invention is to provide anti-IL-23 antagonists,
which have
potent cellular activity.
A further aim of the present invention is to provide anti-IL-23 antagonists,
which have a
favorable bioavailability.
A further aim of the present invention is to provide anti-IL-23 antagonists,
which have
favorable biophysical properties.
A further aim of the present invention is to provide pharmaceutical
compositions for
.. antibody molecules, in particular for anti-IL23p19 antibodies. A particular
aim of the
present invention is to provide pharmaceutical compositions for antibody
molecules
with favorable stability and storability.
Further aims of the present invention include combinations of any of the aims
set forth
above.
Summary of the Invention
The present invention addresses the above needs and provides antibodies that
bind to
the p19 subunit of the IL-23 protein. In one aspect, an antibody of the
present
invention binds to human IL-23 with high affinity. In another aspect, an
antibody of the
present invention inhibits the IL-23 stimulated production of IL-17 from mouse
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
3
splenocytes. In another aspect, an antibody of the present invention does not
bind to
nor antagonize IL-12, which is a closely related family member to IL-23.
In one embodiment, the present invention provides anti-IL-23p19 antibodies
that are
derived from mouse hybridomas, for example monoclonal antibodies. In one
embodiment, the present invention provides full length anti-IL-23p19
antibodies. In
another embodiment, the present invention provides anti-IL-23p19 humanized
antibodies, for example humanized monoclonal anti-IL-23p19 antibodies, for
example
full length humanized monoclonal anti-IL-23p19 antibodies. In one aspect, a
humanized antibody of the present invention binds to human IL-23 with high
affinity. In
another aspect, a humanized antibody of the present invention also binds to
cynomolgus IL-23 with high affinity. In a further aspect, a humanized antibody
of the
present invention inhibits IL-23-induced STAT3 phosphorylation in DB cells. In
another
aspect, a humanized antibody of the present invention antagonizes the action
of IL-23
by binding to the p19 subunit of IL-23, for example as measured by the
inhibition of
cytokines such as IL-17 and IL-22, whose production is stimulated by IL-23. In
a
further aspect, a humanized antibody of the present invention has a favorable
pharmacokinetic (PK) profile. In a further aspect, a humanized antibody of the
present
invention has favorable biophysical properties, such as quality, stability or
solubility, for
example as defined by the percentage of antibody in monomer form.
Further embodiments encompass DNA molecules encoding antibodies of the present
invention, expression vectors and host cells comprising such DNA molecules,
and
methods of making antibodies of the present invention. The present invention
further
provides therapeutic uses for the antibodies of the present invention, in
particular
against immunological and autoimmune diseases.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof comprising a light chain CDR1 (L-CDR1)
sequence of SEQ ID NO:1, 4, 6, 7, 8, 11, 15, 18, 19, 22, 27 or 30; a light
chain CDR2
(L-CDR2) sequence of SEQ ID NO:2, 5, 9, 12, 16, 20, 23, 25,28 or 31; a light
chain
CDR3 (L-CDR3) sequence of SEQ ID NO:3, 10, 13, 14, 17, 21, 24, 26, 29, or 32;
a
heavy chain CDR1 (H-CDR1) sequence of SEQ ID NO:33, 36, 38, 40, 43, 45, 48,
51,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
4
54, 57, 60, 63, 66, 67, 68, 69, 77 or 80; a heavy chain CDR2 (H-CDR2) sequence
of
SEQ ID NO:34, 39, 41, 46, 49, 52, 55, 58, 61, 64, 70, 72, 73, 75, 78 or 81;
and a
heavy chain CDR3 (H-CDR3) sequence of SEQ ID NO:35, 37, 42, 44, 47, 50, 53,
56,
59, 62, 65, 71, 74, 76, 79 or 82. In one embodiment, the anti-IL-23p19
antibody or
antigen-binding fragment thereof comprises a light chain variable region
comprising a
L-CDR1 listed above, a L-CDR2 listed above and a L-CDR3 listed above, and a
heavy
chain variable region comprising a H-CDR1 listed above, a H-CDR2 listed above
and
a H-CDR3 listed above.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-
CDR3 sequence of SEQ ID NO:1, 2, 3, 33, 34, and 35, respectively; or a L-CDR1,
a L-
CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID NO:4, 5,
3, 36, 34 and 37, respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-
CDR2 and a H-CDR3 sequence of SEQ ID NO:1, 2, 3, 38, 39 and 35, respectively;
or
a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence of
SEQ ID NO:6, 2, 3, 40, 41 and 42, respectively; or a L-CDR1, a L-CDR2, a L-
CDR3, a
H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID NO:7, 2, 3, 43, 41 and 44,
respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-
CDR3 sequence of SEQ ID NO:8, 9, 10, 45, 46 and 47, respectively; or a L-CDR1,
a
L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID NO:8,
9, 10, 48, 49 and 50, respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1,
a
H-CDR2 and a H-CDR3 sequence of SEQ ID NO:11, 12, 13, 51, 52 and 53,
respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-
CDR3 sequence of SEQ ID NO:7, 2, 14, 54, 55 and 56, respectively; or a L-CDR1,
a
L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID
NO:15, 16, 17, 57, 58 and 59, respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a
H-
CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID NO:18, 16, 17, 60, 61 and 62,
respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-
CDR3 sequence of SEQ ID NO:19, 20, 21, 63, 66, 67 or 68, 64 and 65,
respectively;
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence
of SEQ ID NO:22, 23, 24, 69, 70 and 71, respectively; or a L-CDR1, a L-CDR2, a
L-
CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID NO:22, 25, 26, 55,
72 and 71, respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2
5 and a H-CDR3 sequence of SEQ ID NO:8, 9, 10,45, 73 and 74, respectively;
or a L-
CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ
ID NO:27, 28, 29, 45, 75 and 76, respectively; or a L-CDR1, a L-CDR2, a L-
CDR3, a
H-CDR1, a H-CDR2 and a H-CDR3 sequence of SEQ ID NO:8, 9, 10, 77, 78 and 79,
respectively; or a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-
CDR3 sequence of SEQ ID NO:30, 31, 32, 80, 81 and 82, respectively. In one
embodiment, the anti-IL-23p19 antibody or antigen-binding fragment thereof
comprises a light chain variable region comprising a L-CDR1, L-CDR2 and L-CDR3
combination listed above, and a heavy chain variable region comprising a H-
CDR1, H-
CDR2 and H-CDR3 combination listed above.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
SEQ ID NO:84 and a heavy chain variable region comprising the amino acid
sequence
SEQ ID NO:121; or a light chain variable region comprising the amino acid
sequence
of SEQ ID NO:86 and a heavy chain variable region comprising the amino acid
sequence SEQ ID NO:123; or a light chain variable region comprising the amino
acid
sequence of SEQ ID NO:88 and a heavy chain variable region comprising the
amino
acid sequence SEQ ID NO:125; or a light chain variable region comprising the
amino
acid sequence of SEQ ID NO:90 and a heavy chain variable region comprising the
amino acid sequence SEQ ID NO:127; or a light chain variable region comprising
the
amino acid sequence of SEQ ID NO:91 and a heavy chain variable region
comprising
the amino acid sequence SEQ ID NO:128; or a light chain variable region
comprising
the amino acid sequence of SEQ ID NO:93 and a heavy chain variable region
comprising the amino acid sequence SEQ ID NO:130; or a light chain variable
region
comprising the amino acid sequence of SEQ ID NO:95 and a heavy chain variable
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
6
region comprising the amino acid sequence SEQ ID NO:132; or a light chain
variable
region comprising the amino acid sequence of SEQ ID NO:97 and a heavy chain
variable region comprising the amino acid sequence SEQ ID NO:134; or a light
chain
variable region comprising the amino acid sequence of SEQ ID NO:99 and a heavy
chain variable region comprising the amino acid sequence SEQ ID NO:136; or a
light
chain variable region comprising the amino acid sequence of SEQ ID NO:101 and
a
heavy chain variable region comprising the amino acid sequence SEQ ID NO:138;
or a
light chain variable region comprising the amino acid sequence of SEQ ID
NO:103 and
a heavy chain variable region comprising the amino acid sequence SEQ ID
NO:140; or
a light chain variable region comprising the amino acid sequence of SEQ ID
NO:105
and a heavy chain variable region comprising the amino acid sequence SEQ ID
NO:142; or a light chain variable region comprising the amino acid sequence of
SEQ
ID NO:107 and a heavy chain variable region comprising the amino acid sequence
SEQ ID NO:144; or a light chain variable region comprising the amino acid
sequence
of SEQ ID NO:109 and a heavy chain variable region comprising the amino acid
sequence SEQ ID NO:146; or a light chain variable region comprising the amino
acid
sequence of SEQ ID NO:111 and a heavy chain variable region comprising the
amino
acid sequence SEQ ID NO:148; or a light chain variable region comprising the
amino
acid sequence of SEQ ID NO:113 and a heavy chain variable region comprising
the
amino acid sequence SEQ ID NO:150; or a light chain variable region comprising
the
amino acid sequence of SEQ ID NO:115 and a heavy chain variable region
comprising
the amino acid sequence SEQ ID NO:152; or a light chain variable region
comprising
the amino acid sequence of SEQ ID NO:117 and a heavy chain variable region
comprising the amino acid sequence SEQ ID NO:154; or a light chain variable
region
comprising the amino acid sequence of SEQ ID NO:119 and a heavy chain variable
region comprising the amino acid sequence SEQ ID NO:156.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising an amino acid
sequence
selected from the group consisting of SEQ ID NO:158, 160, 162 and 164 and a
heavy
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
7
chain variable region comprising an amino acid sequence selected from the
group
consisting of SEQ ID NO:166, 168, 170 and 172.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
.. or antigen-binding fragment thereof, wherein the antibody or antigen-
binding fragment
thereof has a KD for IL-23 of less than 40pM, or a KD for IL-23 of less than
20pM, or KD
for IL-23 of less than 10pM or KD for IL-23 of less than 1pM.
In a further embodiment, the present invention provides an anti-IL-23p19
antibody or
antigen-binding fragment thereof that binds to human IL-23p19 at an epitope
consisting of amino acid residues 108 to 126 and amino acid residues 137 to
151 of
SEQ ID NO: 181.
In a further embodiment, the present invention provides an anti-IL-23p19
antibody or
antigen-binding fragment thereof that competitively binds to human IL-23p19
with an
antibody of the present invention. In one enbodiment, the present invention
provides
an anti-IL-23p19 antibody or antigen-binding fragment thereof that
competitively binds
to human IL-23p19 with a humanized monoclonal anti-IL-23p19 antibody
comprising a
light chain comprising the amino acid sequence of SEQ ID NO:174 and a heavy
chain
comprising the amino acid sequence of SEQ ID NO:176. In one enbodiment, the
present invention provides an anti-IL-23p19 antibody or antigen-binding
fragment
thereof that competitively binds to human IL-23p19 with a humanized monoclonal
anti-
IL-23p19 antibody comprising a light chain comprising the amino acid sequence
of
SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID
NO:178. In one enbodiment, the present invention provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof that competitively binds to human IL-23p19
with a
humanized monoclonal anti-IL-23p19 antibody comprising a light chain
comprising the
amino acid sequence of SEQ ID NO:180 and a heavy chain comprising the amino
acid
sequence of SEQ ID NO:176. In one enbodiment, the present invention provides
an
anti-IL-23p19 antibody or antigen-binding fragment thereof that competitively
binds to
human IL-23p19 with a humanized monoclonal anti-IL-23p19 antibody comprising a
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
8
light chain comprising the amino acid sequence of SEQ ID NO: 180 and a heavy
chain
comprising the amino acid sequence of SEQ ID NO: 178.
In one embodiment, the anti-IL-23p19 antibody is a humanized antibody. In one
embodiment, the anti-IL-23p19 antibody is a monoclonal antibody. In one
embodiment,
the anti-IL-23p19 antibody is a full length antibody. In one embodiment, the
anti-IL-
23p19 antibody is a humanized monoclonal antibody, for example a full length
humanized monoclonal antibody. In one embodiment the antigen-binding fragment
is a
Fab, F(ab')2, or single chain Fv fragment. In one embodiment, the antigen-
binding
fragment comprises a light chain variable region and a heavy chain variable
region.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino
acid sequence of SEQ ID NO:20 (CDR2-L); the amino acid sequence of SEQ ID
NO:21 (CDR3-L): the amino acid sequence of SEQ ID NO:63, 66, 67 or 68 (CDR1-
H);
the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence
of SEQ ID NO:65 (CDR3-H).
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises the amino acid sequence of SEQ ID NO:19 (CDR1-L); the amino
acid sequence of SEQ ID NO:20 (CDR2-L); the amino acid sequence of SEQ ID
NO:21 (CDR3-L): the amino acid sequence of SEQ ID NO:66 (CDR1-H); the amino
acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID
NO:65 (CDR3-H).
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
9
the amino acid sequence of SEQ ID NO:21 (CDR3-L); and a heavy chain variable
region comprising the amino acid sequence of SEQ ID NO: 63, 66, 67 or 68 (CDR1-
H); the amino acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid
sequence of SEQ ID NO:65 (CDR3-H).
In one embodiment, the present invention further provides an anti-IL-23p19 or
antigen-
binding fragment thereof antibody, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
SEQ ID NO:19 (CDR1-L); the amino acid sequence of SEQ ID NO:20 (CDR2-L); and
the amino acid sequence of SEQ ID NO:21 (CDR3-L); and a heavy chain variable
region comprising the amino acid sequence of SEQ ID NO:66 (CDR1-H); the amino
acid sequence of SEQ ID NO:64 (CDR2-H); and the amino acid sequence of SEQ ID
NO:65 (CDR3-H).
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
any one of SEQ ID NO:158, 160, 162 or 164; and a heavy chain variable region
comprising the amino acid sequence any one of SEQ ID NO:166, 168, 170 or 172.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
SEQ ID NO:160 and a heavy chain variable region comprising the amino acid
sequence SEQ ID NO:166.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
SEQ ID NO:160 and a heavy chain variable region comprising the amino acid
sequence SEQ ID NO:168.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
thereof comprises a light chain variable region comprising the amino acid
sequence of
5 SEQ ID NO:158 and a heavy chain variable region comprising the amino acid
sequence SEQ ID NO:166.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, wherein the antibody or antigen-binding
fragment
10 thereof comprises a light chain variable region comprising the amino
acid sequence of
SEQ ID NO:158 and a heavy chain variable region comprising the amino acid
sequence SEQ ID NO:168.
In one embodiment, the anti-IL-23p19 antibody is a humanized antibody. In one
embodiment, the anti-IL-23p19 antibody is a monoclonal antibody. In one
embodiment,
the anti-IL-23p19 antibody is a full length antibody. In one embodiment, the
anti-IL-
23p19 antibody is a humanized monoclonal anti-IL-23p19 antibody, for example a
full
length humanized monoclonal antibody. In one embodiment, the antigen-binding
fragment is a Fab, F(ab)2, or single chain Fv fragment. In one embodiment, the
antigen-binding fragment comprises a light chain variable region and a heavy
chain
variable region.
In one embodiment, the present invention further provides an antibody
comprising the
amino acid sequence SEQ ID NO:166 or 168 linked to a human IgG1, IgG2, IgG3,
IgG4, IgM, IgA or IgE heavy chain constant region. An antibody comprising the
amino
acid sequence of SEQ ID NO: 166 or 168 linked to a human IgG1 heavy chain
constant region. An antibody comprising the amino acid sequence of SEQ ID
NO:158
or 160 linked to a human kappa or lambda light chain constant region. An
antibody
comprising the amino acid sequence of SEQ ID NO: 158 or 160 linked to a human
kappa light chain constant region.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
11
In one embodiment, the present invention further provides an antibody
comprising the
amino acid sequence of SEQ ID NO:166 or 168 linked to a human IgG1 heavy chain
constant region; and the amino acid sequence of SEQ ID NO:158 or 160 linked to
a
human kappa light chain constant region.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain variable region comprising the
amino
acid sequence selected from the group consisting of any one of SEQ ID NO:158,
160,
162 and 164 and a heavy chain variable region comprising the amino acid
sequence
selected from the group consisting of any one of SEQ ID NO:166, 168, 170 and
172.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain variable region comprising the
amino
acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising
the
amino acid sequence SEQ ID NO:166.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain variable region comprising the
amino
acid sequence of SEQ ID NO:160 and a heavy chain variable region comprising
the
amino acid sequence SEQ ID NO:168.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain variable region comprising the
amino
acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising
the
amino acid sequence SEQ ID NO:166.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain variable region comprising the
amino
acid sequence of SEQ ID NO:158 and a heavy chain variable region comprising
the
amino acid sequence SEQ ID NO:168.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
12
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain comprising the amino acid
sequence of
SEQ ID NO:174 or 180 and a heavy chain comprising the amino acid sequence of
SEQ ID NO:176 or 178.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain comprising the amino acid
sequence of
SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID
NO:176.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain comprising the amino acid
sequence of
SEQ ID NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID
NO:178.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain comprising the amino acid
sequence of
SEQ ID NO:180 and a heavy chain comprising the amino acid sequence of SEQ ID
NO:176.
In one embodiment, the present invention further provides a humanized
monoclonal
anti-IL-23p19 antibody comprising a light chain comprising the amino acid
sequence of
SEQ ID NO: 180 and a heavy chain comprising the amino acid sequence of SEQ ID
NO: 178.
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:160 and framework regions having an amino
acid
sequence at least 90% identical to the amino acid sequence of the framework
regions
of the variable domain light chain amino acid sequence of SEQ ID NO:160 and a
humanized heavy chain variable domain comprising the CDRs of SEQ ID NO:166 and
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
13
framework regions having an amino acid sequence at least 90% identical to the
amino
acid sequence of the framework regions of the variable domain heavy chain
amino
acid sequence of SEQ ID NO:166. In one embodiment, the anti-IL-23p19 antibody
is a
humanized monoclonal antibody, for example a full length humanized monoclonal
antibody.
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:160 and framework regions having an amino
acid
sequence at least 90% identical to the amino acid sequence of the framework
regions
of the variable domain light chain amino acid sequence of SEQ ID NO:160 and a
humanized heavy chain variable domain comprising the CDRs of SEQ ID NO:168 and
framework regions having an amino acid sequence at least 90% identical to the
amino
acid sequence of the framework regions of the variable domain heavy chain
amino
acid sequence of SEQ ID NO:168. In one embodiment, the anti-IL-23p19 antibody
is a
humanized monoclonal antibody, for example a full length humanized monoclonal
antibody.
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:158 and framework regions having an amino
acid
sequence at least 90% identical to the amino acid sequence of the framework
regions
of the variable domain light chain amino acid sequence of SEQ ID NO:158 and a
humanized heavy chain variable domain comprising the CDRs of SEQ ID NO:166 and
framework regions having an amino acid sequence at least 90% identical to the
amino
acid sequence of the framework regions of the variable domain heavy chain
amino
acid sequence of SEQ ID NO:166. In one embodiment, the anti-IL-23p19 antibody
is a
humanized monoclonal antibody, for example a full length humanized monoclonal
antibody.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
14
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:158 and framework regions having an amino
acid
sequence at least 90% identical to the amino acid sequence of the framework
regions
of the variable domain light chain amino acid sequence of SEQ ID NO:158 and a
humanized heavy chain variable domain comprising the CDRs of SEQ ID NO:168 and
framework regions having an amino acid sequence at least 90% identical to the
amino
acid sequence of the framework regions of the variable domain heavy chain
amino
acid sequence of SEQ ID NO:168. In one embodiment, the anti-IL-23p19 antibody
is a
humanized monoclonal antibody, for example a full length humanized monoclonal
antibody.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized by a KD for human IL-23 equal or less than 1 pM. In one
aspect,
there is no shift in binding on-rate in 50% human serum.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it blocks IL-23 binding to human IL-23R/Fc in
vitro.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it does not bind to human IL-12.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it inhibits human IL-23 induced IL-17 production
in mouse
splenocytes with IC50's equal or less than 20 pM.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it inhibits human IL-23 induced STAT3
phosphorylation in
human DB cells with IC50's equal or less than 40 pM.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it has no predicted activity in ADCC/CDC.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it has a KD equal or less than_1 pM for
cynomolgus
monkey IL-23.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it has no cross reactivity to mouse or rat IL-
23.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized in that it inhibits human IL-23 induced IL-17 and IL-22
production
5 in a mouse ear at 80% or greater inhibition of both cytokines at 1 mg/kg.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
further characterized by a melting temperature of 83 C as determined by
differential
scanning calorimetry.
In one aspect, a humanized anti-IL-23p19 antibody of the present invention may
be
10 further characterized by solubility equal or greater than 100 mg/ml, as
measured by
UV spectroscopy and monitored by turbidity.
In a further aspect, a humanized anti-IL-23p19 antibody of the present
invention may
be further characterized in that it is present in at least 90% monomer form,
or in at
least 92% monomer form, or in at least 95% monomer form in a buffer.
15 In a further aspect, a humanized anti-IL-23p19 antibody of the present
invention may
be further characterized in that it remains in at least 90% monomer form, or
in at least
92% monomer form, or in at least 95% monomer form in a buffer for one month or
for
four months.
In one aspect, the humanized anti-IL-23p19 antibody is a humanized monoclonal
antibody, for example a full length humanized monoclonal antibody.
Further embodiments encompass a DNA molecule encoding a variable light chain
region above, a DNA molecule encoding a variable heavy chain region above, a
DNA
molecule encoding a light chain region above, or a DNA molecule encoding a
heavy
chain region above.
Further embodiments encompass an expression vector containing a DNA molecule
above. In one embodiment, an expression vector comprises a DNA molecule
encoding
the constant heavy chain and/or the constant light chain, respectively, linked
to the
DNA molecule encoding the variable heavy chain and/or the variable light
chain,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
16
respectively. Further embodiments encompass a host cell carrying one or more
expression vectors above. In one embodiment, a host is a mammalian cell.
Further embodiments encompass a method for producing an antibody or antigen-
binding fragment thereof above comprising transfecting a mammalian host cell
with
one or more of the vectors above, cultivating the host cell and recovering and
purifying
the antibody or antigen-binding fragment thereof.
Further embodiments encompass a method for producing an antibody or antigen-
binding fragment thereof above comprising obtaining a mammalian host cell
comprising one or more of the vectors above, and cultivating the host cell. In
one
embodiment, the method further comprises recovering and purifying the antibody
or
antigen-binding fragment thereof.
In one embodiment, the present invention further provides an anti-IL-23p19
antibody
or antigen-binding fragment thereof, in particular an antibody or antigen-
binding
fragment thereof above, or a pharmaceutical composition comprising the
antibody or
antigen-binding fragment thereof, for example a pharmaceutical composition
disclosed
herein, for use in medicine. In one embodiment, the antibody is Antibody A,
Antibody
B, Antibody C or Antibody D. In one embodiment, the use is the treatment of an
inflammatory disease, of an autoimmune disease, of a respiratory disease, of a
metabolic disorder or of cancer. In one embodiment, the use is for the
treatment of
psoriasis, inflammatory bowel disease (Crohn's disease, ulcerative colitis),
psoriatic
arthritis, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis or
Kawasaki
syndrome. In one embodiment, the use is for the treatment of psoriasis. In one
embodiment, the use is for the treatment of inflammatory bowel disease, for
example
Crohn's disease. In one embodiment, the use is for the treatment of ankylosing
spondylitis.
In one embodiment, the use is for the treatment of plaque psoriasis, for
example
chronic plaque psoriasis, for example moderate to severe chronic plaque
psoriasis, for
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
17
example in adult patients. In one embodiment, the patients are candidates for
systemic
therapy or phototherapy. In one embodiment, the use is for the treatment of
moderate
to severe chronic plaque psoriasis, for example in patients who are candidates
for
systemic therapy or phototherapy, for example adult patients.
In one embodiment, the use is for the treatment of palmar pustular psoriasis,
guttate
psoriasis, inverse psoriasis, pustular psoriasis or erythodermic psoriasis.
In one embodiment, the use is for the treatment of Crohn's disease. In a
further
aspect, the use is for reducing signs and symptoms, improving mucosal healing
and
inducing and maintaining clinical remission in adult patients with moderately
to
severely active Crohn's disease, in particular in patients who have had an
inadequate
response to conventional therapy. In a further aspect, the use is for reducing
the
number of draining enterocutaneous and rectovaginal fistulas and maintaining
fistula
closure in adult patients with fistulizing Crohn's disease.
In one embodiment, the use is for the treatment of spondyloarthritis. In a
further
aspect, the use is for the treatment of ankylosing spondylitis. In a further
aspect, the
use is for reducing signs and symptoms in patients with active ankylosing
spondylitis.
In a further aspect, the use is for the treatment of severe, radiographic
active
ankylosing spondylitis in adult patients, in particular, patients who have
responded
inadequately to conventional therapy.
In a further aspect, the use is for the treatment of non-radiographic axial
spondyloarthritis. In a further aspect, the use is for the treatment of adults
with severe
axial spondyloarthritis without radiographic evidence of AS but with objective
signs of
inflammation by elevated CRP and / or MRI, in particular patients who have had
an
inadequate response to, or are intolerant to nonsteroidal anti-inflammatory
drugs.
In a further aspect, the use is for the treatment of peripheral
spondyloarthritis.
In one embodiment, the use is for the treatment of discoid lupus, malaria,
malignant
melanoma, aplastic anaemia, Huntington's Disease, palmoplantar pustulosis, IgA
nephritis, ANCA-Associated Vasculitis, scleritis or sepsis.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
18
In one embodiment, the use is for the treatment of palmoplantar pustulosis. In
one
embodiment, the use is for the treatment of systemic scleroderma.
In one embodiment, the present invention provides for the use of an anti-IL-
23p19
antibody or antigen-binding fragment thereof, in particular an antibody or
antigen-
binding fragment thereof above, or a pharmaceutical composition comprising the
antibody or antigen-binding fragment thereof, for example a pharmaceutical
composition disclosed herein, in the manufacture of a medicament for the
treatment of
any one of the diseases or disorders disclosed herein. In one embodiment, the
antibody is Antibody A, Antibody B, Antibody C or Antibody D.
In one embodiment, the present invention further provides a pharmaceutical
composition comprising an antibody molecule or antigen-binding fragment above
and
a pharmaceutically acceptable carrier.
In one embodiment, the present invention provides a pharmaceutical composition
comprising an antibody molecule above and succinate buffer. In one embodiment,
the
pharmaceutical composition comprises 50 mM or less succinate buffer.
In one embodiment, the present invention provides a pharmaceutical composition
comprising 1 to 40 mg/ml of an antibody molecule and further comprising 5 to
50 mM
succinate buffer and 50 to 200 mM sodium chloride. In one further embodiment,
the
pH of said pharmaceutical composition is in the range of pH 6.0 to 7Ø In one
further
embodiment, the pharmaceutical composition comprises 2.5 to 30 mg/ml of said
antibody molecule, in a further embodiment 5 to 20 mg/ml of said antibody
molecule.
In a further embodiment, the pharmaceutical composition comprises 10 to 40 mM
succinate buffer, in a further embodiment 20 to 30 mM succinate buffer. In a
further
embodiment, the pharmaceutical composition comprises 75 to 175 mM sodium
chloride, in a further embodiment 100 to 150 mM sodium chloride. In a further
embodiment, the pharmaceutical composition further comprises a detergent, for
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
19
example polysorbate 20 (Tween 20), for example at a concentration of 0.20 g/I.
In one
aspect, the antibody molecule in the pharmaceutical composition is Antibody A,
Antibody B, Antibody C or Antibody D.
In one embodiment, the present invention further provides a pharmaceutical
composition comprising 10 mg/ml of an antibody molecule, 25mM succinate
buffer,
125mM sodium chloride and 0,02% Tween 20 at a pH of 6.0 to 7Ø In one aspect,
the
pH of the pharmaceutical composition is 6.5. In one aspect, the antibody
molecule in
the pharmaceutical composition is Antibody A, Antibody B, Antibody C or
Antibody D.
In one embodiment, the pharmaceutical composition is administered
intravenously to a
patient.
In one embodiment, the present invention provides a pharmaceutical composition
comprising 70 to 100 mg/ml of an antibody molecule and 100 to 300 mM sorbitol.
In a
further embodiment, the pharmaceutical composition further comprises 25 mM or
less
succinate buffer. In one further embodiment, the pH of said pharmaceutical
composition is in the range of pH of 5.5 to 6.5, for example in the range of
pH of 5.5 to
6.1. In one further embodiment, the pharmaceutical composition comprises 80 to
95
mg/mlof said antibody molecule. In a further embodiment, the pharmaceutical
composition comprises 10 mM or less succinate buffer, in a further embodiment
5 mM
or less succinate buffer, in a further embodiment at least 1 mM succinate
buffer, in a
further embodiment at least 2.5 mM succinate buffer, in a further embodiment 1
to 10
mM succinate buffer, in a further embodiment, 2.5 to 5 mM, succinate buffer.
In a
further embodiment the pharmaceutical composition comprises 150 to 300 mM
sorbitol, in a further embodiment 175 to 275 mM sorbitol, in a further
embodiment 200
to 250 mM sorbitol. In a further embodiment, the pharmaceutical composition
further
comprises a detergent, for example polysorbate 20 (Tween 20), for example at a
concentration of 0.20 g/I. In one aspect, the antibody molecule in the
pharmaceutical
composition is Antibody A, Antibody B, Antibody C or Antibody D.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
In one embodiment, the present invention further provides a pharmaceutical
composition comprising 90 mg/ml of an antibody molecule, 4.4mM succinate
buffer,
225mM sorbitol and 0,02% Tween 20 at a pH of 5.5 to 6.5. In one aspect, the pH
of
the pharmaceutical composition is 5.5 to 6.1. In one aspect, the pH of the
5 pharmaceutical composition is 5.8. In one aspect, the antibody molecule
in the
pharmaceutical composition is Antibody A, Antibody B, Antibody C or Antibody
D. In
one embodiment, the pharmaceutical cornposition is administered subcutaneously
to a
patient.
10 .. In one embodiment, the present invention further provides a
pharmaceutical
composition comprising 90 mg/ml of an antibody molecule, 240mM sorbitol and
0,02%
Tween 20 at a pH of 5.5 to 6.5. In one aspect, the pH of the pharmaceutical
composition is 5.5 to 6.1. In one aspect, the pH of the pharmaceutical
composition is
5.8. In one aspect, the antibody molecule in the pharmaceutical composition is
15 Antibody A, Antibody B, Antibody C or Antibody D. In one embodiment, the
pharmaceutical composition is administered subcutaneously to a patient.
In one embodiment, the present invention further provides a method for
treating an
inflammatory disease, an autoimmune disease, a respiratory disease, a
metabolic
20 disorder or cancer comprising administering to a subject in need
thereof, for example a
patient, an effective amount of an anti-IL-23p19 antibody or antigen-binding
fragment
thereof, in particular an anti-IL-23p19 antibody or antigen-binding fragment
thereof
above, or a pharmaceutical composition comprising the antibody or antigen-
binding
fragment thereof, for example a pharmaceutical composition disclosed herein.
In one
embodiment, the antibody is Antibody A, Antibody B, Antibody C or Antibody D.
In one
embodiment, the antibody or antigen-binding fragment is administered by a
parenteral
route of administration, or is administered intravenously or subcutaneously.
In one
embodiment, the antibody or antigen-binding fragment is administered
subcutaneously. In one embodiment, the disease is psoriasis, inflammatory
bowel
disease (Crohn's disease, ulcerative colitis), psoriatic arthritis, multiple
sclerosis,
rheumatoid arthritis, ankylosing spondylitis or Kawasaki syndrome. In one
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
21
embodiment, the disease is psoriasis. In one embodiment, the disease is
inflammatory
bowel disease, for example Crohn's disease. In one embodiment, the disease is
ankylosing spondylitis.
In one embodiment, the disease is plaque psoriasis, for example chronic plaque
psoriasis, for example moderate to severe chronic plaque psoriasis. In one
embodiment, the patients are adult patients, for example who are candidates
for
systemic therapy or phototherapy. In one embodiment, the disease is moderate
to
severe chronic plaque psoriasis.
In one embodiment, the disease is palmar pustular psoriasis, guttate
psoriasis, inverse
psoriasis, pustular psoriasis or erythodermic psoriasis.
In one embodiment, the present invention provides a method for reducing signs
and
symptoms, improving mucosal healing and inducing and maintaining clinical
remission
in adult patients with moderately to severely active Crohn's disease, in
particular in
patients who have had an inadequate response to conventional therapy, said
method
comprising administering to the patient an effective amount of an anti-IL-
23p19
antibody or antigen-binding fragment thereof, in particular an anti-IL-23p19
antibody or
antigen-binding fragment thereof above, or a pharmaceutical composition
comprising
the antibody or antigen-binding fragment thereof, for example a pharmaceutical
composition disclosed herein. In one embodiment, the antibody is Antibody A,
Antibody B, Antibody C or Antibody D. In a further aspect, the present
invention
provides a method for reducing the number of draining enterocutaneous and
rectovaginal fistulas and maintaining fistula closure in adult patients with
fistulizing
Crohn's disease comprising administering to the patient an effective amount of
an anti-
IL-23p19 antibody or antigen-binding fragment thereof above, or a
pharmaceutical
composition comprising the antibody or antigen-binding fragment thereof, for
example
a pharmaceutical composition disclosed herein.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
22
In one embodiment, the present invention provides a method for the treatment
of
spondyloarthritis. In one embodiment, the present invention provides a method
for the
treatment of ankylosing spondylitis. In a further aspect, the present
invention provides
a method for reducing signs and symptoms in patients with active ankylosing
spondylitis. The above methods comprise administering to a subject in need
thereof,
for example a patient, an effective amount of an anti-IL-23p19 antibody or
antigen-
binding fragment thereof, in particular an anti-IL-23p19 antibody or antigen-
binding
fragment thereof above, or a pharmaceutical composition comprising the
antibody or
antigen-binding fragment thereof, for example a pharmaceutical composition
disclosed
herein. In one embodiment, the antibody is Antibody A, Antibody B, Antibody C
or
Antibody D.
In a further aspect, the present invention provides a method for the treatment
of
severe, radiographic active ankylosing spondylitis in adult patients, in
particular,
patients who have responded inadequately to conventional therapy, comprising
administering to the patient an effective amount of an anti-IL-23p19 antibody
or
antigen-binding fragment thereof, in particular an anti-IL-23p19 antibody or
antigen-
binding fragment thereof above, or a pharmaceutical composition comprising the
antibody or antigen-binding fragment thereof, for example a pharmaceutical
composition disclosed herein. In one embodiment, the antibody is Antibody A,
Antibody B, Antibody C or Antibody D.
In one embodiment, the present invention provides a method for the treatment
of non-
radiographic axial spondyloarthritis. In a further aspect, the present
invention provides
a method for the treatment of adults with severe axial spondyloarthritis
without
radiographic evidence of AS but with objective signs of inflammation by
elevated CRP
and / or MRI, in particular patients who have had an inadequate response to,
or are
intolerant to nonsteroidal anti-inflammatory drugs. In one embodiment, the
present
invention provides a method for the treatment of peripheral spondyloarthritis.
The
above methods comprise administering to a subject in need thereof, for example
a
patient, an effective amount of an anti-IL-23p19 antibody or antigen-binding
fragment
thereof, in particular an anti-IL-23p19 antibody or antigen-binding fragment
thereof
above, or a pharmaceutical composition comprising the antibody or antigen-
binding
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
23
fragment thereof, for example a pharmaceutical composition disclosed herein.
In one
embodiment, the antibody is Antibody A, Antibody B, Antibody C or Antibody D.
In one embodiment, the disease is discoid lupus, malaria, malignant melanoma,
aplastic anaemia, Huntington's Disease, palmoplantar pustulosis, IgA
nephritis, ANCA-
Associated Vasculitis, scleritis or sepsis.
In one embodiment, the disease is palmoplantar pustulosis. In one embodiment,
the
disease is systemic scleroderma.
In one embodiment, the present invention further provides a method for
inhibiting the
binding of IL-23 to the IL-23 receptor on a mammalian cell, comprising
administering to
the cell an antibody molecule or antigen-binding fragment above, whereby
signaling
mediated by the IL-23 receptor is inhibited.
In one embodiment, the present invention further provides a method for
treating a
subject having an IL-23-associated disorder, comprising administering to the
subject
an antibody or antigen-binding fragment above or a pharmaceutical composition
comprising the antibody or antigen-binding fragment thereof, for example a
pharmaceutical composition disclosed herein, which antibody or antigen-binding
fragment binds to human IL-23.
In one embodiment, the present invention further provides a method for
detecting
and/or quantifying IL-23 levels in a biological sample by contacting the
sample with an
antibody or antigen binding fragment above and detecting binding of the
antibody or
fragment thereof with IL-23p19. This information can be used to diagnose an IL-
23-
associated disorder. Thus, methods are provided for diagnosing an IL-23-
associated
disorder or for determining if a subject has an increased risk of developing
an IL-23-
associated disorder, wherein the method comprises contacting a biological
sample
from a subject with an antibody or antigen binding fragment above and
detecting
binding of the antibody or antigen binding fragment to IL-23p19 to determine
the
expression or concentration of IL-23.
-24-
In one embodiment, the present invention further provides a method for
inhibiting the
binding of IL-23 to the IL-23 receptor on a cell, comprising administering to
the cell or
cellular environment an antibody or antigen-binding fragment above, whereby
signaling
mediated by the IL-23 receptor is inhibited.
According to one particular aspect, the invention relates to a pharmaceutical
composition
comprising:
90 mg/ml of an antibody and 100 to 300 mM sorbitol,
wherein the pH of said pharmaceutical composition is in the range of pH 5.5 to
6.5;
wherein said antibody is an anti-IL-23p19 antibody comprising a light chain
comprising the amino acid sequence of SEQ ID NO:174 and a heavy chain
comprising the amino acid sequence of SEQ ID NO:176.
According to another particular aspect, the invention relates to the use of a
.. pharmaceutical composition as defined herein, for treating an inflammatory
disease, an
autoimmune disease, a respiratory disease, a metabolic disorder or cancer in a
subject.
According to another particular aspect, the invention relates to the use of a
pharmaceutical as defined herein, for treating discoid lupus, malaria,
malignant
melanoma, aplastic anaemia, Huntington's Disease, palmoplantar pustulosis, IgA
nephritis, ANCA-Associated Vasculitis, scleritis or sepsis.
According to another particular aspect, the invention relates to the use of an
anti-IL-
23p19 antibody comprising a light chain comprising the amino acid sequence of
SEQ ID
NO:174 and a heavy chain comprising the amino acid sequence of SEQ ID NO:176
and
a pharmaceutically acceptable carrier for treating a disease, wherein the
disease is:
i) plaque psoriasis, chronic plaque psoriasis or moderate to severe chronic
plaque psoriasis; or
ii) palmar pustular psoriasis, guttate psoriasis, inverse psoriasis, pustular
psoriasis
or erythodermic psoriasis; or
iii) non-radiographic axial spondyloarthritis or peripheral spondyloarthritis;
or
iv) discoid lupus, malaria, malignant melanoma, aplastic anaemia, Huntington's
Disease, palmoplantar pustulosis, IgA nephritis, ANCA Associated Vasculitis,
scleritis or sepsis.
309582.00004/112599458.1
Date Recue/Date Received 2021-05-17
-24a-
According to another particular aspect, the invention relates to an anti-IL-
23p19 antibody
comprising a light chain comprising the amino acid sequence of SEQ ID NO:174
and a
heavy chain comprising the amino acid sequence of SEQ ID NO:176 for use in the
treatment of a disease, wherein the disease is:
i) plaque psoriasis, chronic plaque psoriasis or moderate to severe chronic
plaque psoriasis; or
ii) palmar pustular psoriasis, guttate psoriasis, inverse psoriasis, pustular
psoriasis
or erythodermic psoriasis; or
iii) non-radiographic axial spondyloarthritis or peripheral spondyloarthritis;
or
iv) discoid lupus, malaria, malignant melanoma, aplastic anaemia, Huntington's
Disease, palmoplantar pustulosis, IgA nephritis, ANCA Associated Vasculitis,
scleritis or sepsis.
Brief Description of the Figures
Figure 1: Alignment of mouse and humanized variable regions. Figure la: Anti-
IL-23p19
6B8 Engineered Vk regions. Figure lb: Anti-IL-23p19 6B8 Engineered VH regions.
The numbering of the amino acids is by the standard Kabat numbering scheme.
Regular
font = Human; italic/underlined font = Murine; shadowed font = Synthetic;
bold/italic/underlined = CDR.
Figure 2: Competition binding assay of human of IL-23 binding to IL-23R/Fc.
Detailed Description
The p19 subunit of IL-23 (also referred to herein as "IL-23p19" and "p19
subunit") is a
189 amino acid polypeptide containing a 21 aa leader sequence (Oppmann et al.
Immunity 13:715 (2000), SEQ ID NO: 181). The biological activity of the
molecule is only
detected when it is partnered with the IL-12p40 subunit to form IL-23. IL-23
is
predominantly expressed by activated dendritic cells (DCs) and phagocytic
cells. The
receptor for IL-23 was found to be composed of the IL-12R131 subunit of IL-12
receptor
partnered with a unique subunit called IL-23R (Parham et al. J. Immunol.
168:5699
(2002)). Expression of the receptor is detected primarily on memory T cells
and NK cells.
Thus, expression of this cytokine:receptor pair appears to be restricted to
specific
populations of immune cells. While it was first thought that IL-12 and IL-23
would share
many functions, the data has shown the picture to be different. Whereas IL-12
has a
309582.00004/108526342.1
Date Recue/Date Received 2020-06-17
-24b-
predominant role in the production of Thl cells, IL-23 was found to be
critically involved
in the production and maintenance of a recently recognized Th cell
309582.00004/108526342.1
Date Recue/Date Received 2020-06-17
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
subset termed Th17 (Kikly et al. Curr. Opin. lmmunol. 18:670 (2006), Kastelein
et al.
Ann. Rev. Immunol. 25:221 (2007)). These cells produce IL-17A, IL-17F, IL-22
and
other pro-inflammatory cytokines such as IL-6 and TNF-a. As described below,
animal
model studies on the role of these Th17 cells show their importance as a
driving force
5 in chronic inflammation and autoimmunity.
The present invention provides antibodies that bind to the p19 subunit of the
IL-23, in
particular human IL-23p19. The present invention also relates to humanized
antibodies
that recognize the p19 subunit of IL-23. In specific embodiments, the sequence
of
10 these humanized antibodies has been identified based on the sequences of
certain
lead mouse antibodies.
The lead mouse antibodies of the present invention were derived from mouse
hybridomas. The immunization of the mice is carried out using different
techniques.
For example, antibodies that are specific for human IL-23p19 proteins or
fragments
15 thereof can be raised against an immunogenic antigen such as an isolated
IL-23p19
protein, an isolated IL-23 protein, an isolated hybrid IL-23 protein, and/or a
portion
thereof of any of the above (including synthetic peptides). For example, a
hybrid IL-23
protein comprising a mouse IL-23p40 subunit and a human IL-23p19 subunit is
used
to immunize mice. Preparation of immunogenic antigens and monoclonal antibody
20 production can be performed using any suitable technique known in the
art.
The lead mouse antibodies were selected based on their high affinity to human
IL-23.
Accordingly, in one aspect, the present invention provides an antibody that
binds to
human IL-23 with high affinity. Selected mouse antibodies were humanized to
result in
humanized antibodies. The humanized antibodies of the present invention bind
to
25 human IL-23 with high affinity. Accordingly, in another aspect, the
present invention
provides a humanized antibody that binds to human IL-23 with high affinity.
Accordingly, in one embodiment, the present invention provides an anti-IL-
23p19
antibody having a KD of less than 40pM. In a further embodiment, the present
invention provides an anti-IL-23p19 antibody having a KD of less than 20pM. In
a
further embodiment, the present invention provides an anti-IL-23p19 antibody
having a
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
26
KD less than 10pM. In a further embodiment, the present invention provides an
anti-IL-
23p19 antibody having a KD less than 1pM.
In another aspect, an antibody of the present invention binds to IL-23p19 with
high
affinity in the absence of human serum or in the presence of 50% human serum.
In a further aspect, a humanized antibody of the present invention also binds
to
cynomolgus monkey IL-23 with high affinity.
In another aspect, an antibody of the present invention binds to IL-23, but
does not
bind to IL-12. In a further aspect, an antibody of the present invention does
not
interfere with the biological activity of IL-12, which is a closely related
family member
to IL-23.
In another aspect, an antibody of the present invention inhibits the IL-23
stimulated
production of IL-17 from mouse splenocytes.
In a further aspect, a humanized antibody of the present invention inhibits IL-
23-
induced STAT3 phosphorylation in DB cells.
.. In a further aspect, a humanized antibody of the present invention
antagonizes the
action of IL-23 by binding to the p19 subunit of IL-23, as measured by the
inhibition of
cytokines such as IL-17 and IL-22, whose production is stimulated by IL-23,
and
detected by the reduction in the levels of these cytokines.
In a further aspect, a humanized antibody of the present invention has a
favorable
pharmacokinetic profile (PK) profile, as exemplified by in vivo half life in
cynomolgus
monkeys.
In a further aspect, a humanized monoclonal anti-IL-23p19 antibody of the
present
invention has favorable biophysical properties, for example quality,
stability, or
solubility.
In one aspect, the anti-IL-23p19 antibody is a humanized antibody. In one
aspect, the
anti-IL-23p19 antibody is a monoclonal antibody. In one aspect, the anti-IL-
23p19
antibody is a full length antibody. In one aspect, the anti-IL-23p19 antibody
is a
humanized monoclonal antibody, for example a full length humanized monoclonal
antibody.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
27
An antibody or antigen-binding fragment thereof of the present invention
recognizes
specific "IL-23p19 antigen epitope" or" IL-23p19 epitope". As used herein
these terms
refer to a molecule (e.g., a peptide) or a fragment of a molecule capable of
immunoreactivity with an anti-IL-23p19 antibody and, for example, include an
IL-23p19
antigenic determinant recognized by the any of the antibodies having a light
chain/heavy chain sequence combination of SEQ ID NO:84/121, 86/123, 88/125,
90/127, 91/128, 93/130, 95/132, 97/134, 99/136, 101/138, 103/140, 105/142,
107/144,
109/146, 111/148, 113/150, 115/152,117/154, 119/156, 160/166, 160/168, 158/166
or
158/168. IL-23p19 antigen epitopes can be included in proteins, protein
fragments,
peptides or the like. The epitopes are most commonly proteins, short
oligopeptides,
oligopeptide mimics (i.e., organic compounds that mimic antibody binding
properties of
the IL-23p19 antigen), or combinations thereof. The minimum size of a peptide
or
polypeptide epitope for an antibody is thought to be about four to five amino
acids.
Peptide or polypeptide epitopes contain for example at least seven amino acids
or for
example at least nine amino acids or for example between about 15 to about 20
amino
acids. Since an antibody can recognize an antigenic peptide or polypeptide in
its
tertiary form, the amino acids comprising an epitope need not be contiguous,
and in
some cases, may not even be on the same peptide chain. Epitopes may be
determined by various techniques known in the art, such as X-ray
crystallography,
Hydrogen/Deuterium Exchange Mass Spectrometry (HXMS), site-directed
mutagenesis, alanine scanning mutagenesis, and peptide screening methods.
The generalized structure of antibodies or immunoglobulin is well known to
those of
skill in the art. These molecules are heterotetrameric glycoproteins,
typically of about
150,000 daltons, composed of two identical light (L) chains and two identical
heavy (H)
chains and are typically referred to as full length antibodies. Each light
chain is
covalently linked to a heavy chain by one disulfide bond to form a
heterodimer, and the
hoterotrameric molecule is formed through a covalent disulfide linkage between
the
two identical heavy chains of the heterodimers. Although the light and heavy
chains
are linked together by one disulfide bond, the number of disulfide linkages
between the
two heavy chains varies by immunoglobulin isotype. Each heavy and light chain
also
has regularly spaced intrachain disulfide bridges. Each heavy chain has at the
amino-
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
28
terminus a variable domain (VH), followed by three or four constant domains
(CHi, CH2,
CH3, and Ch4), as well as a hinge region between CHi and CH2. Each light chain
has
two domains, an amino-terminal variable domain (VL) and a carboxy-terminal
constant
domain (CL). The VI_ domain associates non-covalently with the VH domain,
whereas
the CL domain is commonly covalently linked to the CHi domain via a disulfide
bond.
Particular amino acid residues are believed to form an interface between the
light and
heavy chain variable domains (Chothia et al., 1985, J. Mol. Biol. 186:651-
663).
Variable domains are also referred herein as variable regions.
Certain domains within the variable domains differ extensively between
different
antibodies i.e., are "hypervariable." These hypervariable domains contain
residues
that are directly involved in the binding and specificity of each particular
antibody for its
specific antigenic determinant. Hypervariability, both in the light chain and
the heavy
chain variable domains, is concentrated in three segments known as
complementarity
determining regions (CDRs) or hypervariable loops (HVLs). CDRs are defined by
sequence comparison in Kabat et al., 1991, In: Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National Institutes of
Health,
Bethesda, Md., whereas HVLs (also referred herein as CDRs) are structurally
defined
according to the three-dimensional structure of the variable domain, as
described by
Chothia and Lesk, 1987, J. Mol. Biol. 196: 901-917. These two methods result
in
slightly different identifications of a CDR. As defined by Kabat, CDR-L1 is
positioned at
about residues 24-34, CDR-L2, at about residues 50-56, and CDR-L3, at about
residues 89-97 in the light chain variable domain; CDR-H1 is positioned at
about
residues 31-35, CDR-H2 at about residues 50-65, and CDR-H3 at about residues
95-
102 in the heavy chain variable domain. The exact residue numbers that
encompass a
particular CDR will vary depending on the sequence and size of the CDR. Those
skilled in the art can routinely determine which residues comprise a
particular CDR
given the variable region amino acid sequence of the antibody. The CDR1, CDR2,
CDR3 of the heavy and light chains therefore define the unique and functional
properties specific for a given antibody.
The three CDRs within each of the heavy and light chains are separated by
framework
regions (FR), which contain sequences that tend to be less variable. From the
amino
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
29
terminus to the carboxy terminus of the heavy and light chain variable
domains, the
FRs and CDRs are arranged in the order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and
FR4. The largely p-sheet configuration of the FRs brings the CDRs within each
of the
chains into close proximity to each other as well as to the CDRs from the
other chain.
The resulting conformation contributes to the antigen binding site (see Kabat
et al.,
1991, NIH Publ. No. 91-3242, Vol. I, pages 647-669), although not all CDR
residues
are necessarily directly involved in antigen binding.
FR residues and Ig constant domains are not directly involved in antigen
binding, but
contribute to antigen binding and/or mediate antibody effector function. Some
FR
residues are thought to have a significant effect on antigen binding in at
least three
ways: by noncovalently binding directly to an epitope, by interacting with one
or more
CDR residues, and by affecting the interface between the heavy and light
chains. The
constant domains are not directly involved in antigen binding but mediate
various Ig
effector functions, such as participation of the antibody in antibody
dependent cellular
cytotoxicity (ADCC), complement dependent cytotoxicity (CDC) and antibody
dependent cellular phagocytosis (ADCP).
The light chains of vertebrate immunoglobulins are assigned to one of two
clearly
distinct classes, kappa (K) and lambda (?0, based on the amino acid sequence
of the
constant domain. By comparison, the heavy chains of mammalian immunoglobulins
are assigned to one of five major classes, according to the sequence of the
constant
domains: IgA, IgD, IgE, IgG, and IgM. IgG and IgA are further divided into
subclasses
(isotypes), e.g., Igal, IgG2, IgG3, Igat, IgAi, and IgA2. The heavy chain
constant
domains that correspond to the different classes of immunoglobulins are called
a, 8, c,
y, and [1., respectively. The subunit structures and three-dimensional
configurations of
the classes of native immunoglobulins are well known.
The terms, "antibody", "anti-IL-23p19 antibody", ''humanized anti-IL-23p1 9
antibody",
"humanized anti-IL-23p19 epitope antibody", and "variant humanized anti-IL-
23p1 9
epitope antibody" specifically encompass monoclonal antibodies (including full
length
monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g.,
bispecific
antibodies), and antibody fragments such as variable domains and other
portions of
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
antibodies that exhibit a desired biological activity, e.g., IL-23p19
binding.The term
"monoclonal antibody" (mAb) refers to an antibody that is highly specific,
being
directed against a single antigenic determinant, an "epitope". Therefore, the
modifier
"monoclonal" is indicative of antibodies directed to the identical epitope and
is not to
5 be construed as requiring production of the antibody by any particular
method. It
should be understood that monoclonal antibodies can be made by any technique
or
methodology known in the art; including e.g., the hybridoma method ( Kohler et
al.,
1975, Nature 256:495), or recombinant DNA methods known in the art (see, e.g.,
U.S.
Pat. No. 4,816,567), or methods of isolation of monoclonal recombinantly
produced
10 using phage antibody libraries, using techniques described in Clackson
et al., 1991,
Nature 352: 624-628, and Marks et al., 1991, J. Mol. Biol. 222: 581-597.
The term "monomer" refers to a homogenous form of an antibody. For example,
for a
full-length antibody, monomer means a monomeric antibody having two identical
heavy chains and two identical light chains.
15 Chimeric antibodies consist of the heavy and light chain variable
regions of an
antibody from one species (e.g., a non-human mammal such as a mouse) and the
heavy and light chain constant regions of another species (e.g., human)
antibody and
can be obtained by linking the DNA sequences encoding the variable regions of
the
antibody from the first species (e.g., mouse) to the DNA sequences for the
constant
20 regions of the antibody from the second (e.g. human) species and
transforming a host
with an expression vector containing the linked sequences to allow it to
produce a
chimeric antibody. Alternatively, the chimeric antibody also could be one in
which one
or more regions or domains of the heavy and/or light chain is identical with,
homologous to, or a variant of the corresponding sequence in a monoclonal
antibody
25 from another immunoglobulin class or isotype, or from a consensus or
germline
sequence. Chimeric antibodies can include fragments of such antibodies,
provided
that the antibody fragment exhibits the desired biological activity of its
parent antibody,
for example binding to the same epitope (see, e.g., U.S. Pat. No. 4,816,567;
and
Morrison et al., 1984, Proc. Natl. Acad. Sci. USA 81:6851-6855).
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
31
The terms, "antibody fragment", "anti-IL-23p19 antibody fragment", "anti-IL-
23p19
epitope antibody fragment", "humanized anti-IL-23p19 antibody fragment",
"humanized
anti-IL-23p19 epitope antibody fragment", "variant humanized anti-IL-23p19
epitope
antibody fragment" refer to a portion of a full length anti-IL-23p19 antibody,
in which a
variable region or a functional capability is retained, for example, specific
IL-23p19
epitope binding. Examples of antibody fragments include, but are not limited
to, a Fab,
Fab', F(ab)2, Fd, Fv, scFv and scFv-Fc fragment, a diabody, a linear antibody,
a
single-chain antibody, a minibody, a diabody formed from antibody fragments,
and
multispecific antibodies formed from antibody fragments.
Full length antibodies can be treated with enzymes such as papain or pepsin to
generate useful antibody fragments. Papain digestion is used to produces two
identical
antigen-binding antibody fragments called "Fab" fragments, each with a single
antigen-
binding site, and a residual "Fc" fragment. The Fab fragment also contains the
constant domain of the light chain and the CHl domain of the heavy chain.
Pepsin
treatment yields a F(ab)2 fragment that has two antigen-binding sites and is
still
capable of cross-linking antigen.
Fab' fragments differ from Fab fragments by the presence of additional
residues
including one or more cysteines from the antibody hinge region at the C-
terminus of
the CHi domain. F(ab')2 antibody fragments are pairs of Fab' fragments linked
by
cysteine residues in the hinge region. Other chemical couplings of antibody
fragments
are also known.
"Fv" fragment contains a complete antigen-recognition and binding site
consisting of a
dimer of one heavy and one light chain variable domain in tight, non-covalent
association. In this configuration, the three CDRs of each variable domain
interact to
define an antigen-biding site on the surface of the VH-VL dimer. Collectively,
the six
CDRs confer antigen-binding specificity to the antibody.
A "single-chain Fv" or "scFv" antibody fragment is a single chain Fv variant
comprising
the VH and VL domains of an antibody where the domains are present in a single
polypeptide chain. The single chain Fv is capable of recognizing and binding
antigen.
The scFv polypeptide may optionally also contain a polypeptide linker
positioned
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
32
between the VH and VL domains in order to facilitate formation of a desired
three-
dimensional structure for antigen binding by the scFv (see, e.g., Pluckthun,
1994, In
The Pharmacology of monoclonal Antibodies, Vol. 113, Rosenburg and Moore eds.,
Springer-Verlag, New York, pp. 269-315).
A "diabody" refers to small antibody fragments with two antigen-binding sites,
which
fragments comprise a heavy chain variable domain (V<sub>H</sub>) connected to a
light
chain variable domain (V<sub>L</sub>) in the same polypeptide chain (V<sub>H-V</sub><sub>L</sub>
or
V<sub>L-V</sub><sub>H</sub>). Diabcdies are described more fully in, e.g., Holliger et al.
(1993)
Proc. Natl. Acad. Sci. USA 90: 6444-6448.
Other recognized antibody fragments include those that comprise a pair of
tandem Fd
segments (VH-CH1-VH-CH1) to form a pair of antigen binding regions. These
"linear
antibodies" can be bispecific or monospecific as described in, for example,
Zapata et
al. 1995, Protein Eng. 8(10):1057-1062.
A "humanized antibody" or a "humanized antibody fragment" is a specific type
of
chimeric antibody which includes an immunoglobulin amino acid sequence
variant, or
fragment thereof, which is capable of binding to a predetermined antigen and
which,
comprises one or more FRs having substantially the amino acid sequence of a
human
immunoglobulin and one or more CDRs having substantially the amino acid
sequence
of a non-human immunoglobulin. This non-human amino acid sequence often
referred
to as an "import" sequence is typically taken from an "import" antibody
domain,
particularly a variable domain. In general, a humanized antibody includes at
least the
CDRs or HVLs of a non-human antibody, inserted between the FRs of a human
heavy
or light chain variable domain. The present invention describes specific
humanized
anti-IL-23p19 antibodies which contain CDRs derived from the mouse monoclonal
antibodies or humanized CDRs shown in Tables 3 and 4 inserted between the FRs
of
human germline sequence heavy and light chain variable domains. It will be
understood that certain mouse FR residues may be important to the function of
the
humanized antibodies and therefore certain of the human germline sequence
heavy
and light chain variable domains residues are modified to be the same as those
of the
corresponding mouse sequence.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
33
In another aspect, a humanized anti-IL-23p19 antibody comprises substantially
all of at
least one, and typically two, variable domains (such as contained, for
example, in Fab,
Fab', F(ab')2, Fabc, and Fv fragments) in which all, or substantially all, of
the CDRs
correspond to those of a non-human immunoglobulin, and specifically herein,
all of the
CDRs are mouse or humanized sequences as detailed in Tables 1 through 4 herein
below and all, or substantially all, of the FRs are those of a human
immunoglobulin
consensus or germline sequence. In another aspect, a humanized anti- IL-23p19
antibody also includes at least a portion of an immunoglobulin Fc region,
typically that
of a human immunoglobulin. Ordinarily, the antibody will contain both the
light chain as
well as at least the variable domain of a heavy chain. The antibody also may
include
one or more of the CHi , hinge, CH2, CH3, and/or CH4 regions of the heavy
chain, as
appropriate.
A humanized anti-IL-23p19 antibody can be selected from any class of
immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype,
including
Igal, IgG2, IgG3, IgG4, IgAl and IgA2. For example, the constant domain can be
a
complement fixing constant domain where it is desired that the humanized
antibody
exhibit cytotoxic activity, and the isotype is typically Igal. Where such
cytotoxic activity
is not desirable, the constant domain may be of another isotype, e.g., IgG2.
An
alternative humanized anti-IL-23p19 antibody can comprise sequences from more
than one immunoglobulin class or isotype, and selecting particular constant
domains
to optimize desired effector functions is within the ordinary skill in the
art. In specific
embodiments, the present invention provides antibodies that are IgG1
antibodies and
more particularly, are IgG1 antibodies in which there is a knock-out of
effector
functions.
The FRs and CDRs, or HVLs, of a humanized anti-IL-23p19 antibody need not
correspond precisely to the parental sequences. For example, one or more
residues
in the import CDR, or HVL, or the consensus or germline FR sequence may be
altered
(e.g., mutagenized) by substitution, insertion or deletion such that the
resulting amino
acid residue is no longer identical to the original residue in the
corresponding position
in either parental sequence but the antibody nevertheless retains the function
of
binding to IL-23p19. Such alteration typically will not be extensive and will
be
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
34
conservative alterations. Usually, at least 75% of the humanized antibody
residues will
correspond to those of the parental consensus or germline FR and import CDR
sequences, more often at least 90%, and most frequently greater than 95%, or
greater
than 98% or greater than 99%.
lmmunoglobulin residues that affect the interface between heavy and light
chain
variable regions ("the VL-VH interface") are those that affect the proximity
or orientation
of the two chains with respect to one another. Certain residues that may be
involved in
interchain interactions include VL residues 34, 36, 38, 44, 46, 87, 89, 91,
96, and 98
and VH residues 35, 37, 39, 45, 47, 91, 93, 95, 100, and 103 (utilizing the
numbering
system set forth in Kabat et al., Sequences of Proteins of Immunological
Interest
(National Institutes of Health, Bethesda, Md., 1987)). U.S. Pat. No. 6,407,213
also
discusses that residues such as VI_ residues 43 and 85, and VH residues 43 and
60
also may be involved in this interaction. While these residues are indicated
for human
IgG only, they are applicable across species. Important antibody residues that
are
reasonably expected to be involved in interchain interactions are selected for
substitution into the consensus sequence.
The terms "consensus sequence" and "consensus antibody" refer to an amino acid
sequence which comprises the most frequently occurring amino acid residue at
each
location in all immunoglobulins of any particular class, isotype, or subunit
structure,
e.g., a human immunoglobulin variable domain. The consensus sequence may be
based on immunoglobulins of a particular species or of many species. A
"consensus"
sequence, structure, or antibody is understood to encompass a consensus human
sequence as described in certain embodiments, and to refer to an amino acid
sequence which comprises the most frequently occurring amino acid residues at
each
location in all human immunoglobulins of any particular class, isotype, or
subunit
structure. Thus, the consensus sequence contains an amino acid sequence having
at
each position an amino acid that is present in one or more known
immunoglobulins,
but which may not exactly duplicate the entire amino acid sequence of any
single
immunoglobulin. The variable region consensus sequence is not obtained from
any
naturally produced antibody or immunoglobulin. Kabat et al., 1991, Sequences
of
Proteins of Immunological Interest, 5th Ed. Public Health Service, National
Institutes of
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
Health, Bethesda, Md., and variants thereof. The FRs of heavy and light chain
consensus sequences, and variants thereof, provide useful sequences for the
preparation of humanized anti-IL-23p19 antibodies. See, for example, U.S. Pat.
Nos.
6,037,454 and 6,054,297.
5 Human germline sequences are found naturally in the human population. A
combination of those germline genes generates antibody diversity. Germline
antibody
sequences for the light chain of the antibody come from conserved human
germline
kappa or lambda v-genes and j-genes. Similarly the heavy chain sequences come
from germline v-, d- and j-genes (LeFranc, M-P, and LeFranc, G, "The
lmmunoglobulin
10 Facts Book" Academic Press, 2001).
As used herein, "variant'', "anti- IL-23p19 variant", "humanized anti- IL-
23p19 variant",
or "variant humanized anti- IL-23p19" each refers to a humanized anti-IL-23p19
antibody having at least a light chain variable murine CDR from any of the
sequences
as shown in Table 1 or a heavy chain murine CDR sequence derived from the
murine
15 monoclonal antibody as shown in Table 2. Variants include those having
one or more
amino acid changes in one or both light chain or heavy chain variable domains,
provided that the amino acid change does not substantially impair binding of
the
antibody to IL-23p19. Exemplary humanized antibodies produced herein include
those
designated as Antibody A, Antibody B, Antibody C and Antibody D, and the
various
20 light chains and heavy chains of the same are shown in SEQ ID Nos:174
and 180, and
SEQ ID Nos:176 and 178, respectively.
An "isolated" antibody is one that has been identified and separated and/or
recovered
from a component of its natural environment. Contaminant components of the
antibody's natural environment are those materials that may interfere with
diagnostic
25 or therapeutic uses of the antibody, and can be enzymes, hormones, or other
proteinaceous or nonproteinaceous solutes. In one aspect, the antibody will be
purified
to at least greater than 95% isolation by weight of antibody.
An isolated antibody includes an antibody in situ within recombinant cells in
which it is
produced, since at least one component of the antibody's natural environment
will not
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
36
be present. Ordinarily however, an isolated antibody will be prepared by at
least one
purification step in which the recombinant cellular material is removed.
The term "antibody performance" refers to factors that contribute to antibody
recognition of antigen or the effectiveness of an antibody in vivo. Changes in
the
amino acid sequence of an antibody can affect antibody properties such as
folding,
and can influence physical factors such as initial rate of antibody binding to
antigen
(ka), dissociation constant of the antibody from antigen (kd), affinity
constant of the
antibody for the antigen (Kd), conformation of the antibody, protein
stability, and half
life of the antibody.
The term "epitope tagged" when used herein, refers to an anti-IL-23p19
antibody fused
to an "epitope tag". An "epitope tag" is a polypeptide having a sufficient
number of
amino acids to provide an epitope for antibody production, yet is designed
such that it
does not interfere with the desired activity of the humanized anti-IL-23p19
antibody.
The epitope tag is usually sufficiently unique such that an antibody raised
against the
epitope tag does not substantially cross-react with other epitopes. Suitable
tag
polypeptides generally contain at least 6 amino acid residues and usually
contain
about 8 to 50 amino acid residues, or about 9 to 30 residues. Examples of
epitope
tags and the antibody that binds the epitope include the flu HA tag
polypeptide and its
antibody 120A5 (Field et al., 1988 Mol. Cell. Biol. 8: 2159-2165; c-myc tag
and 8F9,
3C7, 6E10, G4, B7 and 9E10 antibodies thereto (Evan et al., 1985, Mol. Cell.
Biol.
5(12):3610-3616; and Herpes simplex virus glycoprotein D (gD) tag and its
antibody
(Paborsky et al. 1990, Protein Engineering 3(6): 547-553). In certain
embodiments, the
epitope tag is a "salvage receptor binding epitope". As used herein, the term
"salvage
receptor binding epitope" refers to an epitope of the Fc region of an IgG
molecule
(such as IgGi, IgG2, IgG3, or IgG4) that is responsible for increasing the in
vivo serum
half-life of the IgG molecule.
In some embodiments, the antibodies of the present invention may be conjugated
to a
cytotoxic agent. This is any substance that inhibits or prevents the function
of cells
and/or causes destruction of cells. The term is intended to include
radioactive isotopes
(such as 1131, 1125, Y ,,90,
and Re186), chemotherapeutic agents, and toxins such as
enzymatically active toxins of bacterial, fungal, plant, or animal origin, and
fragments
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
37
thereof. Such cytotoxic agents can be coupled to the humanized antibodies of
the
present invention using standard procedures, and used, for example, to treat a
patient
indicated for therapy with the antibody.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of
cancer.
There are numerous examples of chemotherapeutic agents that could be
conjugated
with the therapeutic antibodies of the present invention.
Examples of such
chemotherapeutic agents include alkylating agents such a thiotepa and
cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan, and
piposulfan;
aziridines such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines
and methylamelamines including altretamine, triethylenemelamine,
trietylenephosphoramide, triethylenethiophosphoramide, and
trimethylolomelamine;
acetogenins (especially bullatacin and bullatacinone); camptothecin (including
the
synthetic analogue topotecan); bryostatin; callystatin; 00-1065 (including its
adozelesin, carzelesin, and bizelesin synthetic analogues); cryptophycines
(particularly
cryptophycin 1 and cryptophycin 8); dolastatin, auristatins, (including
analogues
monomethyl-auristatin E and monomethyl-auristatin F); duocarmycin (including
the
synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin;
sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil,
chlomaphazine,
cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine
oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine;
trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin,
fotemustine, lomustine, nimustine, ranimustine; antibiotics such as the
enediyne
antibiotics (e.g., calicheamicin, especially calichemicin gamma1 I and
calicheamicin
phil1, see for example, Agnew, Chem. Intl. Ed. Engl., 33:183-186; dynemicin,
including
dynemicin A; bisphosphonates, such as clodronate; esperamicin; as well as
neocarzinostatin chromophore and related chromoprotein enediyne antibiotic
chromomophores), aclacinomysins, actinomycin, authramycin, azaserine,
bleomycins,
cactinomycin, carabicin, caminomycin, carzinophilin, chromomycins,
dactinomycin,
daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin
(AdriamycinTM)
(including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-
doxorubicin, and deoxydoxorubicin), epirubucin, esorubicin, idarubicin,
marcellomycin,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
38
mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins,
peplomycin, potfiromycin, puromycine, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites
such a
methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as
denopterin,
methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-
mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as
ancitabine,
azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine,
enocitabine, floxuridine; androgens such as calusterone, dromostanolone
propionate,
epitiostanol, mepitiostane, testolactone; anti-adranals such as
aminoglutethimide,
mitotane, trilostane; folic acid replenisher such as frolinic acid;
aceglatone;
aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine;
bestrabucil;
bisantrene; edatraxate; defofamine; democolcine; diaziquone; elfomithine;
elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan;
lonidamine;
maytansinoids such as maytansine and ansamitocins; mitoguazone, mitoxantrone;
mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone;
podophyllinic
acid; 2-ethylhydrazide; procarbazine; PSKO; razoxane; rhizoxin; sizofuran;
spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine;
trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine);
urethan;
vindesine; dacarbazine; mannomustine; mitabronitol; mitolactol; pipobroman;
gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g.,
paclitaxel
(TAXOLO, Bristol-Myers Squibb Oncology, Princeton, N.J.) and doxetaxel
(TAXOTERE , Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine
(GemzarTm); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such
as
cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16);
ifosfamide;
mitoxantrone; vincristine; vinorelbine Navelbinerm); novantrone; teniposide;
edatrexate; daunomycin; aminopterin; xeloda; ibandronate; CPT-11;
topoisomerase
inhibitor RFS 2000; difluoromethylornithine (DMF0); retinoids such as retinoic
acid;
capecitabine; and pharmaceutically acceptable salts, acids, or derivatives of
any of the
above. Also included in this definition are anti-hormonal agents that act to
regulate or
inhibit hormone action on tumors such as anti-estrogens and selective estrogen
receptor modulators (SERMs), including, for example, tamoxifen (including
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
39
NolvadexTm), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene,
keoxifene,
LY117018, onapristone, and toremifene (FarestonTm); aromatase inhibitors that
inhibit
the enzyme aromatase, which regulates estrogen production in the adrenal
glands,
such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate
(MegaceTm), exemestane, formestane, fadrozole, vorozole (RivisorTm), letrozole
(FemaraTm), and anastrozole (ArimidexTm); and anti-androgens such as
flutamide,
nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically
acceptable
salts, acids, or derivatives of any of the above. Any one or more of these
agents may
be conjugated to the humanized antibodies of the present invention to provide
a useful
therapeutic agent for the treatment of various disorders.
The antibodies also may be conjugated to prodrugs. A "prodrug" is a precursor
or
derivative form of a pharmaceutically active substance that is less cytotoxic
to tumor
cells compared to the parent drug and is capable of being enzymatically
activated or
converted into the more active form. See, for example, Wilman, 1986, "Prodrugs
in
Cancer Chemotherapy", In Biochemical Society Transactions, 14, pp. 375-382,
615th
Meeting Belfast and Stella et al., 1985, "Prodrugs: A Chemical Approach to
Targeted
Drug Delivery, In: "Directed Drug Delivery, Borchardt et al., (ed.), pp. 247-
267,
Humana Press. Useful prodrugs include, but are not limited to, phosphate-
containing
prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs
peptide-
containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, 13-
lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing
prodrugs, and optionally substituted phenylacetamide-containing prodrugs, 5-
fluorocytosine and other 5-fluorouridine prodrugs that can be converted into
the more
active cytotoxic free drug. Examples of cytotoxic drugs that can be
derivatized into a
prodrug form include, but are not limited to, those chemotherapeutic agents
described
above.
For diagnostic as well as therapeutic monitoring purposes, the antibodies of
the
invention also may be conjugated to a label, either a label alone or a label
and an
additional second agent (prodrug, chemotherapeutic agent and the like). A
label, as
distinguished from the other second agents refers to an agent that is a
detectable
compound or composition and it may be conjugated directly or indirectly to a
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
humanized antibody of the present invention. The label may itself be
detectable (e.g.,
radioisotope labels or fluorescent labels) or, in the case of an enzymatic
label, may
catalyze chemical alteration of a substrate compound or composition that is
detectable. Labeled humanized anti-IL-23p19 antibody can be prepared and used
in
5 various applications including in vitro and in vivo diagnostics.
The antibodies of the present invention may be formulated as part of a
liposomal
preparation in order to affect delivery thereof in vivo. A "liposome" is a
small vesicle
composed of various types of lipids, phospholipids, and/or surfactant.
Liposomes are
useful for delivery to a mammal of a compound or formulation, such as a
humanized
10 anti-IL-23p19 antibody disclosed herein, optionally, coupled to or in
combination with
one or more pharmaceutically active agents and/or labels. The components of
the
liposome are commonly arranged in a bilayer formation, similar to the lipid
arrangement of biological membranes.
Certain aspects of the present invention related to isolated nucleic acids
that encode
15 one or more domains of the humanized antibodies of the present
invention. An
"isolated" nucleic acid molecule is a nucleic acid molecule that is identified
and
separated from at least one contaminant nucleic acid molecule with which it is
ordinarily associated in the natural source of the antibody nucleic acid. An
isolated
nucleic acid molecule is distinguished from the nucleic acid molecule as it
exists in
20 natural cells.
In various aspects of the present invention one or more domains of the
humanized
antibodies will be recombinantly expressed. Such recombinant expression may
employ one or more control sequences, i.e., polynucleotide sequences necessary
for
expression of an operably linked coding sequence in a particular host
organism. The
25 control sequences suitable for use in prokaryotic cells include, for
example, promoter,
operator, and ribosome binding site sequences. Eukaryotic control sequences
include,
but are not limited to, promoters, polyadenylation signals, and enhancers.
These
control sequences can be utilized for expression and production of humanized
anti-IL-
23p19 antibody in prokaryotic and eukaryotic host cells.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
41
A nucleic acid sequence is "operably linked" when it is placed into a
functional
relationship with another nucleic acid sequence. For example, a nucleic acid
presequence or secretory leader is operably linked to a nucleic acid encoding
a
polypeptide if it is expressed as a preprotein that participates in the
secretion of the
.. polypeptide; a promoter or enhancer is operably linked to a coding sequence
if it
affects the transcription of the sequence; or a ribosome binding site is
operably linked
to a coding sequence if it is positioned so as to facilitate translation.
Generally,
"operably linked" means that the DNA sequences being linked are contiguous,
and, in
the case of a secretory leader, contiguous and in reading frame. However,
enhancers
are optionally contiguous. Linking can be accomplished by ligation at
convenient
restriction sites. If such sites do not exist, synthetic oligonucleotide
adaptors or linkers
can be used.
As used herein, the expressions "cell", "cell line", and "cell culture" are
used
interchangeably and all such designations include the progeny thereof. Thus,
.. "transformants" and "transformed cells" include the primary subject cell
and cultures
derived therefrom without regard for the number of transfers.
The term "mammal" for purposes of treatment refers to any animal classified as
a
mammal, including humans, domesticated and farm animals, and zoo, sports, or
pet
animals, such as dogs, horses, cats, cows, and the like. Preferably, the
mammal is
human.
A "disorder", as used herein, is any condition that would benefit from
treatment with a
humanized anti-IL-23p19 antibody described herein. This includes chronic and
acute
disorders or diseases including those pathological conditions that predispose
the
mammal to the disorder in question. Non-limiting examples or disorders to be
treated
.. herein include inflammatory, angiogenic, autoimmune and immunologic
disorders,
respiratory disorders, cancer, hematological malignancies, benign and
malignant
tumors, leukemias and lymphoid malignancies.
The terms "cancer" and "cancerous" refer to or describe the physiological
condition in
mammals that is typically characterized by unregulated cell growth. Examples
of
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
42
cancer include, but are not limited to, carcinoma, lymphoma, blastoma,
sarcoma, and
leukernia.
As used herein, the term "IL-23-associated disorder" or "IL-23-associated
disease"
refers to a condition in which IL-23 activity contributes to the disease and
typically
where IL-23 is abnormally expressed. An IL-23-associated disorder includes
diseases
and disorders of the immune system, such as autoimmune disorders and
Inflammatory
disorders. Such conditions include, but are not limited to, rheumatoid
arthritis (RA),
systemic lupus erythematosus (SLE), scleroderma, Sjogren's syndrome, multiple
sclerosis, psoriasis, psoriatic arthritis, inflammatory bowel disease (e.g.,
ulcerative
colitis and Crohn's disease), pulmonary inflammation, asthma, idiopathic
thrombocytopenic purara (ITP) and spondyloarthritis, for example ankylosing
spondylitis, non-radiographic axial spondyloarthritis or peripheral
spondyloarthritis.
The term "intravenous infusion" refers to introduction of an agent into the
vein of an
animal or human patient over a period of time greater than approximately 15
minutes,
.. generally between approximately 30 to 90 minutes.
The term "intravenous bolus" or "intravenous push" refers to drug
administration into a
vein of an animal or human such that the body receives the drug in
approximately 15
minutes or less, generally 5 minutes or less.
The term "subcutaneous administration" refers to introduction of an agent
under the
.. skin of an animal or human patient, preferable within a pocket between the
skin and
underlying tissue, by relatively slow, sustained delivery from a drug
receptacle.
Pinching or drawing the skin up and away from underlying tissue may create the
pocket.
The term "subcutaneous infusion" refers to introduction of a drug under the
skin of an
animal or human patient, preferably within a pocket between the skin and
underlying
tissue, by relatively slow, sustained delivery from a drug receptacle for a
period of time
including, but not limited to, 30 minutes or less, or 90 minutes or less.
Optionally, the
infusion may be made by subcutaneous implantation of a drug delivery pump
implanted under the skin of the animal or human patient, wherein the pump
delivers a
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
43
predetermined amount of drug for a predetermined period of time, such as 30
minutes,
90 minutes, or a time period spanning the length of the treatment regimen.
The term "subcutaneous bolus" refers to drug administration beneath the skin
of an
animal or human patient, where bolus drug delivery is less than approximately
15
minutes; in another aspect, less than 5 minutes, and in still another aspect,
less than
60 seconds. In yet even another aspect, administration is within a pocket
between the
skin and underlying tissue, where the pocket may be created by pinching or
drawing
the skin up and away from underlying tissue.
The term "therapeutically effective amount" is used to refer to an amount of
an active
agent that relieves or ameliorates one or more of the symptoms of the disorder
being
treated. In another aspect, the therapeutically effective amount refers to a
target
serum concentration that has been shown to be effective in, for example,
slowing
disease progression. Efficacy can be measured in conventional ways, depending
on
the condition to be treated.
The terms "treatment" and "therapy" and the like, as used herein, are meant to
include
therapeutic as well as prophylactic, or suppressive measures for a disease or
disorder
leading to any clinically desirable or beneficial effect, including but not
limited to
alleviation or relief of one or more symptoms, regression, slowing or
cessation of
progression of the disease or disorder. Thus, for example, the term treatment
includes
the administration of an agent prior to or following the onset of a symptom of
a disease
or disorder thereby preventing or removing one or more signs of the disease or
disorder. As another example, the term includes the administration of an agent
after
clinical manifestation of the disease to combat the symptoms of the disease.
Further,
administration of an agent after onset and after clinical symptoms have
developed
where administration affects clinical parameters of the disease or disorder,
such as the
degree of tissue injury or the amount or extent of metastasis, whether or not
the
treatment leads to amelioration of the disease, comprises "treatment" or
"therapy" as
used herein. Moreover, as long as the compositions of the invention either
alone or in
combination with another therapeutic agent alleviate or ameliorate at least
one
symptom of a disorder being treated as compared to that symptom in the absence
of
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
44
use of the humanized anti-IL-23p19 antibody composition, the result should be
considered an effective treatment of the underlying disorder regardless of
whether all
the symptoms of the disorder are alleviated or not.
The term "package insert" is used to refer to instructions customarily
included in
commercial packages of therapeutic products, that contain information about
the
indications, usage, administration, contraindications and/or warnings
concerning the
use of such therapeutic products.
Antibodies
In one aspect, described and disclosed herein are anti-IL-23 antibodies, in
particular
humanized anti-IL-23p19 antibodies, and compositions and articles of
manufacture
comprising one or more anti-IL-23 antibody, in particular one or more
humanized anti-
IL-23p19 antibody of the present invention. Also described are binding agents
that
include an antigen-binding fragment of an anti-IL-23 antibody, in particular a
humanized anti-IL-23p19 antibody. The humanized anti-IL-23p19 antibodies and
binding agents can inhibit the production of Th17 associated cytokines, which
contribute to chronic autoimmune and inflammatory diseases. The humanized anti-
IL-
23p19 antibodies and binding agents can thus be used in the treatment of a
variety of
diseases or disorders. A humanized anti-IL-23p19 antibody and an IL-23p19
binding
agent each includes at least a portion that specifically recognizes an IL-
23p19 epitope
(i.e., an antigen-binding fragment).
In the initial characterization mouse antibodies were selected based on IL-
23p19
binding characterization.
Accordingly in one aspect, an antibody of the present invention has a KD for
IL-23, in
particular human IL-23, of less than 100pM. In another aspect, an antibody of
the
present invention has a KD of less than 40pM. In another aspect, an antibody
of the
present invention has a KD of less than 20pM. In another aspect, an antibody
of the
present invention has a KD of less than 10pM. In another aspect, a monoclonal
antibody of the present invention has a KD of less than 1pM.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
The selected mouse antibodies have the following light chain variable regions
and
heavy chain variable regions as shown in Table 1 and 2:
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 46 -
Table 1: Anti-IL-23p19 Mouse Leads - VK Sequences
2D1vk GACATTGTGCTGACCCAATCTCCAGGTTCTTTGGCTGTGTCTCTAGGGCAG
AGGGCCACCATATCCTCCAGAACCAGTGAAAGICITTATACTTATCGCCAA
AATTTTATACACTGGTACCAGCAGAAACCAGGACAGCCACCCAAACTCCTC
ATCTATCGTGCATCCAACCTGGAAICTGGGATCCCTGCCAGGTTCAGTGGC
AGTGGGICTAGGACAGACTTCACCCTCACCATGAATCCTGTGGAGGCTGAT
GATGITGCAACCIATTACTGTCAGCAAACTAATGAGGATCCGTACACGTTC
GGAGOGGCCACCAAGCTOGAAATAAGA (SEQ ID NO:83)
DIVLIQSPGSLAVSLGQRATISCRISESVYSYGQNFIHWYQQKPGQPPKLL
IYRASNLESGIPARFSCSGSRIDFILTMNPVEADDVATYYCQQINEDPYTF
GGGTKLEIR (SEQ ID NO:84)
6B8Vk GACATTGTGATGACCCAGTCTCACAAATICTTGTOCACATCAGTGGGAGAC
AGGGTCACCATCACTTGCAAGGCCAGTCGGGATGTGGCTATTGCTGTAGCC
TGGTATCAACAGAAACCAGGGCAATCTCCTAAACTACTTCTTTTCTGGGCA
TCCACCCGACACACTGGGGTCCOTGATCGOTTCACAGGCAGTGGATCTCGG
ACAGAT7TCACTCTCACCATTAGCAATGTGCAGTCTGAAGACTTGGCAGAT
TATTICIGICACCAATATAGCAGCIATCCATICACGTICGGCTCGGGGACA
AAGTTGGAAATAAAG (SEQ ID NO:85)
DIVNITQSHKFLSTSVGDRVTITCKASRDVAIAVAWYQQKPGQSFKLLLFWA
STRITIGVPDRFTGSGSRTDFTLTISNVQSEDLADYFCHQYSSYPFTFGSGT
KLEIK (SEQ ID NO:86)
9D12-Vk GACATTGCGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTGGGGCAG
AGGGCCACCATATCCTGCAGAGCCAGTGAAACTATTAATTTTTATGGCACT
AGTTITATCCACTGGTACCACCAGAAACCAGGACAGICACCCAAACTCCTC
ATCTATCGTGCATCCAACCTAGAATCTGGGATCCCTGCCAGGTTCAGTGGC
AGTGOOTCTAGGACAGACTTCACCCTCACCATTAATCCTOTGGAGGCTGAT
GATGITGCAACCIATTACTGTCAGCAAACTAATGAGGATCCGTACACGTTO
GGAGGGGGGACTAAGTTGGAAATAAAA (SEQ ID NO:87)
DIALTQSPASLAVSLGQRATISCRASETINFYGTSFMHWYQQKPGQSPKLL
IYRASNLESGIPARFSGSGSRTDFILTINPVEADDVATYYCQQTNEDPYTF
CGGTKLEIK (SEQ ID NO:88)
15C1lvk GATGITGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGAT
CAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGA
AACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTC
CTGATC7ACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGT
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 47 -
GGCAGTGGATCAGGGACAGAT T TCACACTCAAGATCAACAGAGTGGAGGCT
GAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTACACG
TTCGGAGGGGGGACCCAGCTGGAAATAAAA (SEQ ID NO: 89)
DVVMTQ7PLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKL
LIYKVSNRFSGVPDRFSGSGSGTDFTLKINRVEAEDLGVYFCSQSTHVPYT
FGGGTQLEIK (SEQ ID NO:90)
15Flvk DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQRSHESPRLLIKYA
SQSISGIPSRFSGSGSGSDFILTINSVEPEDVGVYYCQNGHSFPFTFGSGT
KLEIK (SEQ ID NO:91)
18D3vk GACATTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGAT
AGAGICTCTCTTTCCTGCAGGGCCAGTCAGAGTATTAGCGACTACTTATAC
TGGTATCAACAAAAATCACATGAGTCTCCAAGGCTTCTCATCAAATTTGCT
TCCCAATCCATCTCTGGGATCCCCICCAGGTTCACTGGCAGTGGATCAGGG
TCAGAT7TCACTCTCAGTATCGACAGTGTGGAACCTGATGATGTTGGAGTC
TTTTTC7GTCAAAATGGTCACAGCTTTCCGTTCACGTTCGGAGGGGGGACC
AAGCTGGAAATAAAA (SEQ ID NO:92)
DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLYWYQQKSHESPRLLIKFA
SQSISGIPSRFTGSGSGSDFTLSIDSVEPDDVGVFFCQNGHSFPFTFGGGT
KLEIK (SEQ ID NO:93)
18C4vk GACATTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGAT
AGAGTC7CICTTICCTGCAGGGCCAGCCAGAGTATTAGCGAGTACTTACAC
TGGTATCAACAAAAATCACATGAGICTCCAAGGCTTCTCATCAAATATGCT
TCCCAATCCATCTCTGGGATCCCCTCCAGGTTCAGTGGCAGTGGATCAGGG
TCAGATTTCACTCTCAGTATCAACAGIGIGGAACCTGAAGAIGTIGGAGIG
TATTAC7GTCAAAATGGTCACAGCTTICCATTCACGTTCGGCTCGGGGACA
AAGTTGGAAATAAAA (SEQ ID NO:94)
DIVMTQSPATLSVTPGDRVSLSCRASQSISEYLHWYQQKSNESFRLLIKYA
SQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFGSGT
KLEIK (SEQ ID NO:95)
18E5vk GACATTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGAT
AGAGTC7CTCTTTCCTGCAGGGCCAGCCAGAGTATTAGCGACTACTTATAC
TGGTATCAACAAAAATCACATGAGTCTCCAAGGCTTCTCATCAAATTTGCT
TCCCAATCCATCTCTGGGATCCCCTCCAGGTTCACTGGCAGTGGATCAGGG
TCAGAT-TCACTCTCAGTATCGACAGTGTGGAACCTGATGATGTTGGAGTC
ITTTIC7GICAAAATGGTCACAGCTTTCCGTTCACGTTCGGAGGGGGGACC
AAGCTGGAAATAAAA (SEQ ID NO:96)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 48 -
D IVMTQSPATL SVTPGDRVSL SCRASQS I SDYL YWYQQKS HE SPRLL IKFA
SQSISGIPSRFTGSGSGSDFTLSIDSVEPDDVGVFFCQNGHSFPFTFGGGT
KLEIK (SEQ ID NO:97)
20E8vk GACATTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGAT
AGAGTC7CTCTTTCCTGCAGGGCCAGCCAGAGTATTAGCGAGTATTTACAC
TGGTATCAACAAAAATCACATGAGTCTCCAAGGCTTCTCATCAAATATGCT
TCCCAA7CCATCTCTGGGATCCCCICCAGGTTCAGTGGCAGTGGATCAGGG
TCAGATTTCACTCTCAGTATCAACAGTGTGGAACCTGAAGATGTTGGAGTT
TATTAC7GTCAAAATGGTCACAGCTTTCCATTCACGTTCGGCTCGGGGACA
AAGTTGGAAATAAAA (SEQ ID NO:98)
DIVMTQSPATLSVTPGDRVSLSCRASQSISEYLHWYQQKSHESPRLLIKYA
SQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFGSGT
KLEIK (SEQ ID NO:99)
22E2vk GACATTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAGAT
AGAGTC7CTCTCICCTGCAGGGCCAGCCAGAGTATTAGCGTCTACTTACAC
TGGTATCAACAAAAATCACCTGAGTCTCCAAGGCTTCTCATCAAATATGCT
Trrr4A¨rrATrTrTc;c;c4ATcrrrTrrAqc;TTrAqTqc;rAci,Tc4c;ATrAqc;c2,
TCAGAT7TCACTCTCAGTATCAACAGTGTGGAACCTGAAGATGTTGGAGTT
TATTAC7GTCAAAATGGTCACAGCTTTCCATTCACGTTCGGCTCGGGGACA
AAGTTGGAAATAAAA (SEQ ID NO:100)
DIVMTQSPATLSVTPGDRVSLSCRASQSISVYLHWYQQKSPESPRLLIKYA
SQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSFPFTFGSGT
KLEIK (SEQ ID NO:101)
24A54vk GACATTGTGATGACTCAGTCTCCAGCCACCCTGTCTGTGACTCCAGGAAAT
AGAGTC7CTCTTTCCTGCAGGGCCAGCCAGAGTATTAGCGACTACTTACAC
TGGTATCAACAAAAATCACATGAGTCTOCAAGGCTTCTCATCAAATATGCT
TCCCAA7CCATCTCTGGGATCCCCICCAGGTTCAGTGGCAGTGGATCAGGG
TCAAATTTCACTCTCAGTATCAACAGTGTGGAACCTGAAGATGTTGGAGTG
TATTAT7GTCAAAATGGTCACAGCTTTCCATTCACGTTCGGCTCGGGGACA
AAGTTGGAAATAAAA (SEQ ID NO:102)
DIVMTQSPATLSVTPGNRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYA
SQSISGIPSRFSGSGSGSNFTESINSVEPEDVGVYYCQNGHSFPFTFGSGT
KLEIK (SEQ ID NO:103)
26F7Vk GACATTGTGCTGACACAGTCTCCTGCTTCCTTAGCTGTTTCTCTGGGGCAG
AGGGCCACCATCTCATGCAGGGCCAGCAAAAGTGTCAGATTCTCTGACTAT
TTTTATATGCACTGGTACCAACAGAAACCAGGACAGCCACCCAAACTCCTC
ATCTACCITGCATCCAACCTAGAATCTGGGGICCCTGCCAGGITCAGTGGC
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 49 -
AGTGGG7CTGGGACAGACT TCACCCTCAACATCCATCCTGTGGAGGAGGAG
GATGCTGCAACCTATTACTGTCAGAACAGTAGGGAGCTTCCGTACACGTTC
GGAGGGGGGACCAAGCTGGAGATAAAA (SEQ ID NO:104)
DIVLTQSPASLAVSLGQRATISCRASKSVRFSDYFYMHWYQQKPGQPPKLL
IYLASNLESGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQNSRELPYTF
GGGTKLEIK (SEQ ID NO:105)
27G8vk GACATTGTGTTGACACAGTCTCCTGCTTCCTTAGCTGTATCTCTGGGGCAG
AGGGCCACCATCTCATGCAGGGCCAGCAAAAGTGTCAGTACATCTGGCTAT
AGTTATATACACTGGTACCAACAGAAACCGGGACAGCCACCCAAATTCCTC
ATCTATCTTGCATCCAACCTAGATICTGGGGTCCCTGCCAGGTTCAGTGGC
AGTGGGICIGGGACAGACTTCACCGTCAACATCCATCCTGTGGAGGAGGAG
GATGCTGCAACCIATTACTGTCAGCACAGTAGGGAGCTTCCGTACACGTTC
GGAGGGGGGACCAAGCTGGAAATAAAA (SEQ ID NO: 106)
DIVLIQSPASLAVSLGIQRATISCRASKSVSTSGYSYTHWYNKPGQPPKFL
IYLASNLDSGVPARFSGSGSGTDFTLNIHPVEEEDAATYYCQHSRELPYTF
GGGTKLEIK (SEQ ID NO:107)
31H9vk GACATTGTGATGACTCAGTCTCCAGCCACCCTCTCTCTGACTCCAGGAGAT
AGAGICTCTCTTTCCTGCAGGGCCAGCCAGAGTATTAGCGACTACTTACAC
IGGTATCAACAAAAATCACATGAGTCTCCAAGGCTTCTCATCAAATATGCT
TCCCAATCCATCTCTGGGATCCCCTCCAGGTTCAGTGGCAGTGGATCAGGG
TCAGATTTCACTCTCAGTATCAACAGTGTGGAACCTGAAGATGTTGGAGTG
TATTACTGICAAAATGGTCACAGCTTTCCGTACACGTTCGGAGGGGGGACC
AAGCTGGAAATAAAA (SEQ ID NO:108)
DIVMTQSPATLSVTPGDRVSLSCRASQSISDYLHWYQQKSHESPRLLIKYA
SQSISGIPSRFSGSGSGSDFTLSINSVEPEDVGVYYCQNGHSEPYTFGGGT
KLEIK (SEQ ID NO:109)
34G3Vk GATGITGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGAGAT
CAAGCCICCATCTCTIGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGA
AACACCIATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTC
CTGATC7ACAAAGTTTCCAACCGATTTTCTGGGGTCCCCGACAGGTTCAGT
GGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCT
GAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTACACG
TTCGGAGGGGGGACCAAGCTGGAAATAAAT (SEQ ID NO:110)
DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLQKPGQSPKL
LIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYT
EGGGTKLEIN (SEQ ID NO:111)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 50 -
34D 9Vk GACATTATGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGAC
AGGGTCAGCATCACCTGCAAGGCCAGTCAGGATGTGGGTAATGCTGTGGTC
TGGTATCAACAAAAACCAGGGCAATCTCCTAAACTACTGATTTACTGGGCA
TCCACCCGGCACATTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGG
ACAGATETCACTCTCACCATTACCAATGTGCAGTCTGAAGACTTGGCAGAT
TATTICIGICAGCAATATAGCAGCTATCTCACGTTCGGTGCTGGGACCAAG
CTGGAGCTGAAA (SEQ ID NO:112)
DIMMTQSHKFMSTSVGDRVSITCKASQDVGNAVVWYQQKPGQSPKLLIYWA
STRHIGVPDRFTGSGSGTDFTLTITNVQSEDLADYFCQQYSSYLTFGAGTK
LELK (SEQ ID NO:113)
43F5vk GATGITGTGATGACCCAATCTCCACTCTCCCTGCCTGTCAGTCTTGGAGAT
CAAGCC7CCATCTCTIGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGA
AACACCTATCTACATIGGTACCTGCTGAAGCCAGGCCAGTCTCCAAAGCTC
CTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCAGACAGGTTCAGT
GGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCT
GAGGATCTGGGAGTTTATTTCTGCTCTCAAAGTACACATGTTCCGTACACG
TTCGGAGGGGGGACCAAGCTGGAAATAAAA (SEQ ID NO:114)
DVVMTQSPLSLPVSLGDQASISCRSSQSLVHSNGNTYLHWYLLKPGQSPKL
LIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPYT
FGGGTKLEIK (SEQ ID NO:115)
73H1OVk GACATCCAGATGACTCAGTCTCCAGTTTTCCTGTCTGCATCTGTGGGAGAA
ACTGICACCATCACATGTCGAGCAAGTGAGAATATTGACAGTTATTTAGCA
TGGTATCAGCAGAAACAGGGAAAATCTCCTCAGCTCCTGGTCTTTGCTGCA
CGAAACETAGCAGATGGTGTGCCATCAAGGTTCAGTGGCAGTGGATCAGGC
ACACAGIATTCTCTCAAGATCAACAGAATGCAGTCTGAAGATGTTGCGAGA
TACTACEGTCAACATTATTATAGTACTCCATTCACGTTCGGCTCGGGGACA
AAGTTGGAAATAGAA (SEQ ID NO:116)
DIQMTQSPVFLSASVGETVTITCRASENIDSYLAWYQQKQGKSPQLLVFAA
RNLADGVPSRFSGSGSGTQYSLKINRMQSEDVARYYCQHYYSTPFTFGSGT
KLEIE (SEQ ID NO:117)
74H3Vk GACATCCAGATGACTCAGTCGCCAGCTTCCCTGTCTGCATCTGTGGGAGAA
ACTGTCATCTTCACATGTCGAGCAAGTGAGAATATTGACAGTTATTTAGCA
TGGTATCAGCAGAAACAGGGAAAATCTCCTCAGCTCCTGGTCTATGCTGCA
ACAAACITAGCAGATGGTGTGCCATCAAGGTTCAGTGGCAGTGGATCAGGC
ACACAGFATTCTCTCAAGATCAACAGCCTGCAGTCTGAAGATGTTGCGAGA
TATTACEGTCTACATTATTATAGTACTCCATTCACGTTCGGCTCGGGGACA
GAGTTGGAAATAAAA (SEQ ID NO:118)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 51 -
D IQMTQSPASL SASVGE TVIF TCRASENI DSYLAWYQQKQGK SPQLLVYAA
INLADGVPSRFSGSGSGTQYSLKINSLQSEDVARYYCLHYYSTPFTFGSGT
ELEIK (SEQ ID NO:119)
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 52 -
Table 2: Anti-IL-23p19 Mouse Leads - VH Sequences
2D1vh CAGGIGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGC
CTGICCATCACATGCACTGICTCTGGGITCTCATTAACCACCTATGCTATA
AGCTGGGTTCGCCAGTCACCAGGAAAGGGTCTGGAGTGGCTTGGAGTCATA
TGGACTGGTGGAGGCACAAAATATAATTCAGCTCTCAAATCCAGACTGAGC
ATCAGCAAAGACAACTCCAAGAGTCAAGTTTTCTTAAAAATGAACAGTCTG
CAAACTGATGACACAGCCAGGTACTACTGTGCCAGAAAGGACTATAATTAC
GCCCGTGCTATGGACTACTCGCCTCAAGGAACCTCAGICACCGTCTOCTCA
(SEQ ID NO:120)
QVQLKESGPGLVAPSQSLSITCTVSGFSLITYAISWVRQSPGKGLEWLGVI
WTGGGTKYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCARKDYNY
GGAMDYWGQGTSVTVSS (SEQ ID NO:121)
6B8VH CAGGTTCAGCTGCAACAGTCTGACGCTGAGTTGGTGAAACCTGGCACTTCA
GTGAAGACATCCTGCAAAATTTCTGGCAACACCTTCACTGACCAAACTATT
CACTGGATGAAGGAGAGGCCTGAACAGGGCCTGGAATGGATTGGATATATT
TATCCTAGAGATGATAGTCCTAAGTACAATGAGAACTTCAAGGGCAAGGCC
ACATTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAACAGT
CTGACATCTGAGGACTCTGCAGTCTATTTCTGTGCAATCCCAGACAGGTCA
GGCTACGCCTGGITTATTTACTGGGGCCAAGGGACTCTGGICACTGTCTCT
TCA (SEQ ID NO:122)
QVQLQQSDAELVKPGTSVKTSCKISGNTFTDQTIHWMKQRPEQGLEWIGYI
YPRDDSPKYNENFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCAIPDRS
GYAWFIYWGQGTLVTVSS (SEQ ID NO:123)
9D12VH CAGGIGCAGCTGAAGGAGTCAGGACCTGICCIGGTGGCGCCCICACAGAGC
CTGTCCATCACATGCACTGTCTCTGGGTTCTCATTAAACAACTTTGCTATA
ACTTGGGTTCGTCACCCACCAGGAAAGGGTOTCGAGTCGCTTGGAGCAATA
TGGACTGGTGGAGGCACAAATTATAATTCAGCTCTCAAATCCAGACTGAGC
ATCAGCAAAGACAACTCCAAGAGTCAAGTTTTCTTAAAAATGAACAGTCTG
CAAACTGATGACACAGCCAGGTATTATTGTGTCAGAAAGGACTATAGTTAC
GGGGGTGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCICA
(SEQ ID NO:124)
QVQLKESGPVLVAPSQSLSITCTVSGFSLNNFAISWVRQPPGKGLEWLGAI
WTGGGTNYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTARYYCVRKDYSY
GGAMDYWGQGTSVTVSS (SEQ ID NO:125)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 53 -
15C11vh GAGGTCCAGCTGCAACAGTCTGGACCTGTGCTGGTGAAGCCTGGGGCTTCA
GTGAAGATGICCTGTAAGGCTICTGGATAGACATTCAGTGACTACTATATG
AACTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGAGTTATT
ATTCCTTACAAGGGTGGTACTAGCTACAACCAGAAGTTCAAGGGCAAGGCC
ACATTGACTGTTGACAAGTCCTCCAGCACAGCCTACATGGAGCTCAACAGC
CTGACA7CTGAGGACTCTGCAGTCTATTACTGTGCACGAGATGGTCAC000
IGGTAGTTCGATGTGTGGGGCACAGGGACCACGGTCACCGTCTCCIGA
(SEQ ID NO:126)
EVQLQQSGPVLVKPGASVKMSCKASGYTFTDYYMNWVKQSHGKSLEWIGVI
IDYNGG7SYNUFKGKATLTVDKSSSTAYMELNSLTSEDSAVYYCARDSHR
WYFDVWGIGITTIVSS (SEQ ID NO:127)
15F1vh EVQLQQSGPELVKPGASVKMSCKASGYTFTCCIMHWVKQKPGQGLEWIGYI
NPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARRWDE
AYWGQGTLVIVSA (SEQ ID NO:128)
18D3vh GAGGICCAGCTGCAGCAGTCTGGACGTGAGCTGGICAAGCCTGGGGCTTCA
GTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTCGCTATCTTATT
CACTGGGTGAAACAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATATT
AATCCTTACAATGATGGTACTAAATACAATGACAAGTICAAAGGCAAGGCC
ACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGGAGC
CTGACCTGIGAGGACTCTGCGGTCTATTAGIGTACCTCTAACTGGGACCTC
GACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA (SEQ ID
NO: 129)
EVOLOOSGPELVKPGASVKMSCKASGYTFTRYLIHWVKOKPGOGLEWIGYI
NPYNDG7KYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCTSNWDL
DYWGQGTTLTVSS (SEQ ID NO:130)
18C4vh GAGGTCCAGCTGCAGCAGTCTGGACCTGAAGTGGTAAAGCCTGGGGCTTCA
GIGAAGAIGFCCTGCAAGGCCIGIGGATACACATfCACTAGIIGIGIIATA
CACTGGGTGAAGCAGAAGGCTGGGCAGGGCCTTGAGTGGATTGGATATATC
AATCCCTATAATGATGGTACTAAGTACAATGAGAAGTTCAAAGGCAAGGCC
ACACTGACTTCAGACAGATCCTCCAGCACAGCCTACATGGAGCTCAGGAGC
CTGACC:CTGAGGACTCTGCGGTCTATTACTGTACAAGACGGTTGGACGAG
GGITACTGGGGCCAAGGGAGTGTGCTCACTGTCTCTGCA (SEQ ID
NO: 131)
EVQLQQSGPEVVKPCASVKMSCKASGYTFTSSVIHWVKQKACQGLEWICYI
NPYNDG7KYNEKFKGKATLTSDRSSSTAYMELSSLTSEDSAVYYCTRRLDE
AYWGQG7LVTVSA (SEQ ID NO:132)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 54 -
18E5vh GAGGICCAGOTGCAGCAGTOTGGACCTGAGOTGGTAAAGCCTGGGGCTGOA
GTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTCGCTATCTTATT
CACTGGGTGAAGCAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATATT
AATCCTTACAATGATGGTACTAAATATAATGAGAAGTTCAAAGGCAAGGCC
ACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGC
CTGACC7CTGAGGACTCTGCGGTCTATTACTGTACCTCTAATTGGGACCTC
GACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA (SEQ ID
NO: 133)
EVQLQQSGPELVKPGAAVKMSCKASGYTFTRYLIHWVKQKPGQGLEWIGYI
NPYNDGTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCTSNWDL
DYWGQGTTLTVSS (SEQ ID NO:134)
20E8vh GAGGICCAGCTGCAGCAGTCTGGACCTGAACTGGTAAAGCCTGGGGCTTCA
GTGAAGATGTCCIGCAAGGCCTCTGGATACACATTCACTAGTTCTGTTATG
CACTGGGTGAAGCAGAAGGCTGGGCAGGGCCTTGAGTGGATTGGATATATC
AATCCC-ATAATGATGGTACTCAGTACAATGAGAAGTTCAAAGGCAAGGCC
ACACTGACTTCAGACAAATTTTCCAGCACAGCCTACATGGAGCTCAGCAGC
CTGACC7CTGAGGACTCTGCGGTCTATTACTGTACAAGACGGTTGGACGAG
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID
NO: 135)
EVQLQQSGPELVKPGASVKMSCKASGYTFTSSVMHWVKQKAGQGLEWIGYI
NPYNDGTQYNEKFKGKATLTSDKESSTAYMELSSLTSEDSAVYYCTRRLDE
AYWGQ=VTVSA (SEQ ID NO:136)
22E2vh GAGGICCAOCTGCAGCAUTCTGGACCTGAGCTGOTAAAGCCTGGOGCTICA
GTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTAGCTOTATTATT
CACTGGGTGAAGCAGAGGCCTGGGCAGGGCCTTGAGTGGATTGGATATATT
AATCCTTACGATGATGITACTAAGTACAATGAGAAGTTCAAAGGCAAGGCC
ACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGC
CTCACCTCTGAGGACTCTCCGCTCTATTACTCTGCAAGACCGTCGGACGAC
TCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID
NO: 137)
EVQLQQSGPELVKPGASVKMSCKASGYTFTSSIIHWVKQRPGQGLEWIGYI
NPYDDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARRWDE
SYWGQGTLVTVSA (SEQ ID NO:138)
24A5vh GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCA
GTGAAGATGTCCTGCAAGGCTTCTGGATACACTTTCACTACCTCTATTATG
CACTGGGTGAAACAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATATT
AATCCTIACGATGATGITACTAAGTACAATGAAAAGTTCAAAGGCAAGGCC
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 55 -
ACAT TGACT TCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGC
CTGACCICTGAGGACTCTGCAGTCIATTACTGIGTAAGACGGIGGGACGAG
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID
NO: 139)
EVQLQQSGPELVKPGASVKMSCKASGYTETTSIMHWVKQKPGQGLEWIGYI
NPYDDVIKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCVRRWDE
AYWGQGCLVTVSA (SEQ ID NO:140)
26F7VH GAGGTCCAGCTGCAACAATCTGGACCTGAGCTGGTGAAGCCIGGGGCTTCA
GIGAAGATAICCIGTAAGGCTICICGATACACGTTIACIGACTACTACATG
AACTGGGTGAGGCAGAGCCATGGAGAGAGCCTTGAGTGGATIGGAGATTIT
AATCATAACAATGATGITATTACTIACAACCCGAAGTTCAAGGGCAAGGTC
ACATTGACTGTAGAGAAGTCTTCCACCACAGCCTACATGGAGCTCCGCAGC
CTGTCATCTGAGGACTCTGCAGTCIATTACTGIGCAAGGGGGCTACGAGGC
TACIATCCIATGGACTACTGGGGICAAGGAACCTCAGICACCGICTCCICA
(SEQ ID NO:141)
EVQLQQSGPELVKPGASVKISCKASGYIFTDYYMNWVRQSHGESLEWIGDF
NHNNDV-TYNPKEKGKVTLTVEKSSTTAYMELRSLSSEDSAVYYCARGLRG
YYAMDYWGQGTSVTVSS (SEQ ID NO:142)
27G8vh CAGGITCAGCTGCAACAGTCTGACGCTGAGTTGGTGAAACCTGGAGCTICA
GTGAAGATATCCIGCAAGGTTTCTGGCTACACCTTCACTGACCATACTATT
CACTGGATGAAGCAGAGGCCTGAACAGGGCCTGGAATGGATTGGATATATT
TATCCTAGAGATGGTTATCCTAAGITCAATGAGAAGTTCAAGGGCAAGGCC
ACAITGACTGCAGACAAATCCICCAGCACAGCCIACAIGCAGCTCAACAGC
CTGACACCTGAGGACTCTGCAGTCTATTICTGIGCAAGACGGCCCCCTTAC
TATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCGCCGTCTCCTCA
(SEQ ID NO:143)
QVQLQQSDAELVKPGASVKISCKVSGYTFTDHTIHWMKQRPEQGLEWIGYI
YPRDGYPKFNEKFKGKATLTADKSSSTAYMQLNSLTSEDSAVYFCARRPPY
YAMDYWGQGTSVAVSS (SEQ ID NO:144)
31H9vh GAGGICCAACTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCA
GTGAAGATGTCCTGCAAGGCTTCTGGATACACATTCACTAGGTATCTTATG
CACTGGGIGAAGCAGAAGCCIGGGCAGGGCCTIGAGIGGATIGGITATAIT
AATCCTIACAATGATGGTACTAATIACAATGAGAAGTTCAAAGGCAAGGCC
ACACTGACTTCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCAGCAGC
CTGACC7CTGAGGACTCTGCGGTCIATTACTGTTCCCTTAACTGGGACTAT
GCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID
NO: 145)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 56 -
EVQLQQSGPELVKPGASVKMS CKASGYTF TRYLMHWVKQKPGQGLEWI GY I
NPYNDGINYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCSLNWDY
AYWGQG7LVTVSA (SEQ ID NO:146)
34G3VH GAGTTCCAGOTGCAGCAGTCTGGACCTGAGOTGGTGAAGCCTGGCGCTTCA
GTGAAGATATCCIGCAAGGCTTCTGGTTACTCATTCACTGACTACAACATG
AACTGGGTGAAGCAGAGCAAAGGAAAGAGCCTTGAGTGGATTGGAGTAATT
ATTCCTAACTATGGTITTACTAGCTACAATCAGAACTTCAAGGGCAAGGCC
ACTTTGACTGTAGACCAGTCTTCCAGCACAGCCCACATGCACCTCAACAGT
GTGACA7CTGAGGACTCTGCAGTCTATTACTGTGTAAGAGATGGGGGAATA
CTCCICTGGTATCTCGATGTCTGGGGCACAGGGACCACGGICACCGTCTCC
TCA (SEQ ID NO:147)
EFQLQQSGPELVKPGASVKISCKASGYSFTDYNMNWVKQSKGKSLEWIGVI
IPNYGFISYNQNFKGKATLTVDUSSTAHMQLNSVTSEDSAVYYCVRDGGI
LLWYLDVWGTGTIVTVSS (SEQ ID NO:148)
34D9VH7 GAGGICCAGCTGCAACAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCA
GTGAAGATACCCIGCAAGGCTTCTGGATACACATTCACTGACTACAACATG
C4ACTTC4AA(-44A(-4AC;CCATC;(-4A4AC4AC4CrTTC;AC4TC;(-4ATTC4-4AC4ATATC
AATCCTCACAATGGTGGTACTATCTACAACCAGAAGTTCAAGGGCAAGGCC
ACATTGACTGTAGACAAGTCCTCCAGCACAGCCCACATGGAGCTCCGCAGC
CTGACA7CTGAGGACACTGCAGTCTATTACTGTGCAAGAAATTACTACGGT
AGTAG=ACGGCTGGTACTTCGATC,TCTGGGGCACAGGGACCACGGTCACC
GTCTCG7CA (SEQ ID NO:149)
EVQLQQSGPELVKPGASVKIPCKASGYTFTDYNMDWVKKSHGKSLEWIGDI
NPHNGG7IYNQKFKGKATLIVDKSSSTAHMELRSLISEDTAVYYCARNYYG
SSYGWYEDVWGTGTTVIVSS (SEQ ID NO:150)
43F5vh GAGGICCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTICA
GTGAAGATITCCIGCAGGGCTTCTGGTTACTCATTCACTGGCTACTACATG
AACTGGGTGAAGCAAAGTCCICAAAAGAGCCTTGAGTCGATTGGAGAGATT
ATTCCTACCACTGGTGGTACTTCCTACAACCAGAAGTTCAAGGCCAAGGCC
ACATTGACTGTAGACAAATCCTCCAGGACAGOCTACATGCAGCTCAAGAGC
CTGACATCTGAGGACTCTGCAGTCTATTACTGIGCAAGAGAGAGCGGIGGG
ITCTACTGGTACTTCGATGTCTGGGGCACAGGGACCACGGTCACCGTCTCC
TCA (SEQ ID NO:151)
EVQLQQSGPELVKPGASVKISCRASGYSFTGYYMNWVKQSPEKSLEWIGEI
IPTTGGTSYNQKEKAKATLTVDKSSSTAYMQLKSLTSEDSAVYYCARESGG
FYWYEDVWGTGTIVTVSS (SEQ ID NO:152)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 57 -
73H1OVH GAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCA
GTGAAGATGICCTGCAAGGCTICTGGATACACATTCACTAGGTATGITATG
CACTGGGTGAAGCAGAAGCCTGGGCAGGGCCTTGAGTGGATTGGATATATT
AATCCT7ACAATGATGITACTAAGTACAATGAGAAGTICAAAGGCAAGGCC
ACACTGACTTCAGACAGATCCTCCAGCACAGCCTACATGAAACTCAGGAGC
CTGACC7CTGAGGACTCTGCGGTCTATTATTGIGCAAGAAACTGGGACGIT
CCITACTGGGGCCAAGGGACTCTGATCACTGTCTCTGCA (SEQ ID
NO: 153)
EVQLQQSGPELVHPGASVKMSCKASGYTFTRYVMHWVKQKPGQGLEWIGYI
NPYNDV7KYNEKFKGKAILTSDRSSSTAYMKLSSLTSEDSAVYYCARNWDV
PYWGQGTLITVSA (SEQ ID NO:154)
74H3VH GAGGICCAGCTGCAGCAGTCTGGACCTGAGCTGGTAAAGCCIGGGGCTTCA
GTGAAGATGICCICCAAGGCTICTGGATACACATTCACTACGTAICITATG
CACTGGGTGAAGCAGAAGCCTGGACAGGGCCTTGAGTGGATTGGATATATT
AATCCT7ACAATGATGGTACTAAGTACAATGAGAGGITCAAAGGCAAGGCC
ACACTGACTTCAGACAAATCCTCCAGCACAGCGTACATGGAGCTCAGCAGC
CTGACC7CTGAGGACTCTGCGGTCTATTACTGIGCAAGAAACTGGGACGTA
CCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA (SEQ ID
NO: 155)
EVQLQQSGPELVKPCASVKMSGKASGYTFTRYLMHWVKQKPGQCLEWIGYI
NPYNDG7KYNERFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCARNWDV
PYWGQG7LVIVSA (SEQ ID NO:156)
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 58 -
Human framework sequences were selected for each of the mouse leads based on
the
framework homology, CDR structure, conserved canonical residues, conserved
interface
packing residues and other parameters.
The mouse light chain and heavy chain CDRs of the various mouse antibodies are
shown in Table 3 and Table 4, respectively. Table 4 also shows three heavy
chains
CDRs derived from the mouse antibody 6B8 through the humanization process.
CA 02871985 2014-10-28
WO 2013/165791 PCT/1JS2013/038109
- 59 -
Table 3: LIGHT CHAIN CDR sequences
L-CDR1 L-CDR2 L-CDR3
RASQSISEYLH YASQSIS QNGHSFPFT
18C4 (SEQ ID NO:1) (SEQ ID NO:2) (SEQ ID NO:3)
RASQSISDYLY FASQSIS QNGHSFPFT
18E5 (SEQ ID NO:4) (SEQ ID NO:5) (SEQ ID NO:3)
RASQSISDYLY FASQSIS QNGHSFPFT
1803 (SEQ ID NO:4) (SEQ ID NO:5) (SEQ ID NO:3)
RASQSISEYLH YASQSIS QNGHSFPFT
20E8 (SEQ ID NO:1) (SEQ ID NO:2) (SEQ ID NO:3)
RASQSISVYLH YASQSIS QNGHSFPFT
22E2 (SEQ ID NO:6) (SEQ ID NO:2) (SEQ ID NO:3)
RASQSISDYLH YASQSIS QNGHSFPFT
24A5 (SEQ ID NO:7) (SEQ ID NO:2) (SEQ ID NO:3)
RSSQSLVHSNGNTYLH KVSNRFS SQSTHVPYT
15C11 (SEQ ID NO:8) (SEQ ID NO:9) (SEQ ID NO:10)
RSSQSLVHSNGNTYLH KVSNRFS SQSTHVPYT
43F5 (SEQ ID NO:8) (SEQ ID NO:9) (SEQ ID NO:10)
RASKSVSTSGYSYIH LASNLDS QHSRELPYT
27G8 (SEQ ID NO:11) (SEQ ID NO:12) (SEQ ID NO:13)
RASQSISDYLH YASQSIS QNGHSFPYT
31H9 (SEQ ID NO:7) (SEQ ID NO:2) (SEQ ID NO:14)
RTSESVYSYGQNFIH RASNLES QQTNEDPYT
201 (SEQ ID NO:15) (SEQ ID NO:16) (SEQ ID NO:17)
RASETINFYGTSFMH RASNLES QQTNEDPYT
9012 (SEQ ID NO:18) (SEQ ID NO:16) (SEQ ID NO:17)
KASRDVAIAVA WASTRHT HQYSSYPFT
6B8 (SEQ ID NO:19) (SEQ ID NO:20) (SEQ ID NO:21)
RASENIDSYLA AARNLAD QHYYSTPFT
73H10 (SEQ ID NO:22) (SEQ ID NO:23) (SEQ ID NO:24)
CA 02871985 2014-10-28
WO 2013/165791 PCT/1JS2013/038109
- 60 -
RASENIDSYLA AATNLAD LHYYSTPFT
74H3 (SEQ ID NO:22) (SEQ ID NO:25) (SEQ ID
NO:26)
RSSQSLVHSNGNTYLH KVSNRFS SQSTHVPYT
35H8 (SEQ ID NO:8) (SEQ ID NO:9) (SEQ ID
NO:10)
RASKSVRFSDYFYMH LASNLES QNSRELPYT
26F7 (SEQ ID NO:27) (SEQ ID NO:28) (SEQ ID
NO:29)
RSSQSLVHSNGNTYLH KVSNRFS SQSTHVPYT
34G3 (SEQ ID NO:8) (SEQ ID NO:9) (SEQ ID
NO:10)
KASQDVGNAVV WASTRHI QQYSSYLT
3409 (SEQ ID NO:30) (SEQ ID NO:31) (SEQ ID
NO:32)
CA 02871985 2014-10-28
WO 2013/165791
PCT/1JS2013/038109
-61 -
Table 4: HEAVY CHAIN CDR sequences
H-CDR1 H-CDR2 H-CDR3
GYTFTSSVIH YINPYNDGTKYN EKFKG RLDEAY
18C4 (SEQ ID NO:33) (SEQ ID NO:34) (SEQ ID
NO:35)
GYTFTRYLIH YINPYNDGTKYN EKFKG NWDLDY
18E5 (SEQ ID NO:36) (SEQ ID NO:34) (SEQ ID
NO:37)
GYTFTRYLIH YINPYNDGTKYN EKFKG NWDLDY
18D3 (SEQ ID NO:36) (SEQ ID NO:34) (SEQ ID
NO:37)
GYTFTSSVMH YINPYNDGTQYNEKFKG RLDEAY
20E8 (SEQ ID NO:38) (SEQ ID NO:39) (SEQ ID
NO:35)
GYTFTSSI I H YINPYDDVTKYNEKFKG RWDESY
22E2 (SEQ ID NO:40) (SEQ ID NO:41) (SEQ ID
NO:42)
GYTFTTSIMH YINPYDDVTKYNEKFKG RWDEAY
24A5 (SEQ ID NO:43) (SEQ ID NO:41) (SEQ ID
NO:44)
GYTFTDYYMN VII PYNGGTSYNQKFKG DGHRWYFDV
15C11 (SEQ ID NO:45) (SEQ ID NO:46) (SEQ ID
NO:47)
GYSFTGYYMN El I PTTGGTSYNQKFKA ESGGFYWYFDV
43F5 (SEQ ID NO:48) (SEQ ID NO:49) (SEQ ID
NO:50)
GYTFTDHTIH YIYPRDGYPKFNEKFKG RPPYYAMDY
27G8 (SEQ ID NO:51) (SEQ ID NO:52) (SEQ ID
NO:53)
GYTFTRYLMH YINPYNDGTNYN EKFKG NWDYAY
31 H9 (SEQ ID NO:54) (SEQ ID NO:55) (SEQ ID
NO:56)
GFSLTTYAIS VIWTGGGTKYNSALKS KDYNYGGAMDY
201 (SEQ ID NO:57) (SEQ ID NO:58) (SEQ ID
NO:59)
GFSLNNFAIS AIWTGGGTNYNSALKS KDYSYGGAMDY
9D12 (SEQ ID NO:60) (SEQ ID NO:61) (SEQ ID
NO:62)
GNTFTDQTIH YIYPRDDSPKYN EN FKG PDRSGYAWFIY
6B8 (SEQ ID NO:63) (SEQ ID NO:64) (SEQ ID
NO:65)
GYTFTDQTIH YIYPRDDSPKYN EN FKG PDRSGYAWFIY
Hu_6B8-2 (SEQ ID NO:66) (SEQ ID NO:64) (SEQ ID
NO:65)
GFTFTDQTIH YIYPRDDSPKYN EN FKG PDRSGYAWFIY
Hu_6B8-5 (SEQ ID NO:67) (SEQ ID NO:64) (SEQ ID
NO:65)
CA 02871985 2014-10-28
WO 2013/165791 PCT/1JS2013/038109
- 62 -
Hu 6B8 GGTFTDQTIH YIYPRDDSPKYNENFKG PDRSGYAWFIY
-36/65 (SEQ ID NO:68) (SEQ ID NO:64) (SEQ ID NO:65)
GYTFTRYVMH YINPYNDVTKYNEKFKG NWDVPY
73H10 (SEQ ID NO:69) (SEQ ID NO:70) (SEQ ID NO:71)
GYTFTRYLMH YINPYNDGTKYNERFKG NWDVPY
74H3 (SEQ ID NO:54) (SEQ ID NO:72) (SEQ ID NO:71)
GYTFTDYYMN VII PYNGGISYNQKFKG NDYDWYFDV
35H8 (SEQ ID NO:45) (SEQ ID NO:73) (SEQ ID NO:74)
GYTFTDYYMN DFNHNNDVITYNPKFKG GLRGYYAMDY (SEQ
26F7 (SEQ ID NO:45) (SEQ ID NO:75) ID NO:76)
GYSFTDYNMN VII PNYGFTSYNQNFKG DGGILLWYLDV
34G3 (SEQ ID NO:77) (SEQ ID NO:78) (SEQ ID NO:79)
GYTFTDYNMD DINPHNGGTIYNQKFKG NYYGSSYGWYFDV
34D9 (SEQ ID NO:80) (SEQ ID NO:81) (SEQ ID NO:82)
The CDRs listed above in Tables 3 and 4 are defined using the Chothia
numbering
system (Al-Lazikani et al., (1997) JMB 273,927-948).
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 63 -
Fabs that showed better or equal binding as compared to the chimeric parent
Fab were
selected for conversion to IgG. 6B8 was converted to an IgG1K0 format. IgG1K0
(knock-out of effector functions) has two mutations in the Fc region,
Leu234Ala and
Leu235Ala, which reduce effector function such as FcyR and complement binding.
The
IgG format is described in the literature (see for example Hezareh et al.
(2001) Journal
of Virology 75: 12161-12168). Example 1 describes the humanization process in
further
detail. The results of such humanization resulted in humanized antibody
sequences. A
representative number of humanized light chain and heavy chain variable
regions
derived from mouse antibody 6B8 are provided and shown in Tables 5 and 6. An
alignment between the humanized light chain and heavy chain variable regions
derived
from mouse antibody 6B8 and the chain and heavy chain variable regions from
mouse
antibody 6B8 is shown in Figure 1.
Selected combination of humanized light chain and heavy chain variable regions
derived
from mouse antibody 6B8 resulted in Antibodies A, B, C and D:
Antibody A: 6B8-IgG1K0-2 with IgK-66 (heavy chain variable region 6B8CVH-02
and
light chain variable region 6B8CVK-66);
Antibody B: 6B8-IgG1K0-5 with IgK-66 (heavy chain variable region 6B8CVH-05
and
light chain variable region 6B8CVK-66);
Antibody C: 6138-IgG1K0-2 with IgK-65 (heavy chain variable region 6B8CVH-02
and
light chain variable region 6B8CVK-65);
Antibody D: 6138-IgG1K0-5 with IgK-65 (heavy chain variable region 6B8CVH-05
and
light chain variable region 6B8CVK-65).
Antibodies A, B, C and D have the heavy and light chain sequences shown in
Table 7.
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 64 -
Table 5: Humanized 6B8-VK Sequences
6B8CVK-65
Gacatccagatgacccagagcccaagcagcctgagcgccagcgtggg
cgaccgcgtgaccatcacctgcaaggccagccgcgacgtggccatcg
ccgtggcctggtaccagcagaagccaggcaaggtgccaaagctgctg
ctgttctgggccagcacccgccacaccggcgtgccagaccgcttcag
cggcagcggcagcggcaccgacttcaccctgaccatcagcagcctgc
agccagaggacctggccgactactactgccaccagtacagcagctac
ccattcaccttoggccagggcaccaagctggagatcaag (SEQ ID
NO: 157)
DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLL
LFWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDLADYYCHQYSSY
PFTFGQGTKLEIK (SEQ ID NO:158)
6B8CVK-66 Gacatccagatgacccagagcccaagcagcctgagcgccagcgtggg
cgaccgcgtgaccatcacctgcaaggccagccgcgacgtggccatcg
c_cyLyyucLyyLdcudyc:eyddyucayyuddyyLyccdadyLLycLy
atCtaCtgggCCagCaCCCgCCaCaCCggCgtgCCaagCCgCttCag
cggcagcggcagccgcaccgacttcaccctgaccatcagcagcctgc
agccagaggacgtggccgactacttctgccaccagtacagcagctac
ccattcaccttcggcagcggcaccaagctggagatcaag (SEQ ID
NO: 159)
DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLL
TYWASTRHTGVPSPFSC4SP,SRTDFTITTSSLOPFDVADYFrHQYSSY
PFTFGSGTKLEIK (SEQ ID NO:160)
6B8CVK-67 Gacatccagatgacccagagcccaagcagcctgagcgccagcgtggg
cgaccgcgtgaccatcacctgcaaggccagccgcgacgtggccatcg
ccgtggcctggtaccagcagaagccaggcaaggtgccaaagctgctg
ctgtactgggccagcacccgccacaccggcgtgccaagccgcttcag
cggcagcggcagccgcaccgacttcaccctgaccatcagcagcctgc
agccagaggacgtggccacctactactgccaccagtacagcagctac
ccattcaccttcggcagoggcaccaagctggagatcaag (SEQ ID
NO: 161)
DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLL
LYWASTRHTGVPSRFSGSGSRTDFTLTISSLQPEDVATYYCHQYSSY
PFTFGSGTKLEIK (SEQ ID NO:162)
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 65 -
6B 8CVK - 78
Gacatccagatgacccagagcccaagcagcctgagcgccagcgtggg
cgaccgcgtgaccatcacctgcaaggccagccgcgacgtggccatcg
ccgtggcctggtaccagcagaagccaggcaaggtgccaaagctgctg
ctgttctgggccagcacccgccacaccggcgtgccagaccgcttcag
oggcagoggcagccgcaccgacttcaccotgaccatcagcagcctgc
agccagaggacctggccgactactactgccaccagtacagcagctac
ccattcaccttoggcagcggcaccaagctggagatcaag (SEQ ID
NO: 163)
DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQQKPGKVPKLL
LFWASTRHTGVPDRESGSGSRTDETLTISSLQPEDLADYYCHQYSSY
PETFGSGTKLEIK (SEQ ID NO:164)
(OLT:ON GI OHS) SSAIA7I5O5MAI3MVX5SUGdIV3X
AAVICHSWISS=VaVISISHOVIIIA'USH3NHNXHdSOCUdXIADVI
MHJSO9dØ2JAMPIIIOGI3I55SVH3SIMASSOdMAHVDSOA70A0
(691:0N GI CEs) obeabpbgboo-2bgbbq000pobbbpoobbb
bqo-2qoTeoqqbbqopboeqobbobpoboopbppooqpoobobqoPq
opqbqbooboo-eaebbpboLpobobqocbpa5-2.6qa6pbEcTeoqop
boopobecouobube-2oubooboopoq-Eoppoqbaboobbbpuoggo
pp&eboepopqbppeocaU2opbopboboppoopqoTeo-eqobbbTe
bbgbpbbqoabbbpoobbeopobobpocbobqbbbqopooqpoopbp
ooebooecqqoopobbobbobuoobbp-2obqabpoopbpebqbabpo
bpobbpoobpebppbqbbeboabobbobpbeob.455q35-20.5.45bpD 9E-HAD8g9
(891 0N GI nas) SSAIA71,505MXI,3MVX5S.HUdIVOX
AAVIGHS211SS'IHWAVISISA.UViJIANHNANdSUCI2ddAlA5W
MHTSODEVMJAMHIIOGIZIZSSVN3SANASSOdH?lAHVSSOAq0A0
(L9T:o1 GI Cas) obe0bpfilbo3-2bT65qpo0120bbbp00bbb
bgo-pqoqpoqqbbqopboegobbobpaboop5p000Teoobobqopq
opqbqbooboo-eopbbpbobpobobqoobpobpbqabpbbTeoeqop
bpopofreoppobpbp-eopboaboopboopoqb6-2pabbbppoqqo
ppb-aboepopqbppepoob-2aebopbobopooppqcqpoeqabbbqp
F)F)ihp5hinnhhF)pp=n55pnnF)nF)-16F)F)inp=ipl-mpF)p
ooebopeoggoopoggobbobroobbp-2obgcbpbqbbp'ebgbobpo
bpobb-ecobpebppbqbbeboobobbobpbpobT55qobeobqbbpo 80-14A38g9,
(991:0N GI Oas) SSAIA7ISOSMXIZMVXSSUCdIV3A
XAVIGHSWISS'IHNAVISISHOVIIIAH5H3NIN=dSOGUdXIASI
MHMODdVO2IAMPIIOGIZIX5SVHDSAHASSDAHVSSOAqOAO
(891:ON GI as) obeabpbgbooabqbbq000PobbbPoobbb
bqopqoqpo4q.bbi_ooboeqobbobPoboopbpopoTeoabobqopq
opqbgboobopeopbbpbobpabobqoobpob-ebqobpbbqpo'egoo
booPob-eoppob-ebePoPboobo3PoT2oopoqb&epobbbppoqqo
ppb-pboe.paegbppepoob-2opbopbobop000pqoqpo'egobboqp
bbqbabbqoobbb-epobbec000bb-epobobTebbqo-eooTeopab-e,
ooeboopqq3opoegob53.5ppobbp-2a6-43bpbqbbe-ebqbobpo
bpobbPoobpebppbqbbeboobobbobpbpobqbbqob'eobqbbPD n-HA38E9
Gouanbas HA-299 pezpewnH :9 eiciP_L
- 99 -
60180/10ZSAIEM 16L01/10Z OM
8Z-0T-VTOU S86TL8Z0 VD
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 67 -
6B8CVH- 6 5 Caggtgcagctggtgcagagoggcgccgaggtgaagaagccaggcag
cagcgtgaaggtgagctgcaaggccagcggcggcaccttcaccgacc
agaccatccactgggtgcgocaggccccaggccagggcctggagtgg
atgggctacatctacccacgcgacgacagoccaaagtacaacgagaa
tttcaagggccgcgtcaccctgaccgccgacaagagcaccagcaccg
cctacatggagctgagcagcctgcgcagcgaggacaccgccgtgtac
ttctgcgcccgcccagaccgcagoggctacgcctggttcatctactg
gggccagggcaccctggtgaccgtgagcagc (SEQ ID NO:171)
QVQLVQSGAEVKKPGSSVKVSCKASGGTFTDQTIHWVRQAPGQGLEW
MGYIYPRDDSPKYNENFKGRVTLTADKSTSTAYMELSSLRSEDTAVY
FCARPDRSGYAWFIYWGQGTLVTVSS (SEQ ID NO: 172)
CA 02871985 2014-10-28
WO 2013/165791 PCT/1JS2013/038109
- 68 -
Table 7: Heavy and Light Chain DNA and Amino Acid Sequences for Antibodies A,
B, C,
and D
Antibody A IgK Gacatccagatgacccagagcccaagcagcctgagcg
light ccagcgtgggcgaccgcgtgaccatcacctgcaaggc
Chain cagccgcgacgtggccatcgccgtggcctggtaccag
#66 cagaagccaggcaaggtgccaaagctgctgatct act
gggccagcacccgccacaccggcgtgccaagccgctt
cagcggcagcggcagccgcaccgacttcaccctgacc
atcagcagcctgcagccagaggacgtggccgactact
tctgccaccagtacagcagctacccattcaccttcgg
cagcggcaccaagctggagatcaagcgtactgtggct
gcaccatctgtcttcatcttcccgccatctgatgagc
agttgaaatctggaactgcctctgttgtgtgcctgct
gaataacttctatcccagagaggccaaagtacagtgg
aaggtggataacgccctccaatcgggtaactcccagg
agagtgtcacagagcaggacagcaaggacagcaccta
cagcctcagcagcaccctgacgctgagcaaagcagac
tacgagaaacacaaagtctacgcctgcgaagtcaccc
atcagggcctgagctcgcccgtcacaaagagcttcaa
caggggagagtgt (SEQ ID NO:173)
DIQMTQSPSSLSASVGDRVTITCKASRDVAIAVAWYQ
QKPGKVPKLLIYWASTRHTGVPSRFSGSGSRTDFTLT
ISSLQPEDVADYFCHQYSSYPFTEGSGTKLEIKRTVA
APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKAD
YEKHKVYACEVTHQGLSSPVTKSENRGEC (SEQ ID
NO: 174)
Ig01 KO Caqqtqcagctqqtqcagagccmcgccciacmtgaacia
Heavy agccaggcagcagcgtgaaggtgagctgcaaggccag
Chain cggctacaccttcaccgaccagaccatccactggatg
#2 cgccaggccccaggccagggcctggagtggatcggct
acatctacccacgcgacgacagcccaaagtacaacga
gaacttcaagggcaaggtcaccatcaccgccgacaag
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 69 -
agcaccagcaccgcctacatggagctgagcagcctgc
gcagcgaggacaccgccgtgtactactgcgccatccc
agacccicagcggctacgcctggttcatctactgoicigc
cagggcaccctggtgaccgtgagcagcgcctccacca
agggcccatoggtottcccoctggcaccotcctccaa
gagcacctctgggggcacagcggccctgggctgcctg
gtcaaggactacttccccgaaccggtgacggtgtcgt
ggaactcaggcgccctgaccageggcgtgcacacctt
cccggctgtoctacagtoctcaggactotactccctc
agcagcgtggtgaccgtgccctccagcagcttgggca
cccagacctacatctgcaacgtgaatcacaagcccag
raaracraaggtrgaraagagagttgagcccaaatct
tgtgacaaaactcacacatgcccaccgtgcccagcac
cagaagctgctgggggaccgtcagtottcctcttocc
cccaaaacccaaggacaccctcatgatctccoggacc
cctgaggtcacatgcgtcgtggtggacgtgagccacg
aagaccctgaggtcaagttcaactggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggag
gagcagtacaacagcacgtaccgtgtggtcagcgtcc
tcaccgtcctgcaccaggactggctgaatggcaagga
gtacaagtgcaaggtctccaacaaagccctcccagcc
cccatcgagaaaaccatctccaaagccaaagggcagc
occgagaaccacaggtgtacaccotgoccccatoccg
ggaggagatgaccaagaaccaggtcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtgg
agtgggagagcaatgggcagccggagaacaactacaa
gaccacgcctcccgtgctggactccgacggctccttc
ttcctctacagcaagctcaccgtggacaagagcaggt
ggcagcaggggaacgtcttctcatgctccgtgatgca
tgaggctctgcacaaccactacacgcagaagagcctc
tccctgtctccgggt (SEQ ID NO:175)
OVOLVOSGAEVKKPGSSVKVSCKASGYTFTDOTIHWM
ROAPGOGLEWIGYIYPRDDSPKYNENFKGKVTITADK
STSTAYMELSSLRSEDTAVYYCAIPDRSGYAWFIYWG
OGILVIVSSASTKOPSVFPLAPSSKSTSGGTAALGCL
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 70 -
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS
CDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSF
FLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSL
SLSPG (SEQ ID NO:176)
Antibody B IgK (SEQ ID NO:173)
light
Chain
#66
(SEQ ID NO:174)
IgG1K0 caggtgcagctggtgcagagcggcgccgaggtgaaga
Heavy agccaggcagcagcgtgaaggtgagctgcaaggccag
Chain cggcttcaccttcaccgaccagaccatccactgggtg
#5 cgccaggccccaggccacmgcctggagtggatggcfct
acatctacccacgcgacgacagcccaaagtacaacga
gaacttcaagggcaaggtcaccctgaccgccgacaag
agcaccagcaccgcctacatqqagctqagcagcctgc
gcagcgaggacaccgccgtgtactactgcgccatccc
agaccgcagcggctacgcctggttcatctactggggc
cagggcaccctggtgaccgtgagcagcgcctccacca
agggcccatcggtottcccoctggcaccctoctccaa
gagcacctotgggggcacagoggccctgggctgcctg
gtcaaggactacttccccgaaccggtgacggtgtcgt
ggaactcaggcgccctgaccagcggcgtgcacacctt
cccggctgtcctacagtcctcaggactctactccctc
agcagcgtggtgaccgtgccctccagcagcttgggca
cccagacctacatctgcaacgtgaatcacaagcccag
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
-71 -
caacaccaaggtcgacaagagagttgagcccaaatct
tgtgacaaaactcacacatgcccaccgtgcccagcac
cagaagctgctgggggaccgtcagtcttcctcttccc
cccaaaacccaaggacaccotcatgatctoccggacc
cctgaggtcacatgcgtcgtggtggacgtgagccacg
aagaccctgaggtcaagttcaactggtacgtggacgg
cgtggaggtgcataatgccaagacaaagccgcgggag
gagcagtacaacagcacgtaccgtgtggtcagcgtcc
tcaccgtcctgcaccaggactggctgaatggcaagga
gtacaagtgcaaggtctccaacaaagccctcccagcc
cccatcgagaaaaccatctccaaagccaaagggcagc
cccgagaaccacaggtgtacaccctgoccecatcccg
ggaggagatgaccaagaaccaggtcagcctgacctgc
ctggtcaaaggcttctatcccagcgacatcgccgtgg
agtgggagagcaatgggcagccggagaacaactacaa
gaccacgcctcccgtgctggactccgacggctccttc
ttcctotacagcaagctcaccgtggacaagagcaggt
ggcagcaggggaacgtcttctcatgctccgtgatgca
tgaggctctgcacaaccactacacgcagaagagcctc
tccctgtctccgggt (SEQ ID NO:177)
OVOLVOSGAEVKKPGSSVKVSCKASGFTFTDOTIHWV
ROAPGOGLEWMGYIYPRDDSPKYNENFKGKVTLTADK
STSTAYMELSSLRSEDTAVYYCAIDDRSCYAWFIYWC
OGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL
VKDYFPEPVIVSWNSGALTSGVHTFPAVLOSSGLYSL
SSVVTVPSSSLGTQTYIONVNHKPSNIKVDKRVEPKS
CDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRT
PEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHODWLNGKEYKOKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSREEMTKNOVSLTC
LVKGFYPSDIAVEWESNGOPENNYKTIPPVLDSDGSF
FLYSKLTVDKSRWOOGNVFSCSVMHEALHNHYTOKSL
SLSPG (SEO ID NO:178)
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 72 -
Antibody C IgK Gacatccagatgacccagagcccaagcagcctgagcg
light ccagcgtgggcgaccgcgtgaccatcacctgcaaggc
Chain cagccgcgacgtggccatcgccgtggcctggtaccag
#65 cagaagccaggcaaggtgccaaagctgctgctgttct
gggccagcacccgccacaccggcgtgccagaccgctt
cagcggcagcggcagcggcaccgacttcaccctgacc
atcagcagcctgcagccagaggacctggccgactact
actgccaccagtacagcagctacccattcaccttcgg
ccagggcaccaagctggagatcaagcgtactgtggct
gcaccatctgtcttcatcttcccgccatctgatgagc
agttgaaatctggaactgcctctgttgtgtgcctgct
gaataacttctatoccagagaggccaaagtacagtgg
aaggtggataacgccctccaatcgggtaactcccagg
agagtgtcacagagcaggacagcaaggacagcaccta
cagcctcagcagcaccctgacgctgagcaaagcagac
tacgagaaacacaaagtctacgcctgcgaagtcaccc
atcagggcctgagctcgcccgtcacaaagagcttcaa
caggggagagtgt (SEQ ID NO:179)
DIONTOSPSSLSASVGDRVTITCKASRDVAIAVAWYQ
OKPGKVPKLLLFWASTRHIGVPDRFSGSGSGTDFTLT
ISSLOPEDLADYYCHOYSSYPFTFGQGTKLEIKRTVA
APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW
KVDNALQSCNSQESVTEQDSKDSTYSLSSTLILSKAD
YEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID
NO: 180)
IgG1K0 (SEQ ID NO:175)
Heavy
Chain
#2
(SEQ ID NO:176)
CA 02871985 2014-10-28
WO 2013/165791
PCT/1JS2013/038109
- 73 -
Antibody D IgK (SEQ ID NO:179)
light
Chain
#65
(SEQ ID NO:180)
IgG1K0 (SEQ ID NO:177)
Heavy
Chain
#5
(SEQ ID NO:178)
Light chains and heavy chain variable regions of Antibodies A, B, C, and D are
underlined in Table 7 above.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 74 -
In one aspect, a humanized anti-IL-23p19 antibody of the present invention has
at least
one of the properties below. In a further aspect, a humanized anti-IL-23p19
antibody of
the present invention has any combination of at least two, or at least 3, 4,
5, 6, 7, 8, 9,
10, or 11 of the properties below. In a further aspect, a humanized anti-IL-
23p19
antibody of the present invention has all the properties below.
= KD for human IL-23 1 pM (no shift in binding on-rate in 50% human serum)
= Blocks IL-23 binding to human IL-23R/Fc in vitro
= No binding to human IL-12
= Inhibits human IL-23 induced IL-17 production in mouse splenocytes with
IC50's 20
pM
= Inhibits human IL-23 induced STAT3 phosphorylation in human DB cells with
10505
40 pM
= No predicted activity in ADCC/CDC
= KD <1 pM for cynomolgus monkey IL-23
= No cross reactivity to mouse or rat IL-23
= Inhibits human IL-23 induced IL-17 and IL-22 production in mouse ear
(>80% inhibition
of both cytokines at 1 mg/kg)
= Stability 83 C (melting temperature 83 C as determined by differential
scanning
calorimetry)
= Solubility >100 mg/ml (as measured by UV spectroscopy and monitored by
turbidity)
= Subcutaneous administration of 1.0 mg/kg in three cynomolgus monkeys
shows
sustained 10 nM exposure for approximately 28 days with a bioavailability of
approximately 70%.
By no predicted activity in ADCC/DC, it is meant herein that a humanized anti-
IL-23p19
antibody of the present invention has reduced affinity to Fe receptor and
therefore is
predicted not to have activity in ADCC/CDC.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 75 -
In one aspect, a humanized anti-IL-23p19 antibody of the present invention has
at least
one of the properties below. In a further aspect, a humanized anti-IL-23p19
antibody of
the present invention has any combination of at least two, or at least 3, 4,
5, 6, 7, 8, 9, or
of the properties below. In a further aspect, a humanized anti-IL-23p19
antibody of
5 the present invention has all the properties below.
= KD for human IL-23 1 pM (no shift in binding on-rate in 50% human serum)
= Blocks IL-23 binding to human IL-23R/Fc in vitro
= No binding to human IL-12
= Inhibits human IL-23 induced IL-17 production in mouse splenocytes with
1050's 20
10 pM
= Inhibits human IL-23 induced STAT3 phosphorylation in human DB cells with
1050's
40 pM
= No predicted activity in ADCC/CDC
= KD <1 pM for cynomolgus monkey IL-23
= No cross reactivity to mouse or rat IL-23
= Inhibits human IL-23 induced IL-17 and IL-22 production in mouse ear
(>80% inhibition
of both cytokines at 1 mg/kg)
= Stability 83 C (melting temperature 83 C as determined by differential
scanning
calorimetry)
= Solubility >100 mg/ml (as measured by UV spectroscopy and monitored by
turbidity).
In a further aspect, a humanized antibody of the present invention has at
least one of
the following binding properties (properties A). In a further aspect, a
humanized anti-IL-
23p19 antibody of the present invention has any combination of at least two,
or at least
3, of the properties below. In a further aspect, a humanized anti-IL-23p19
antibody of the
present invention has all the properties below.
= KD for human IL-23 1 pM (no shift in binding on-rate in 50% human serum)
= No binding to human IL-12
= KD <1 pM for cynomolgus monkey IL-23
= No cross reactivity to mouse or rat IL-23.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 76 -
In particular, a humanized antibody of the present invention has a KD for
human IL-23
1 pM (no shift in binding on-rate in 50% human serum) and no binding to human
IL-12.
In a further aspect, a humanized antibody of the present invention has at
least one of
the following functional properties (properties B). In a further aspect, a
humanized anti-
IL-23p19 antibody of the present invention has any combination of at least
two, or at
least 3, of the properties below. In a further aspect, a humanized anti-IL-
23p19 antibody
of the present invention has all the properties below.
= Blocks IL-23 binding to human IL-23R/Fc in vitro
= Inhibits human IL-23 induced IL-17 production in mouse splenocytes with
1050's 20
PM
= Inhibits human IL-23 induced STAT3 phosphorylation in human DB cells with
1050's
40 pM
= Inhibits human IL-23 induced IL-17 and IL-22 production in mouse ear
(>80% inhibition
of both cytokines at 1 mg/kg).
In a further aspect, a humanized antibody of the present invention has at
least one of
the following properties (properties C). In a further aspect, a humanized anti-
IL-23p19
antibody of the present invention has any combination of at least two, or at
least 3, of
the properties below. In a further aspect, a humanized anti-IL-23p19 antibody
of the
present invention has all the properties below.
= No predicted activity in ADCC/CDC
= Stability 83 C (melting temperature 83 C as determined by differential
scanning
calorimetry)
= Solubility >100 mg/ml (as measured by UV spectroscopy and monitored by
turbidity)
= Subcutaneous administration of 1.0 mg/kg in three cynomolgus monkeys
shows
sustained 10 nM exposure for approximately 28 days with a bioavailability of
approximately 70%.
In a further aspect, a humanized antibody of the present invention has at
least one of
the following properties (properties C). In a further aspect, a humanized anti-
IL-23p19
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 77 -
antibody of the present invention has any combination of at least two of the
properties
below. In a further aspect, a humanized anti-IL-23p19 antibody of the present
invention
has all the properties below.
= No predicted activity in ADCC/CDC
= Stability 83 C (melting temperature 83 C as determined by differential
scanning
calorimetry)
= Solubility >100 mg/ml (as measured by UV spectroscopy and monitored by
turbidity).
In a further aspect, a humanized antibody of the present invention has at
least one
property A, at least one property B and at least one property C. In a further
aspect, a
humanized anti-IL-23p19 antibody of the present invention has any combination
of at
least two, or at least 3, of the properties A, B, and C.
In some aspects, the humanized antibody displays blocking activity, whereby it
decreases the binding of IL-23 to IL-23 receptor by at least 45%, by at least
50%, by at
least 55%, by at least 60%, by at least 65%, by at least 70%, by at least 75%,
by at least
80%, by at least 85%, by at least 90%, or by at least 95%. The ability of an
antibody to
block binding of IL-23 to the IL-23 receptor can be measured using competitive
binding
assays known in the art. Alternatively, the blocking activity of an antibody
can be
measured by assessing the biological effects of IL-23, such as the production
of IL-17
and IL-22 to determine if signaling mediated by the IL-23 receptor is
inhibited.
In a further aspect, the present invention provides a humanized anti-IL-23p19
antibody
having favorable biophysical properties. In one aspect, a humanized anti-IL-
23p19
antibody of the present invention is present in at least 90% monomer form, or
in at least
92% monomer form, or in at least 95% monomer form in a buffer. In a further
aspect, a
humanized anti-IL-23p19 antibody of the present invention remains in at least
90%
monomer form, or in at least 92% monomer form, or in at least 95% monomer form
in a
buffer for one month or for four months.
In one aspect, a humanized antibody of the present invention is Antibody A,
Antibody B,
Antibody C or Antibody D. Accordingly, in one embodiment, a humanized antibody
of the
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 78 -
present invention comprises the light chain sequence of SEQ ID NO:174 and the
heavy
chain sequence of SEQ ID NO:176 (Antibody A). In another embodiment, a
humanized
antibody of the present invention comprises the light chain sequence of SEQ ID
NO:174
and the heavy chain sequence of SEQ ID NO:178 (Antibody B). In another
embodiment,
a humanized antibody of the present invention comprises the light chain
sequence of
SEQ ID NO:180 and the heavy chain sequence of SEQ ID NO:176 (Antibody C). In
another embodiment, a humanized antibody of the present invention comprises
the light
chain sequence of SEQ ID NO:180 and the heavy chain sequence of SEQ ID NO:178
(Antibody D).
.. In a further embodiment, a humanized antibody of the present invention
consists of the
light chain sequence of SEQ ID NO:174 and the heavy chain sequence of SEQ ID
NO:176 (Antibody A). In a further embodiment, a humanized antibody of the
present
invention consists of the light chain sequence of SEQ ID NO:174 and the heavy
chain
sequence of SEQ ID NO:178 (Antibody B). In a further embodiment, a humanized
antibody of the present invention consists of the light chain sequence of SEQ
ID NO:180
and the heavy chain sequence of SEQ ID NO:176 (Antibody C). In a further
embodiment, a humanized antibody of the present invention consists of the
light chain
sequence of SEQ ID NO:180 and the heavy chain sequence of SEQ ID NO:178
(Antibody D).
.. In some embodiments, the humanized anti-IL-23p19 antibodies, including
antigen-
binding fragments thereof, such as heavy and light chain variable regions,
comprise an
amino acid sequence of the residues derived from Antibody A (light chain
sequence =
SEQ ID NO:174; heavy chain sequence = SEQ ID NO:176), Antibody B (light chain
sequence = SEQ ID NO:174; heavy chain sequence = SEQ ID NO:178), Antibody C
(light chain sequence = SEQ ID NO:180; heavy chain sequence = SEQ ID NO:176)
or
Antibody D (light chain sequence = SEQ ID NO:180; heavy chain sequence = SEQ
ID
NO:178).
In a further embodiment, the present invention provides an anti-IL-23p19
antibody or an
antigen-binding fragment thereof that binds to human IL-23p19 at an epitope
consisting
of amino acid residues 108 to 126 and amino acid residues 137 to 151 of SEQ ID
NO:
181.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 79 -
In a further embodiment, the present invention provides an anti-IL-23p19
antibody or
antigen-binding fragment thereof that competitively binds to human IL-23p19
with an
antibody of the present invention, for example Antibody A, Antibody B,
Antibody C or
Antibody D described herein. The ability of an antibody or antigen-binding
fragment to
competitively bind to IL-23p19 can be measured using competitive binding
assays
known in the art.
The humanized anti-IL-23p19 antibodies optionally include specific amino acid
substitutions in the consensus or germline framework regions. The specific
substitution
of amino acid residues in these framework positions can improve various
aspects of
antibody performance including binding affinity and/or stability, over that
demonstrated
in humanized antibodies formed by "direct swap" of CDRs or HVLs into the human
germline framework regions.
In some embodiments, the present invention describes other monoclonal
antibodies with
a light chain variable region having the amino acid sequence set forth in of
SEQ ID NO:
84, 86, 88, 90, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115,
117 or 119. In
some embodiments, the present invention describes other monoclonal antibodies
with a
heavy chain variable region having the amino acid sequence set forth in of SEQ
ID NO:
121, 123, 125, 127, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148,
150, 152,
154 or 156 (see Tables 1 and 2 above). The CDR sequence of these mouse
antibodies
are shown in Tables 3 and 4. Placing such CDRs into FRs of the human consensus
heavy and light chain variable domains will yield useful humanized antibodies
of the
present invention.
In particular, the present invention provides monoclonal antibodies with the
combinations of light chain variable and heavy chain variable regions of SEQ
ID
NO:84/121, 86/123, 88/125, 90/127, 91/128, 93/130, 95/132, 97/134, 99/136,
101/138,
103/140, 105/142, 107/144, 109/146, 111/148, 113/150, 115/152, 117/154 or
119/156.
Such variable regions can be combined with human constant regions.
In some embodiments, the present invention describes other humanized
antibodies with
light chain variable region sequences having the amino acid sequence set forth
in of
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 80 -
SEQ ID NO:158, 160, 162 or 164. In some embodiments, the present invention
describes other humanized antibodies with heavy chain variable region
sequences
having the amino acid sequence set forth in of SEQ ID NO:166, 168, 170 or 172
(see
Tables 5 and 6 above). The CDR sequences of these antibodies are shown in
Tables 3
and 4. In particular, the present invention provides monoclonal antibodies
with the
combinations of light chain variable and heavy chain variable regions of SEQ
ID NO:
160/166, 160/168, 158/166 or 158/168. Such variable regions can be combined
with
human constant regions.
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:160 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain light
chain amino
acid sequence of SEQ ID NO:160 and a humanized heavy chain variable domain
comprising the CDRs of SEQ ID NO:166 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain heavy
chain
amino acid sequence of SEQ ID NO:166. In one embodiment, the anti-IL-23p19
antibody is a humanized monoclonal antibody.
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:160 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain light
chain amino
acid sequence of SEQ ID NO:160 and a humanized heavy chain variable domain
comprising the CDRs of SEQ ID NO:168 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain heavy
chain
amino acid sequence of SEQ ID NO:168. In one embodiment, the anti-IL-23p19
antibody is a humanized monoclonal antibody.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 81 -
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:158 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain light
chain amino
acid sequence of SEQ ID NO:158 and a humanized heavy chain variable domain
comprising the CDRs of SEQ ID NO:166 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain heavy
chain
amino acid sequence of SEQ ID NO:166. In one embodiment, the anti-IL-23p19
antibody is a humanized monoclonal antibody.
In a further embodiment, the present invention relates to an anti-IL-23p19
antibody or
antigen-binding fragment thereof comprising a humanized light chain variable
domain
comprising the CDRs of SEQ ID NO:158 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain light
chain amino
acid sequence of SEQ ID NO:158 and a humanized heavy chain variable domain
comprising the CDRs of SEQ ID NO:168 and framework regions having an amino
acid
sequence at least 90% identical, at least 93% identical or at least 95%
identical to the
amino acid sequence of the framework regions of the variable domain heavy
chain
amino acid sequence of SEQ ID NO:168. In one embodiment, the anti-IL-23p19
antibody is a humanized monoclonal antibody.
In some specific embodiments, the humanized anti-IL-23p19 antibodies disclosed
herein
comprise at least a heavy or a light chain variable domain comprising the CDRs
or HVLs
of the murine monoclonal antibodies or humanized antibodies as shown in Tables
1
through 6 above and the FRs of the human germline heavy and light chain
variable
domains.
The CDRs of these sequences are shown in Tables 3 and 4. Accordingly, in one
aspect, the present invention provides an anti-IL-23p19 antibody or antigen-
binding
fragment thereof comprising a light chain CDR1 (L-CDR1) sequence of SEQ ID
NO:1, 4,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 82 -
6, 7, 8, 11, 15, 18, 19, 22, 27 or 30; a light chain CDR2 (L-CDR2) sequence of
SEQ ID
NO:2, 5, 9, 12, 16, 20, 23, 25, 28 or 31; a light chain CDR3 (L-CDR3) sequence
of SEQ
ID NO:3, 10, 13, 14, 17, 21, 24, 26, 29, or 32; a heavy chain CDR1 (H-CDR1)
sequence
of SEQ ID NO:33, 36, 38, 40, 43, 45, 48, 51, 54, 57, 60, 63, 66, 67, 68, 69,
77 or 80; a
heavy chain CDR2 (H-CDR2) sequence of SEQ ID NO:34, 39, 41, 46, 49, 52, 55,
58,
61, 64, 70, 72, 73, 75, 78 or 81; and a heavy chain CDR3 (H-CDR3) sequence of
SEQ
ID NO:35, 37, 42, 44, 47, 50, 53, 56, 59, 62, 65, 71, 74, 76, 79 or 82. In one
aspect, the
anti-IL-23p19 antibody or antigen-binding fragment thereof comprises a light
chain
variable region comprising a L-CDR1 listed above, a L-CDR2 listed above and a
L-
CDR3 listed above, and a heavy chain variable region comprising a H-CDR1
listed
above, a H-CDR2 listed above and a H-CDR3 listed above.
In a further aspect, the present invention provides an anti-IL-23p19 antibody
or antigen-
binding fragment thereof comprising:
a) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:1, 2, 3, 33, 34, and 35, respectively; or
b) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:4, 5, 3, 36, 34 and 37, respectively; or
c) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:1, 2, 3, 38, 39 and 35, respectively; or
d) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:6, 2, 3, 40, 41 and 42, respectively; or
e) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:7, 2, 3, 43, 41 and 44, respectively; or
f) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:8, 9, 10, 45, 46 and 47, respectively; or
g) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:8, 9, 10, 48, 49 and 50, respectively; or
h) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:11, 12, 13, 51, 52 and 53, respectively; or
i) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:7, 2, 14, 54, 55 and 56, respectively; or
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 83 -
j) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:15, 16, 17, 57,58 and 59, respectively; or
k) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:18, 16, 17, 60,61 and 62, respectively; or
I) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:19, 20, 21, 63, 66, 67 or 68, 64 and 65, respectively;
or
m) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:22, 23, 24, 69, 70 and 71, respectively; or
n) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:22, 25, 26, 55, 72 and 71, respectively; or
o) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:8, 9, 10, 45, 73 and 74, respectively; or
p) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:27, 28, 29, 45, 75 and 76, respectively; or
q) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:8, 9, 10, 77, 78 and 79, respectively; or
r) a L-CDR1, a L-CDR2, a L-CDR3, a H-CDR1, a H-CDR2 and a H-CDR3
sequence of SEQ ID NO:30, 31, 32, 80, 81 and 82, respectively.
In one aspect, the anti-IL-23p19 antibody or antigen-binding fragment thereof
comprises
a light chain variable region comprising a L-CDR1, L-CDR2 and L-CDR3
combination
listed above, and a heavy chain variable region comprising a H-CDR1, H-CDR2
and H-
CDR3 combination listed above.
In specific embodiments, it is contemplated that chimeric antibodies with
switched CDR
regions (i.e., for example switching one or two CDRs of one of the mouse
antibodies or
humanized antibody derived therefrom with the analogous CDR from another mouse
antibody or humanized antibody derived therefrom) between these exemplary
immunoglobulins may yield useful antibodies.
In certain embodiments, the humanized anti-IL-23p19 antibody is an antibody
fragment.
Various antibody fragments have been generally discussed above and there are
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 84 -
techniques that have been developed for the production of antibody fragments.
Fragments can be derived via proteolytic digestion of intact antibodies (see,
e.g.,
Morimoto et al., 1992, Journal of Biochemical and Biophysical Methods 24:107-
117; and
Brennan et al., 1985, Science 229:81). Alternatively, the fragments can be
produced
directly in recombinant host cells. For example, Fab'-SH fragments can be
directly
recovered from E. coli and chemically coupled to form F(ab1)2 fragments (see,
e.g.,
Carter et al., 1992, Bio/Technology 10:163-167). By another approach, F(a131)2
fragments can be isolated directly from recombinant host cell culture. Other
techniques
for the production of antibody fragments will be apparent to the skilled
practitioner.
Accordingly, in one aspect, the present invention provides antibody fragments
comprising the CDRs described herein, in particular one of the combinations of
L-CDR1,
L-CDR2, L-CDR3, H-CDR1, H-CDR2 and H-CDR3 described herein. In a further
aspect,
the present invention provides antibody fragments comprising the variable
regions
described herein, for example one of the combinations of light chain variable
regions
and heavy chain variable regions described herein.
Certain embodiments include an F(ab')2 fragment of a humanized anti-IL-23p19
antibody
comprise a light chain sequence of any of SEQ ID NO: 174 or 180 in combination
with a
heavy chain sequence of SEQ ID NO: 176 or 178. Such embodiments can include an
intact antibody comprising such an F(ab')2.
In some embodiments, the antibody or antibody fragment includes a constant
region that
mediates effector function. The constant region can provide antibody-dependent
cellular
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and/or
complement-dependent cytotoxicity (CDC) responses against an IL-23 expressing
target
cell. The effector domain(s) can be, for example, an Fc region of an Ig
molecule.
The effector domain of an antibody can be from any suitable vertebrate animal
species
and isotypes. The isotypes from different animal species differ in the
abilities to mediate
effector functions. For example, the ability of human immunoglobulin to
mediate CDC
and ADCC/ADCP is generally in the order of IgM=IgG1--zIgG3>IgG2>IgG4 and
IgG1rzIgG3>IgG2/1gM/Iga4, respectively. Murine immunoglobulins mediate CDC and
ADCC/ADCP generally in the order of murine 10.0--IgG3>AgG2bAgG2a IgGi and
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 85 -
IgG2b>IgG2a>lgal IgG3, respectively. In another example, murine IgG2. mediates
ADCC while both murine IgG2. and IgM mediate CDC.
Antibody Modifications
The humanized anti-IL-23p19 antibodies and agents can include modifications of
the
humanized anti-IL-23p19 antibody or antigen-binding fragment thereof. For
example, it
may be desirable to modify the antibody with respect to effector function, so
as to
enhance the effectiveness of the antibody in treating cancer. One such
modification is
the introduction of cysteine residue(s) into the Fc region, thereby allowing
interchain
disulfide bond formation in this region. The homodimeric antibody thus
generated can
have improved internalization capability and/or increased complement-mediated
cell
killing and/or antibody-dependent cellular cytotoxicity (ADCC). See, for
example, Caron
et al., 1992, J. Exp Med. 176:1191-1195; and Shopes, 1992, J. lmmunol.
148:2918-
2922. Homodimeric antibodies having enhanced anti-tumor activity can also be
prepared using heterobifunctional cross-linkers as described in Wolff et al.,
1993,
Cancer Research 53: 2560-2565. Alternatively, an antibody can be engineered to
contain dual Fc regions, enhancing complement lysis and ADCC capabilities of
the
antibody. See Stevenson et al., 1989, Anti-Cancer Drug Design 3:219-230.
Antibodies with improved ability to support ADCC have been generated by
modifying the
glycosylation pattern of their Fc region. This is possible since antibody
glycosylation at
the asparagine residue, N297, in the CH2 domain is involved in the interaction
between
IgG and Fcy receptors prerequisite to ADCC. Host cell lines have been
engineered to
express antibodies with altered glycosylation, such as increased bisecting N-
acetylglucosamine or reduced fucose. Fucose reduction provides greater
enhancement
to ADCC activity than does increasing the presence of bisecting N-
acetylglucosamine.
Moreover, enhancement of ADCC by low fucose antibodies is independent of the
FcyRIlla V/F polymorphism.
Modifying the amino acid sequence of the Fc region of antibodies is an
alternative to
glycosylation engineering to enhance ADCC. The binding site on human IgGi for
Fcy
receptors has been determined by extensive mutational analysis. This led to
the
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 86 -
generation of humanized Igai antibodies with Fc mutations that increase the
binding
affinity for FcyRIlla and enhance ADCC in vitro. Additionally, Fc variants
have been
obtained with many different permutations of binding properties, e.g.,
improved binding
to specific FcyR receptors with unchanged or diminished binding to other FcyR
receptors.
Another aspect includes immunoconjugates comprising the humanized antibody or
fragments thereof conjugated to a cytotoxic agent such as a chemotherapeutic
agent, a
toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or
animal origin, or
fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
Chemotherapeutic agents useful in the generation of such immunoconjugates have
been described above. Enzymatically active toxins and fragments thereof that
can be
used to form useful immunoconjugates include diphtheria A chain, nonbinding
active
fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa),
ricin A
chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii
proteins, dianthin
.. proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica
charantia
inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin,
mitogellin, restrictocin,
phenomycin, enomycin, the tricothecenes, and the like. A variety of
radionuclides are
available for the production of radioconjugated humanized anti-IL-23p19
antibodies.
Examples include 212Bi, 1311, 131in, , 90¨Y and 186Re.
.. Conjugates of the humanized anti-IL-23p19 antibody and cytotoxic or
chemotherapeutic
agent can be made by known methods, using a variety of bifunctional protein
coupling
agents such as N-succinimidy1-3-(2-pyridyldithiol) propionate (SP DP),
iminothiolane (IT),
bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL),
active esters
(such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-
azido
compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium
derivatives
(such as bis-(p-diazoniumbenzoyI)-ethylenediamine), diisocyanates (such as
toluene
2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-
dinitrobenzene). For example, a ricin immunotoxin can be prepared as described
in
Vitetta et al., 1987, Science 238:1098. Carbon-14-labeled 1-
isothiocyanatobenzy1-3-
methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating
agent
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 87 -
for conjugation of radionucleotide to the antibody. Conjugates also can be
formed with a
cleavable linker.
The humanized anti-IL-23p19 antibodies disclosed herein can also be formulated
as
immunoliposomes. Liposomes containing the antibody are prepared by methods
known
in the art, such as described in Epstein et al., 1985, Proc. Natl. Acad. Sci.
USA 82:3688;
Hwang et al., 1980, Proc. Natl. Acad. Sci. USA 77:4030; and U.S. Pat. Nos.
4,485,045
and 4,544,545. Liposomes having enhanced circulation time are disclosed, for
example,
in U.S. Pat. No. 5,013,556.
Particularly useful liposomes can be generated by the reverse phase
evaporation
method with a lipid composition comprising phosphatidylcholine, cholesterol
and PEG-
derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through
filters
of defined pore size to yield liposomes with the desired diameter. Fab'
fragments of an
antibody disclosed herein can be conjugated to the liposomes as described in
Martin et
al., 1982, J. Biol. Chem. 257:286-288 via a disulfide interchange reaction. A
chemotherapeutic agent (such as doxorubicin) is optionally contained within
the
liposome. See, e.g., Gabizon et al., 1989, J. National Cancer Inst.
81(19):1484.
The antibodies described and disclosed herein can also be used in ADEPT
(Antibody-
Directed Enzyme Prodrug Therapy) procedures by conjugating the antibody to a
prodrug-activating enzyme that converts a prodrug (e.g., a peptidyl
chemotherapeutic
agent), to an active anti-cancer drug. See, for example, WO 81/01145, WO
88/07378,
and U.S. Pat. No. 4,975,278. The enzyme component of the immunoconjugate
useful for
ADEPT is an enzyme capable of acting on a prodrug in such a way so as to
covert it into
its more active, cytotoxic form. Specific enzymes that are useful in ADEPT
include, but
are not limited to, alkaline phosphatase for converting phosphate-containing
prodrugs
into free drugs; arylsulfatase for converting sulfate-containing prodrugs into
free drugs;
cytosine deaminase for converting non-toxic 5-fluorocytosine into the anti-
cancer drug,
5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin,
carboxypeptidases, and cathepsins (such as cathepsins B and L), for converting
peptide-containing prodrugs into free drugs; D-alanylcarboxypeptidases, for
converting
prodrugs containing D-amino acid substituents; carbohydrate-cleaving enzymes
such as
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 88 -6-galactosidase and neuraminidase for converting glycosylated prodrugs
into free drugs;
6-lactamase for converting drugs derivatized with 6-lactams into free drugs;
and
penicillin amidases, such as penicillin V amidase or penicillin G amidase, for
converting
drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl
groups,
respectively, into free drugs. Alternatively, antibodies having enzymatic
activity
("abzymes") can be used to convert the prodrugs into free active drugs (see,
for
example, Massey, 1987, Nature 328: 457-458). Antibody-abzyme conjugates can be
prepared by known methods for delivery of the abzyme to a tumor cell
population, for
example, by covalently binding the enzyme to the humanized anti-IL-
23p19antibody/heterobifunctional crosslin king reagents discussed above.
Alternatively,
fusion proteins comprising at least the antigen binding region of an antibody
disclosed
herein linked to at least a functionally active portion of an enzyme as
described above
can be constructed using recombinant DNA techniques (see, e.g., Neuberger et
al.,
1984, Nature 312:604-608).
In certain embodiments, it may be desirable to use a humanized anti-IL-23p19
antibody
fragment, rather than an intact antibody, to increase tissue penetration, for
example. It
may be desirable to modify the antibody fragment in order to increase its
serum half life.
This can be achieved, for example, by incorporation of a salvage receptor
binding
epitope into the antibody fragment. In one method, the appropriate region of
the
antibody fragment can be altered (e.g., mutated), or the epitope can be
incorporated into
a peptide tag that is then fused to the antibody fragment at either end or in
the middle,
for example, by DNA or peptide synthesis. See, e.g., WO 96/32478.
In other embodiments, covalent modifications of the humanized anti-IL-23p19
antibody
are also included. Covalent modifications include modification of cysteinyl
residues,
histidyl residues, lysinyl and amino-terminal residues, arginyl residues,
tyrosyl residues,
carboxyl side groups (aspartyl or glutamyl), glutaminyl and asparaginyl
residues, or
seryl, or threonyl residues. Another type of covalent modification involves
chemically or
enzymatically coupling glycosides to the antibody. Such modifications may be
made by
chemical synthesis or by enzymatic or chemical cleavage of the antibody, if
applicable.
Other types of covalent modifications of the antibody can be introduced into
the
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 89 -
molecule by reacting targeted amino acid residues of the antibody with an
organic
derivatizing agent that is capable of reacting with selected side chains or
the amino- or
carboxy-terminal residues.
Removal of any carbohydrate moieties present on the antibody can be
accomplished
.. chemically or enzymatically. Chemical deglycosylation is described by
Hakimuddin et
al., 1987, Arch. Biochem. Biophys. 259:52 and by Edge et al., 1981, Anal.
Biochem.,
118:131. Enzymatic cleavage of carbohydrate moieties on antibodies can be
achieved
by the use of a variety of endo- and exo-glycosidases as described by
Thotakura et al.,
1987, Meth. Enzymol 138:350.
Another type of useful covalent modification comprises linking the antibody to
one of a
variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene
glycol, or
polyoxyalkylenes, in the manner set forth in one or more of U.S. Pat. No.
4,640,835,
U.S. Pat. No. 4,496,689, U.S. Pat. No. 4,301,144, U.S. Pat. No. 4,670,417,
U.S. Pat.
No. 4,791,192 and U.S. Pat. No. 4,179,337.
Humanization and Amino Acid Sequence Variants
Amino acid sequence variants of the anti-IL-23p19 antibody can be prepared by
introducing appropriate nucleotide changes into the anti-IL-23p19 antibody
DNA, or by
peptide synthesis. Such variants include, for example, deletions from, and/or
insertions
into and/or substitutions of, residues within the amino acid sequences of the
anti-IL-
23p19 antibodies of the examples herein. Any combination of deletions,
insertions, and
substitutions is made to arrive at the final construct, provided that the
final construct
possesses the desired characteristics. The amino acid changes also may alter
post-
translational processes of the humanized or variant anti-IL-23p19 antibody,
such as
changing the number or position of glycosylation sites.
A useful method for identification of certain residues or regions of the anti-
IL-23p19
antibody that are preferred locations for mutagenesis is called "alanine
scanning
mutagenesis," as described by Cunningham and Wells (Science, 244:1081-1085
(1989)). Here, a residue or group of target residues are identified (e.g.,
charged residues
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 90 -
such as arg, asp, his, lys, and glu) and replaced by a neutral or negatively
charged
amino acid (typically alanine) to affect the interaction of the amino acids
with IL-23p19
antigen. Those amino acid locations demonstrating functional sensitivity to
the
substitutions then are refined by introducing further or other variants at, or
for, the sites
of substitution. Thus, while the site for introducing an amino acid sequence
variation is
predetermined, the nature of the mutation per se need not be predetermined.
For
example, to analyze the performance of a mutation at a given site, alanine
scanning or
random mutagenesis is conducted at the target codon or region and the
expressed anti-
IL-23p19 antibody variants are screened for the desired activity.
Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions
ranging
in length from one residue to polypeptides containing a hundred or more
residues, as
well as intrasequence insertions of single or multiple amino acid residues.
Examples of
terminal insertions include an anti-IL-23p19 antibody fused to an epitope tag.
Other
insertional variants of the anti-IL-23p19 antibody molecule include a fusion
to the N- or
C-terminus of the anti-IL-23p19 antibody of an enzyme or a polypeptide which
increases
the serum half-life of the antibody.
Another type of variant is an amino acid substitution variant. These variants
have at
least one amino acid residue in the anti-IL-23p19 antibody molecule removed
and a
different residue inserted in its place. The sites of greatest interest for
substitutional
mutagenesis include the hypervariable regions, but FR alterations are also
contemplated. Conservative substitutions are shown in Table 5 under the
heading of
"preferred substitutions". If such substitutions result in a change in
biological activity,
then more substantial changes, denominated "exemplary substitutions", or as
further
described below in reference to amino acid classes, may be introduced and the
products
screened.
TABLE 8:
Original Residue Exemplary Substitutions Preferred Substitutions
Ala (A) val; leu; ile val
Arg (R) lys; gin; asn
lys
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 91 -
Asn (N) gin; his; asp, lys; arg
gin
Asp (D) glu; asn glu
Cys (C) ser; ala ser
Gin (Q) asn; glu asn
Glu (E) asp; gin asp
Gly (G) ala ala
His (H) arg; asn; gin; lys;
arg
Ile (I) leu; val; met; ala;
phe; norleucine leu
Leu (L) ile; norleucine;
val;
met; ala; phe ile
Lys (K) arg; gin; asn arg
Met (M) leu; phe; ile leu
Phe (F) tyr; leu; val; ile; ala;
tyr
Pro (P) ala ala
Ser (S) thr thr
Thr (T) ser ser
Trp (W) tyr; phe tyr
Tyr (Y) phe;trp; thr;
ser
phe
Val (V) leu; ile; met; phe
ala; norleucine; leu
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 92 -
In protein chemistry, it is generally accepted that the biological properties
of the antibody
can be accomplished by selecting substitutions that differ significantly in
their effect on
maintaining (a) the structure of the polypeptide backbone in the area of the
substitution,
for example, as a sheet or helical conformation, (b) the charge or
hydrophobicity of the
molecule at the target site, or (c) the bulk of the side chain. Naturally
occurring residues
are divided into groups based on common side-chain properties:
(1) hydrophobic: norleucine, met, ala, val, leu, ile;
(2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic: asn, gin, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and
(6) aromatic: trp, tyr, phe.
Non-conservative substitutions will entail exchanging a member of one of these
classes
for another class.
Any cysteine residue not involved in maintaining the proper conformation of
the
humanized or variant anti-IL-23p19 antibody also may be substituted, generally
with
serine, to improve the oxidative stability of the molecule, prevent aberrant
crosslinking,
or provide for established points of conjugation to a cytotoxic or cytostatic
compound.
Conversely, cysteine bond(s) may be added to the antibody to improve its
stability
(particularly where the antibody is an antibody fragment such as an Fv
fragment).
A type of substitutional variant involves substituting one or more
hypervariable region
residues of a parent antibody (e.g., a humanized or human antibody).
Generally, the
resulting variant(s) selected for further development will have improved
biological
properties relative to the parent antibody from which they are generated. A
convenient
way for generating such substitutional variants is affinity maturation using
phage display.
Briefly, several hypervariable region sites (e.g., 6-7 sites) are mutated to
generate all
possible amino substitutions at each site. The antibody variants thus
generated are
displayed in a monovalent fashion from filamentous phage particles as fusions
to the
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 93 -
gene III product of M13 packaged within each particle. The phage-displayed
variants are
then screened for their biological activity (e.g., binding affinity). In order
to identify
candidate hypervariable region sites for modification, alanine scanning
mutagenesis can
be performed to identify hypervariable region residues contributing
significantly to
antigen binding. Alternatively, or in addition, it may be beneficial to
analyze a crystal
structure of the antigen-antibody complex to identify contact points between
the antibody
and human IL-23p19. Such contact residues and neighboring residues are
candidates
for substitution according to the techniques elaborated herein. Once such
variants are
generated, the panel of variants is subjected to screening as described herein
and
antibodies with superior properties in one or more relevant assays may be
selected for
further development.
Another type of amino acid variant of the antibody alters the original
glycosylation
pattern of the antibody. By "altering" is meant deleting one or more
carbohydrate
moieties found in the antibody, and/or adding one or more glycosylation sites
that are
not present in the antibody.
In some embodiments, it may be desirable to modify the antibodies of the
invention to
add glycosylations sites. Glycosylation of antibodies is typically either N-
linked or 0-
linked. N-linked refers to the attachment of the carbohydrate moiety to the
side chain of
an asparagine residue. The tripeptide sequences asparagine-X-serine and
asparagine-
X-threonine, where X is any amino acid except proline, are the recognition
sequences
for enzymatic attachment of the carbohydrate moiety to the asparagine side
chain. Thus,
the presence of either of these tripeptide sequences in a polypeptide creates
a potential
glycosylation site. 0-linked glycosylation refers to the attachment of one of
the sugars N-
aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly
serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be
used.
Thus, in order to glycosylate a given protein, e.g., an antibody, the amino
acid sequence
of the protein is engineered to contain one or more of the above-described
tripeptide
sequences (for N-linked glycosylation sites). The alteration may also be made
by the
addition of, or substitution by, one or more serine or threonine residues to
the sequence
of the original antibody (for 0-linked glycosylation sites).
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 94 -
Nucleic acid molecules encoding amino acid sequence variants of the anti-IL-
23p19
antibody are prepared by a variety of methods known in the art. These methods
include,
but are not limited to, isolation from a natural source (in the case of
naturally occurring
amino acid sequence variants) or preparation by oligonucleotide-mediated (or
site-
directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier
prepared variant or a non-variant version of the anti-IL-23p19 antibody.
Polynucleotides, Vectors, Host Cells, and Recombinant Methods
Other embodiments encompass isolated polynucleotides that comprise a sequence
encoding a humanized anti-IL-23p19 antibody, vectors, and host cells
comprising the
polynucleotides, and recombinant techniques for production of the humanized
antibody.
The isolated polynucleotides can encode any desired form of the anti-IL-23p19
antibody
including, for example, full length monoclonal antibodies, Fab, Fab', F(ab1)2,
and Fv
fragments, diabodies, linear antibodies, single-chain antibody molecules, and
multispecific antibodies formed from antibody fragments.
Some embodiments include isolated polynucleotides comprising sequences that
encode
the light chain variable region of an antibody or antibody fragment having the
amino acid
sequence of any of SEQ ID NO: SEQ ID NO:84, 86, 88, 90, 91, 93, 95, 97, 99,
101, 103,
105, 107, 109, 111, 113, 115, 117 or 119. Exemplary polynucleotide sequences
encoding such amino acid sequences are SEQ ID NO:83, 85, 87, 89, 92, 94, 96,
98,
100, 102, 104, 106, 108, 110, 112, 114, 116 and 118. Some embodiments include
isolated polynucleotides comprising sequences that encode the heavy chain
variable
region of an antibody or antibody fragment having the amino acid sequence of
SEQ ID
NO:121, 123, 125, 127, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148,
150,
152, 154 or 156. Exemplary polynucleotide sequences encoding such amino acid
sequences are SEQ ID NO: 120, 122, 124, 126, 129, 131, 133, 135, 137, 139,
141, 143,
145, 147, 149, 151, 153 or 155.
Some embodiments include isolated polynucleotides comprising sequences that
encode
the light chain variable region of an antibody or antibody fragment having the
amino acid
sequence of any of SEQ ID NO:158, 160, 162 or 164. Exemplary polynucleotide
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 95 -
sequences encoding such amino acid sequences are SEQ ID NO:157, 159, 161 or
163.
Some embodiments include isolated polynucleotides comprising sequences that
encode
the heavy chain variable region of an antibody or antibody fragment having the
amino
acid sequence of SEQ ID NO: 166, 168, 170 or 172. Exemplary polynucleotide
sequences encoding such amino acid sequences are SEQ ID NO: 165, 167, 169 or
171.
Some embodiments include isolated polynucleotides comprising sequences that
encode
the light chain of an antibody having the amino acid sequence of any of SEQ ID
NO:174
or 180. Exemplary polynucleotide sequences encoding such amino acid sequences
are
SEQ ID NO:173 or 179. Some embodiments include isolated polynucleotides
comprising
sequences that encode the heavy chain of an antibody having the amino acid
sequence
of SEQ ID NO:176 or 178. Exemplary polynucleotide sequences encoding such
amino
acid sequences are SEQ ID NO:175 or 177.
In one aspect, the isolated polynucleotide sequence(s) encodes an antibody or
antibody
fragment having a light chain and a heavy chain variable region comprising the
amino
acid sequences of SEQ ID NO:174 and SEQ ID NO:176, respectively; SEQ ID NO:174
and SEQ ID NO:178, respectively; SEQ ID NO:180 and SEQ ID NO:176,
respectively;
SEQ ID NO:180 and SEQ ID NO:178, respectively. Exemplary polynucleotide
sequences encoding such amino acid sequences are SEQ ID NO: 173 and 175,
respectively, SEQ ID NO: 173 and 177, respectively, SEQ ID NO: 179 and 175,
respectively. SEQ ID NO: 179 and 177, respectively.
The polynucleotide(s) that comprise a sequence encoding a humanized anti-IL-
23p19
antibody or a fragment or chain thereof can be fused to one or more regulatory
or
control sequence, as known in the art, and can be contained in suitable
expression
vectors or host cell as known in the art. Each of the polynucleotide molecules
encoding
the heavy or light chain variable domains can be independently fused to a
polynucleotide sequence encoding a constant domain, such as a human constant
domain, enabling the production of intact antibodies. Alternatively,
polynucleotides, or
portions thereof, can be fused together, providing a template for production
of a single
chain antibody.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 96 -
For recombinant production, a polynucleotide encoding the antibody is inserted
into a
replicable vector for cloning (amplification of the DNA) or for expression.
Many suitable
vectors for expressing the recombinant antibody are available. The vector
components
generally include, but are not limited to, one or more of the following: a
signal sequence,
an origin of replication, one or more marker genes, an enhancer element, a
promoter,
and a transcription termination sequence.
The humanized anti-IL-23p19 antibodies can also be produced as fusion
polypeptides,
in which the antibody is fused with a heterologous polypeptide, such as a
signal
sequence or other polypeptide having a specific cleavage site at the amino
terminus of
the mature protein or polypeptide. The heterologous signal sequence selected
is
typically one that is recognized and processed (i.e., cleaved by a signal
peptidase) by
the host cell. For prokaryotic host cells that do not recognize and process
the
humanized anti-IL-23p19 antibody signal sequence, the signal sequence can be
substituted by a prokaryotic signal sequence. The signal sequence can be, for
example,
alkaline phosphatase, penicillinase, lipoprotein, heat-stable enterotoxin II
leaders, and
the like. For yeast secretion, the native signal sequence can be substituted,
for example,
with a leader sequence obtained from yeast invertase alpha-factor (including
Saccharomyces and Kluyveromyces a-factor leaders), acid phosphatase, C.
albicans
glucoamylase, or the signal described in W090/13646. In mammalian cells,
mammalian
signal sequences as well as viral secretory leaders, for example, the herpes
simplex gD
signal, can be used. The DNA for such precursor region is ligated in reading
frame to
DNA encoding the humanized anti-IL-23p19 antibody.
Expression and cloning vectors contain a nucleic acid sequence that enables
the vector
to replicate in one or more selected host cells. Generally, in cloning vectors
this
sequence is one that enables the vector to replicate independently of the host
chromosomal DNA, and includes origins of replication or autonomously
replicating
sequences. Such sequences are well known for a variety of bacteria, yeast, and
viruses.
The origin of replication from the plasmid pBR322 is suitable for most Gram-
negative
bacteria, the 2-1). plasmid origin is suitable for yeast, and various viral
origins (SV40,
polyoma, adenovirus, VSV, and BPV) are useful for cloning vectors in mammalian
cells.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 97 -
Generally, the origin of replication component is not needed for mammalian
expression
vectors (the SV40 origin may typically be used only because it contains the
early
promoter).
Expression and cloning vectors may contain a gene that encodes a selectable
marker to
facilitate identification of expression. Typical selectable marker genes
encode proteins
that confer resistance to antibiotics or other toxins, e.g., ampicillin,
neomycin,
methotrexate, or tetracycline, or alternatively, are complement auxotrophic
deficiencies,
or in other alternatives supply specific nutrients that are not present in
complex media,
e.g., the gene encoding D-alanine racemase for Bacilli.
One example of a selection scheme utilizes a drug to arrest growth of a host
cell. Those
cells that are successfully transformed with a heterologous gene produce a
protein
conferring drug resistance and thus survive the selection regimen. Examples of
such
dominant selection use the drugs neomycin, mycophenolic acid, and hygromycin.
Common selectable markers for mammalian cells are those that enable the
identification
of cells competent to take up a nucleic acid encoding a humanized anti-IL-
23p19
antibody, such as DHFR (dihydrofolate reductase), thymidine kinase,
metallothionein-I
and -II (such as primate metallothionein genes), adenosine deaminase,
ornithine
decarboxylase, and the like. Cells transformed with the DHFR selection gene
are first
identified by culturing all of the transformants in a culture medium that
contains
methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell
when
wild-type DHFR is employed is the Chinese hamster ovary (CHO) cell line
deficient in
DHFR activity (e.g., DG44).
Alternatively, host cells (particularly wild-type hosts that contain
endogenous DHFR)
transformed or co-transformed with DNA sequences encoding anti-IL-23p19
antibody,
wild-type DHFR protein, and another selectable marker such as aminoglycoside
3'-
phosphotransferase (APH), can be selected by cell growth in medium containing
a
selection agent for the selectable marker such as an aminoglycosidic
antibiotic, e.g.,
kanamycin, neomycin, or G418. See, e.g., U.S. Pat. No. 4,965,199.
Where the recombinant production is performed in a yeast cell as a host cell,
the TRP1
gene present in the yeast plasmid YRp7 (Stinchcomb et al., 1979, Nature 282:
39) can
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 98 -
be used as a selectable marker. The TRP1 gene provides a selection marker for
a
mutant strain of yeast lacking the ability to grow in tryptophan, for example,
ATCC No.
44076 or PEP4-1 (Jones, 1977, Genetics 85:12). The presence of the trp1 lesion
in the
yeast host cell genome then provides an effective environment for detecting
transformation by growth in the absence of tryptophan. Similarly, Leu2p-
deficient yeast
strains such as ATCC 20,622 and 38,626 are complemented by known plasmids
bearing the LEU2 gene.
In addition, vectors derived from the 1.6 pm circular plasmid pKD1 can be used
for
transformation of Kluyveromyces yeasts. Alternatively, an expression system
for large-
scale production of recombinant calf chymosin was reported for K. lactis (Van
den Berg,
1990, Bio/Technology 8:135). Stable multi-copy expression vectors for
secretion of
mature recombinant human serum albumin by industrial strains of Kluyveromyces
have
also been disclosed (Fleer et al., 1991, Bio/Technology 9:968-975).
Expression and cloning vectors usually contain a promoter that is recognized
by the host
organism and is operably linked to the nucleic acid molecule encoding an anti-
IL-23p19
antibody or polypeptide chain thereof. Promoters suitable for use with
prokaryotic hosts
include phoA promoter, p-lactamase and lactose promoter systems, alkaline
phosphatase, tryptophan (trp) promoter system, and hybrid promoters such as
the tac
promoter. Other known bacterial promoters are also suitable. Promoters for use
in
bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably
linked to
the DNA encoding the humanized anti-IL-23p19 antibody.
Many eukaryotic promoter sequences are known. Virtually all eukaryotic genes
have an
AT-rich region located approximately 25 to 30 bases upstream from the site
where
transcription is initiated. Another sequence found 70 to 80 bases upstream
from the start
of transcription of many genes is a CNCAAT region where N may be any
nucleotide. At
the 3' end of most eukaryotic genes is an AATAAA sequence that may be the
signal for
addition of the poly A tail to the 3' end of the coding sequence. All of these
sequences
are suitably inserted into eukaryotic expression vectors.
Examples of suitable promoting sequences for use with yeast hosts include the
promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, such as
enolase,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 99 -
glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase,
phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase,
pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and
glucokinase.
Inducible promoters have the additional advantage of transcription controlled
by growth
conditions. These include yeast promoter regions for alcohol dehydrogenase 2,
isocytochrome C, acid phosphatase, derivative enzymes associated with nitrogen
metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and
enzymes responsible for maltose and galactose utilization. Suitable vectors
and
promoters for use in yeast expression are further described in EP 73,657.
Yeast
enhancers also are advantageously used with yeast promoters.
Humanized anti-IL-23p19 antibody transcription from vectors in mammalian host
cells is
controlled, for example, by promoters obtained from the genomes of viruses
such as
polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine
papilloma
.. virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B
virus and Simian
Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin
promoter or
an immunoglobulin promoter, or from heat-shock promoters, provided such
promoters
are compatible with the host cell systems.
The early and late promoters of the 5V40 virus are conveniently obtained as an
5V40
restriction fragment that also contains the SV40 viral origin of replication.
The immediate
early promoter of the human cytomegalovirus is conveniently obtained as a
HindlIl E
restriction fragment. A system for expressing DNA in mammalian hosts using the
bovine
papilloma virus as a vector is disclosed in U.S. Pat. No. 4,419,446. A
modification of this
system is described in U.S. Pat. No. 4,601,978. See also Reyes et al., 1982,
Nature
297:598-601, disclosing expression of human p-interferon cDNA in mouse cells
under
the control of a thymidine kinase promoter from herpes simplex virus.
Alternatively, the
Rous sarcoma virus long terminal repeat can be used as the promoter.
Another useful element that can be used in a recombinant expression vector is
an
enhancer sequence, which is used to increase the transcription of a DNA
encoding a
humanized anti-IL-23p19 antibody by higher eukaryotes. Many enhancer sequences
are
-100-
now known from mammalian genes (e.g., globin, elastase, albumin, a-
fetoprotein, and
insulin). Typically, however, an enhancer from a eukaryotic cell virus is
used. Examples
include the SV40 enhancer on the late side of the replication origin (bp 100-
270), the
cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side
of the
replication origin, and adenovirus enhancers. See also Yaniv, 1982, Nature
297:17-18 for
a description of enhancing elements for activation of eukaryotic promoters.
The enhancer
may be spliced into the vector at a position 5' or 3' to the humanized anti-IL-
23p19
antibody-encoding sequence, but is preferably located at a site 5' from the
promoter.
Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant,
animal,
human, or nucleated cells from other multicellular organisms) can also contain
sequences necessary for the termination of transcription and for stabilizing
the mRNA.
Such sequences are commonly available from the 5' and, occasionally 3',
untranslated
regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide
segments transcribed as polyadenylated fragments in the untranslated portion
of the
mRNA encoding anti-IL-23p19 antibody. One useful transcription termination
component
is the bovine growth hormone polyadenylation region. See W094/11026 and the
expression vector disclosed therein. In some embodiments, humanized anti-IL-
23p19
antibodies can be expressed using the CHEF system. (See, e.g., U.S. Pat. No.
5,888,809).
Suitable host cells for cloning or expressing the DNA in the vectors herein
are the
prokaryote, yeast, or higher eukaryote cells described above. Suitable
prokaryotes for
this purpose include eubacteria, such as Gram-negative or Gram-positive
organisms, for
example, Enterobacteriaceae such as Escherichia, e.g., E. coli, Enterobacter,
Erwinia,
Klebsiella, Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g.,
Serratia
marcescans, and Shigella, as well as Bacilli such as B. subtilis and B.
licheniformis (e.g.,
B. licheniformis 41 P disclosed in DD 266,710 published Apr. 12, 1989),
Pseudomonas
such as P. aeruginosa, and Streptomyces. One preferred E. coli cloning host is
E. coli
294 (ATCC 31,446), although other strains such as E. coli B, E. coli X1776
(ATCC
CA 2871985 2019-07-03
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
-101 -
31,537), and E. coli W3110 (ATCC 27,325) are suitable. These examples are
illustrative
rather than limiting.
In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or
yeast are
suitable cloning or expression hosts for humanized anti-IL-23p19antibody-
encoding
vectors. Saccharomyces cerevisiae, or common baker's yeast, is the most
commonly
used among lower eukaryotic host microorganisms. However, a number of other
genera,
species, and strains are commonly available and useful herein, such as
Schizosaccharomyces pombe; Kluyveromyces hosts such as, e.g., K. lactis, K.
fragilis
(ATCC 12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178), K.
waltii
(ATCC 56,500), K. drosophilarum (ATCC 36,906), K. thermotolerans, and K.
marxianus;
yarrowia (EP 402,226); Pichia pastors (EP 183,070); Candida; Trichoderma
reesia (EP
244,234); Neurospora crassa; Schwanniomyces such as Schwanniomyces
occidentalis;
and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium,
and
Aspergillus hosts such as A. nidulans and A. niger.
Suitable host cells for the expression of glycosylated humanized anti-IL-23p19
antibody
are derived from multicellular organisms. Examples of invertebrate cells
include plant
and insect cells, including, e.g., numerous baculoviral strains and variants
and
corresponding permissive insect host cells from hosts such as Spodoptera
frugiperda
(caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito),
Drosophila
melanogaster (fruitfly), and Bombyx mori (silk worm). A variety of viral
strains for
transfection are publicly available, e.g., the L-1 variant of Autographa
californica NPV
and the Bm-5 strain of Bombyx mori NPV, and such viruses may be used,
particularly
for transfection of Spodoptera frugiperda cells.
Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, and
tobacco can
also be utilized as hosts.
In another aspect, expression of humanized anti-IL-23p19 is carried out in
vertebrate
cells. The propagation of vertebrate cells in culture (tissue culture) has
become routine
procedure and techniques are widely available. Examples of useful mammalian
host cell
lines are monkey kidney CV1 line transformed by 5V40 (COS-7, ATCC CRL 1651),
human embryonic kidney line (293 or 293 cells subcloned for growth in
suspension
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 102 -
culture, (Graham et al., 1977, J. Gen Virol. 36: 59), baby hamster kidney
cells (BHK,
ATCC CCL 10), Chinese hamster ovary cells/-DHFR1 (CHO. Urlaub et al., 1980,
Proc.
Natl. Acad. Sci. USA 77: 4216; e.g., DG44), mouse sertoli cells (TM4, Mather,
1980,
Biol. Reprod. 23:243-251), monkey kidney cells (CV1 ATCC CCL 70), African
green
monkey kidney cells (VERO-76, ATCC CRL-1587), human cervical carcinoma cells
(HELA, ATCC CCL 2), canine kidney cells (MDCK, ATCC CCL 34), buffalo rat liver
cells
(BRL 3A, ATCC CRL 1442), human lung cells (W138, ATCC CCL 75), human liver
cells
(Hep G2, HB 8065), mouse mammary tumor (MMT 060562, ATCC CCL51), TR1 cells
(Mather et al., 1982, Annals N.Y. Acad. Sci. 383: 44-68), MRC 5 cells, FS4
cells, and
human hepatoma line (Hep G2).
Host cells are transformed with the above-described expression or cloning
vectors for
humanized anti-IL-23p19 antibody production and cultured in conventional
nutrient
media modified as appropriate for inducing promoters, selecting transformants,
or
amplifying the genes encoding the desired sequences.
The host cells used to produce a humanized anti-IL-23p19 antibody described
herein
may be cultured in a variety of media. Commercially available media such as
Ham's F10
(Sigma-Aldrich Co., St. Louis, Mo.), Minimal Essential Medium ((MEM), (Sigma-
Aldrich
Co.), RPMI-1640 (Sigma-Aldrich Co.), and Dulbecco's Modified Eagle's Medium
((DMEM), Sigma-Aldrich Co.) are suitable for culturing the host cells. In
addition, any of
the media described in one or more of Ham et al., 1979, Meth. Enz. 58: 44,
Barnes et
al., 1980, Anal. Biochem. 102: 255, U.S. Pat. No. 4,767,704, U.S. Pat. No.
4,657,866,
U.S. Pat. No. 4,927,762, U.S. Pat. No. 4,560,655, U.S. Pat. No. 5,122,469, WO
90/103430, and WO 87/00195 may be used as culture media for the host cells.
Any of
these media may be supplemented as necessary with hormones and/or other growth
factors (such as insulin, transferrin, or epidermal growth factor), salts
(such as sodium
chloride, calcium, magnesium, and phosphate), buffers (such as HEPES),
nucleotides
(such as adenosine and thymidine), antibiotics (such as gentamicin), trace
elements
(defined as inorganic compounds usually present at final concentrations in the
micromolar range), and glucose or an equivalent energy source. Other
supplements
may also be included at appropriate concentrations that would be known to
those skilled
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 103 -
in the art. The culture conditions, such as temperature, pH, and the like, are
those
previously used with the host cell selected for expression, and will be
apparent to the
ordinarily skilled artisan.
When using recombinant techniques, the antibody can be produced
intracellularly, in the
periplasmic space, or directly secreted into the medium. If the antibody is
produced
intracellularly, the cells may be disrupted to release protein as a first
step. Particulate
debris, either host cells or lysed fragments, can be removed, for example, by
centrifugation or ultrafiltration. Carter et al., 1992, Bio/Technology 10:163-
167 describes
a procedure for isolating antibodies that are secreted to the periplasmic
space of E. coli.
Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5),
EDTA, and
phenylmethylsulfonylfluoride (PMSF) over about 30 minutes. Cell debris can be
removed by centrifugation. Where the antibody is secreted into the medium,
supernatants from such expression systems are generally first concentrated
using a
commercially available protein concentration filter, for example, an Amicon or
Millipore
Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be
included in any of
the foregoing steps to inhibit proteolysis and antibiotics may be included to
prevent the
growth of adventitious contaminants. A variety of methods can be used to
isolate the
antibody from the host cell.
The antibody composition prepared from the cells can be purified using, for
example,
hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity
chromatography, with affinity chromatography being a typical purification
technique. The
suitability of protein A as an affinity ligand depends on the species and
isotype of any
immunoglobulin Fc domain that is present in the antibody. Protein A can be
used to
purify antibodies that are based on human gamma1, gamma2, or gamma4 heavy
chains
(see, e.g., Lindmark et al., 1983 J. lmmunol. Meth. 62:1-13). Protein G is
recommended
for all mouse isotypes and for human gamma3 (see, e.g., Guss et al., 1986 EMBO
J.
5:1567-1575). A matrix to which an affinity ligand is attached is most often
agarose, but
other matrices are available. Mechanically stable matrices such as controlled
pore glass
or poly(styrenedivinyl)benzene allow for faster flow rates and shorter
processing times
than can be achieved with agarose. Where the antibody comprises a CH3 domain,
the
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 104 -
Bakerbond ABXTM resin (J. T. Baker, Phillipsburg, N.J.) is useful for
purification. Other
techniques for protein purification such as fractionation on an ion-exchange
column,
ethanol precipitation, reverse phase HPLC, chromatography on silica,
chromatography
on heparin SEPHAROSETM chromatography on an anion or cation exchange resin
(such
as a polyaspartic acid column), chromatofocusing, SDS-PAGE, and ammonium
sulfate
precipitation are also available depending on the antibody to be recovered.
Following any preliminary purification step(s), the mixture comprising the
antibody of
interest and contaminants may be subjected to low pH hydrophobic interaction
chromatography using an elution buffer at a pH between about 2.5-4.5,
typically
performed at low salt concentrations (e.g., from about 0-0.25M salt).
Also included are nucleic acids that hybridize under low, moderate, and high
stringency
conditions, as defined herein, to all or a portion (e.g., the portion encoding
the variable
region) of the nucleotide sequence represented by isolated polynucleotide
sequence(s)
that encode an antibody or antibody fragment of the present invention.The
hybridizing
portion of the hybridizing nucleic acid is typically at least 15 (e.g., 20,
25, 30 or 50)
nucleotides in length. The hybridizing portion of the hybridizing nucleic acid
is at least
80%, e.g., at least 90%, at least 95%, or at least 98%, identical to the
sequence of a
portion or all of a nucleic acid encoding an anti-IL-23p19 polypeptide (e.g.,
a heavy
chain or light chain variable region), or its complement. Hybridizing nucleic
acids of the
type described herein can be used, for example, as a cloning probe, a primer,
e.g., a
FOR primer, or a diagnostic probe.
Some embodiments include isolated polynucleotides including sequences that
encode
an antibody or antibody fragment having the amino acid sequence of any one of
SEQ ID
NO: 84, 86, 88, 90, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113,
115, 117 or
119, and that is at least 80%, at least 90%, at least 95%, at least 98%, or at
least 99%
identical to the polynucleotide sequences of SEQ ID NO:83, 85, 87, 89, 92, 94,
96, 98,
100, 102, 104, 106, 108, 110, 112, 114, 116 or 118.
Some embodiments include isolated polynucleotides including sequences that
encode
an antibody or antibody fragment having the amino acid sequence of any one of
SEQ ID
NO: 158, 160, 162 or 164, and that is at least 80%, at least 90%, at least
95%, at least
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 105 -
98%, or at least 99% identical to the polynucleotide sequences of SEQ ID
NO:157, 159,
161 or 163.
Some embodiments include isolated polynucleotides including sequences that
encode
an antibody or antibody fragment haying the amino acid sequence of any one of
SEQ ID
NO: 121, 123, 125, 127, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148,
150,
152, 154 or 156, and that is at least 80%, at least 90%, at least 95%, at
least 98%, or at
least 99% identical to the polynucleotide sequences of SEQ ID NO: 120, 122,
124, 126,
129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153 or 155.
Some embodiments include isolated polynucleotides including sequences that
encode
an antibody or antibody fragment having the amino acid sequence of any one of
SEQ ID
NO: 166, 168, 170 or 172, and that is at least 80%, at least 90%, at least
95%, at least
98%, or at least 99% identical to the polynucleotide sequences of SEQ ID NO:
165, 167,
169 or 171.
Some embodiments include isolated polynucleotides including sequences that
encode
an antibody or antibody fragment having the light chain variable region amino
acid
sequence that is at least 80%, at least 90%, at least 95%, at least 98%, or at
least 99%
identical to the amino acid sequence of any one of SEQ ID NO: 84, 86, 88, 90,
91, 93,
95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117 or 119. Some
embodiments
include isolated polynucleotides including sequences that encode an antibody
or
antibody fragment having the light chain variable region amino acid sequence
that is at
least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identical
to the
amino acid sequence of any one of SEQ ID NO:158, 160, 162 or 164. Some
embodiments include isolated polynucleotides including sequences that encode
an
antibody or antibody fragment having the heavy chain variable region amino
acid
sequence that is at least 80%, at least 90%, at least 95%, at least 98%, or at
least 99%
identical to the amino acid sequence of any one of SEQ ID NO:121, 123, 125,
127, 128,
130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154 or 156. Some
embodiments include isolated polynucleotides including sequences that encode
an
antibody or antibody fragment having the heavy chain variable region amino
acid
sequence that is at least 80%, at least 90%, at least 95%, at least 98%, or at
least 99%
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 106 -
identical to the amino acid sequence of any of one SEQ ID NO:166, 168, 170 or
172. As
used herein, the terms "identical" or "percent identity," in the context of
two or more
nucleic acids or polypeptide sequences, refer to two or more sequences or
subsequences that are the same or have a specified percentage of nucleotides
or amino
acid residues that are the same, when compared and aligned for maximum
correspondence. To determine the percent identity, the sequences are aligned
for
optimal comparison purposes (e.g., gaps can be introduced in the sequence of a
first
amino acid or nucleic acid sequence for optimal alignment with a second amino
or
nucleic acid sequence). The amino acid residues or nucleotides at
corresponding amino
acid positions or nucleotide positions are then compared. When a position in
the first
sequence is occupied by the same amino acid residue or nucleotide as the
corresponding position in the second sequence, then the molecules are
identical at that
position. The percent identity between the two sequences is a function of the
number of
identical positions shared by the sequences (i.e., % identity.# of identical
positions/total
# of positions (e.g., overlapping positions)x100). In some embodiments, the
two
sequences that are compared are the same length after gaps are introduced
within the
sequences, as appropriate (e.g., excluding additional sequence extending
beyond the
sequences being compared). For example, when variable region sequences are
compared, the leader and/or constant domain sequences are not considered. For
sequence comparisons between two sequences, a "corresponding" CDR refers to a
CDR in the same location in both sequences (e.g., CDR-H1 of each sequence).
The determination of percent identity or percent similarity between two
sequences can
be accomplished using a mathematical algorithm. A preferred, non-limiting
example of a
mathematical algorithm utilized for the comparison of two sequences is the
algorithm of
Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, modified
as in
Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an
algorithm
is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990,
J. Mol.
Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST
program, score=100, wordlength=12, to obtain nucleotide sequences homologous
to a
nucleic acid encoding a protein of interest. BLAST protein searches can be
performed
with the XBLAST program, score=50, wordlength=3, to obtain amino acid
sequences
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 107 -
homologous to protein of interest. To obtain gapped alignments for comparison
purposes, Gapped BLAST can be utilized as described in Altschul et al., 1997,
Nucleic
Acids Res. 25:3389-3402. Alternatively, PSI-Blast can be used to perform an
iterated
search which detects distant relationships between molecules (Id.). When
utilizing
BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the
respective programs (e.g., XBLAST and NBLAST) can be used. Another preferred,
non-
limiting example of a mathematical algorithm utilized for the comparison of
sequences is
the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is
incorporated
into the ALIGN program (version 2.0) which is part of the GCG sequence
alignment
software package. When utilizing the ALIGN program for comparing amino acid
sequences, a PAM120 weight residue table, a gap length penalty of 12, and a
gap
penalty of 4 can be used. Additional algorithms for sequence analysis are
known in the
art and include ADVANCE and ADAM as described in Torellis and Robotti, 1994,
Comput. Appl. Biosci. 10:3-5; and FASTA described in Pearson and Lipman, 1988,
Proc. Natl. Acad. Sci. USA 85:2444-8. Within FASTA, ktup is a control option
that sets
the sensitivity and speed of the search. If ktup=2, similar regions in the two
sequences
being compared are found by looking at pairs of aligned residues; if ktup=1,
single
aligned amino acids are examined. ktup can be set to 2 or 1 for protein
sequences, or
from 1 to 6 for DNA sequences. The default if ktup is not specified is 2 for
proteins and 6
for DNA. Alternatively, protein sequence alignment may be carried out using
the
CLUSTAL W algorithm, as described by Higgins et al., 1996, Methods Enzymol.
266:383-402.
Non-Therapeutic Uses
The antibodies described herein are useful as affinity purification agents. In
this process,
the antibodies are immobilized on a solid phase such a Protein A resin, using
methods
well known in the art. The immobilized antibody is contacted with a sample
containing
the IL-23p19 protein (or fragment thereof) to be purified, and thereafter the
support is
washed with a suitable solvent that will remove substantially all the material
in the
sample except the IL-2319 protein, which is bound to the immobilized antibody.
Finally,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 108 -
the support is washed with another suitable solvent that will release the IL-
23p19 protein
from the antibody.
Anti-IL-23p19 antibodies, for example humanized anti-IL-23p19 antibodies, are
also
useful in diagnostic assays to detect and/or quantify IL-23 protein, for
example,
detecting IL-23 expression in specific cells, tissues, or serum. The anti-IL-
23p19
antibodies can be used diagnostically to, for example, monitor the development
or
progression of a disease as part of a clinical testing procedure to, e.g.,
determine the
efficacy of a given treatment and/or prevention regimen. Detection can be
facilitated by
coupling the anti-IL-23p19 antibody. Examples of detectable substances include
various
enzymes, prosthetic groups, fluorescent materials, luminescent materials,
bioluminescent materials, radioactive materials, positron emitting metals
using various
positron emission tomographies, and nonradioactive paramagnetic metal ions.
See, for
example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to
antibodies for use as diagnostics according to the present invention.
The anti-IL-23p19 antibodies can be used in methods for diagnosing an IL-23-
associated disorder (e.g., a disorder characterized by abnormal expression of
IL-23) or
to determine if a subject has an increased risk of developing an IL-23-
associated
disorder. Such methods include contacting a biological sample from a subject
with an
IL-23p19 antibody and detecting binding of the antibody to IL-23p19. By
"biological
sample" is intended any biological sample obtained from an individual, cell
line, tissue
culture, or other source of cells potentially expressing IL-23. Methods for
obtaining
tissue biopsies and body fluids from mammals are well known in the art.
In some embodiments, the method can further comprise comparing the level of IL-
23 in
a patient sample to a control sample (e.g., a subject that does not have an IL-
23-
associated disorder) to determine if the patient has an IL-23-associated
disorder or is at
risk of developing an IL-23-associated disorder.
It will be advantageous in some embodiments, for example, for diagnostic
purposes to
label the antibody with a detectable moiety. Numerous detectable labels are
available,
including radioisotopes, fluorescent labels, enzyme substrate labels and the
like. The
label may be indirectly conjugated with the antibody using various known
techniques.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 109 -
For example, the antibody can be conjugated with biotin and any of the three
broad
categories of labels mentioned above can be conjugated with avidin, or vice
versa.
Biotin binds selectively to avidin and thus, the label can be conjugated with
the antibody
in this indirect manner. Alternatively, to achieve indirect conjugation of the
label with the
antibody, the antibody can be conjugated with a small hapten (such as digoxin)
and one
of the different types of labels mentioned above is conjugated with an anti-
hapten
antibody (e.g., anti-digoxin antibody). Thus, indirect conjugation of the
label with the
antibody can be achieved.
Exemplary radioisotopes labels include 35,
14c, 125., 3H, and 1311. The antibody can be
labeled with the radioisotope, using the techniques described in, for example,
Current
Protocols in Immunology, Volumes 1 and 2, 1991, Coligen et al., Ed. Wiley-
Interscience,
New York, N.Y., Pubs. Radioactivity can be measured, for example, by
scintillation
counting.
Exemplary fluorescent labels include labels derived from rare earth chelates
(europium
.. chelates) or fluorescein and its derivatives, rhodamine and its
derivatives, dansyl,
Lissamine, phycoerythrin, and Texas Red are available. The fluorescent labels
can be
conjugated to the antibody via known techniques, such as those disclosed in
Current
Protocols in Immunology, for example. Fluorescence can be quantified using a
fluori meter.
There are various well-characterized enzyme-substrate labels known in the art
(see,
e.g., U.S. Pat. No. 4,275,149 for a review). The enzyme generally catalyzes a
chemical
alteration of the chromogenic substrate that can be measured using various
techniques.
For example, alteration may be a color change in a substrate that can be
measured
spectrophotometrically. Alternatively, the enzyme may alter the fluorescence
or
chemiluminescence of the substrate. Techniques for quantifying a change in
fluorescence are described above. The chemiluminescent substrate becomes
electronically excited by a chemical reaction and may then emit light that can
be
measured, using a chemiluminometer, for example, or donates energy to a
fluorescent
acceptor.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 1 10 -
Examples of enzymatic labels include luciferases such as firefly lucif erase
and bacterial
luciferase (U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones,
malate
dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO),
alkaline
phosphatase, 13-galactosidase, glucoamylase, lysozyme, saccharide oxidases
(such as
glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase),
heterocydic oxidases (such as uricase and xanthine oxidase), lactoperoxidase,
microperoxidase, and the like. Techniques for conjugating enzymes to
antibodies are
described, for example, in O'Sullivan et al., 1981, Methods for the
Preparation of
Enzyme-Antibody Conjugates for use in Enzyme Immunoassay, in Methods in Enzym.
(J. Langone & H. Van Vunakis, eds.), Academic press, N.Y., 73: 147-166.
Examples of enzyme-substrate combinations include, for example: Horseradish
peroxidase (HRPO) with hydrogen peroxidase as a substrate, wherein the
hydrogen
peroxidase oxidizes a dye precursor such as orthophenylene diamine (OP D) or
3,3',5,5'-
tetramethyl benzidine hydrochloride (TMB); alkaline phosphatase (AP) with para-
Nitrophenyl phosphate as chromogenic substrate; and (3-D-galactosidase (13-D-
Gal) with
a chromogenic substrate such as p-nitropheny1-13-D-galactosidase or
fluorogenic
substrate 4-methylumbelliferyl-3-D-galactosidase.
Numerous other enzyme-substrate combinations are available to those skilled in
the art.
For a general review of these, see U.S. Pat. No. 4,275,149 and U.S. Pat. No.
4,318,980.
In another embodiment, the humanized anti-IL-23p19 antibody is used unlabeled
and
detected with a labeled antibody that binds the humanized anti-IL-23p19
antibody.
The antibodies described herein may be employed in any known assay method,
such as
competitive binding assays, direct and indirect sandwich assays, and
immunoprecipitation assays. See, e.g., Zola, Monoclonal Antibodies: A Manual
of
Techniques, pp. 147-158 (CRC Press, Inc. 1987).
The anti-IL-23p19 antibody or antigen binding fragment thereof can be used to
inhibit
the binding of IL-23 to the IL-23 receptor. Such methods comprise
administering an
anti-IL-23p19 antibody or antigen binding fragment thereof to a cell (e.g., a
mammalian
cell) or cellular environment, whereby signaling mediated by the IL-23
receptor is
inhibited. These methods can be performed in vitro or in vivo. By "cellular
environment"
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 1 1 1 -
is intended the tissue, medium, or extracellular matrix surrounding a cell.
The anti-IL-
23p19 antibody or antigen binding fragment thereof is administered to the
cellular
environment of a cell in such a manner that the antibody or fragment is
capable of
binding to IL-23 molecules outside of and surrounding the cell, therefore,
preventing the
binding of IL-23 to its receptor.
Diagnostic Kits
An anti-IL-23p19 antibody can be used in a diagnostic kit, i.e., a packaged
combination
of reagents in predetermined amounts with instructions for performing the
diagnostic
assay. Where the antibody is labeled with an enzyme, the kit may include
substrates
and cofactors required by the enzyme such as a substrate precursor that
provides the
detectable chromophore or fluorophore. In addition, other additives may be
included
such as stabilizers, buffers (for example a block buffer or lysis buffer), and
the like. The
relative amounts of the various reagents may be varied widely to provide for
concentrations in solution of the reagents that substantially optimize the
sensitivity of the
assay. The reagents may be provided as dry powders, usually lyophilized,
including
excipients that on dissolution will provide a reagent solution having the
appropriate
concentration.
Therapeutic Uses
In another embodiment, a humanized anti-IL-23p19 antibody disclosed herein is
useful
in the treatment of various disorders associated with the expression of IL-
23p19 as
described herein. Methods for treating an IL-23 associated disorder comprise
administering a therapeutically effective amount of a humanized anti-IL-23p19
antibody
to a subject in need thereof.
The humanized anti-IL-23p19 antibody or agent is administered by any suitable
means,
including parenteral, subcutaneous, intraperitoneal, intrapulmonary, and
intranasal, and,
if desired for local immunosuppressive treatment, intralesional administration
(including
perfusing or otherwise contacting the graft with the antibody before
transplantation). The
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 112 -
humanized anti-IL-23p19 antibody or agent can be administered, for example, as
an
infusion or as a bolus. Parenteral infusions include intramuscular,
intravenous,
intraarterial, intraperitoneal, or subcutaneous administration. In addition,
the humanized
anti-IL-23p19 antibody is suitably administered by pulse infusion,
particularly with
declining doses of the antibody. In one aspect, the dosing is given by
injections, most
preferably intravenous or subcutaneous injections, depending in part on
whether the
administration is brief or chronic.
For the prevention or treatment of disease, the appropriate dosage of antibody
will
depend on a variety of factors such as the type of disease to be treated, as
defined
above, the severity and course of the disease, whether the antibody is
administered for
preventive or therapeutic purposes, previous therapy, the patient's clinical
history and
response to the antibody, and the discretion of the attending physician. The
antibody is
suitably administered to the patient at one time or over a series of
treatments.
Depending on the type and severity of the disease, about 1 jig/kg to 20 mg/kg
(e.g., 0.1-
15 mg/kg) of antibody is an initial candidate dosage for administration to the
patient,
whether, for example, by one or more separate administrations, or by
continuous
infusion. A typical daily dosage might range from about 1 pg/kg to 100 mg/kg
or more,
depending on the factors mentioned above. For repeated administrations over
several
days or longer, depending on the condition, the treatment is sustained until a
desired
suppression of disease symptoms occurs. However, other dosage regimens may be
useful. The progress of this therapy is easily monitored by conventional
techniques and
assays. An exemplary dosing regimen is that disclosed in WO 94/04188.
The term "suppression' is used herein in the same context as "amelioration"
and
"alleviation" to mean a lessening of one or more characteristics of the
disease.
The antibody composition will be formulated, dosed, and administered in a
fashion
consistent with good medical practice. Factors for consideration in this
context include
the particular disorder being treated, the particular mammal being treated,
the clinical
condition of the individual patient, the cause of the disorder, the site of
delivery of the
agent, the method of administration, the scheduling of administration, and
other factors
known to medical practitioners. The ''therapeutically effective amount" of the
antibody to
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 113 -
be administered will be governed by such considerations, and is the minimum
amount
necessary to prevent, ameliorate, or treat the disorder associated with IL-23
expression.
The antibody need not be, but is optionally, formulated with one or more
agents
currently used to prevent or treat the disorder in question. The effective
amount of such
other agents depends on the amount of humanized anti-IL-23p19 antibody present
in
the formulation, the type of disorder or treatment, and other factors
discussed above.
These are generally used in the same dosages and with administration routes as
used
hereinbef ore or about from 1 to 99% of the heretofore employed dosages.
IL-23-Associated Disorders
The anti-IL-23p19 antibodies or agents are useful for treating or preventing
an
immunological disorder characterized by abnormal expression of IL-23, e.g., by
inappropriate activation of immune cells (e.g., lymphocytes or dendritic
cells). Such
abnormal expression of IL-23 can be due to, for example, increased IL-23
protein levels.
The anti-IL-23p19 antibodies or antigen binding fragments thereof also find
use in the
treatment or prevention of respiratory disorders, metabolic disorders, for
example
diabetes mellitus, and certain cancers. Treatment or prevention of the
immunological
disorder, respiratory disorder, metabolic disorder or cancer, according to the
methods
described herein, is achieved by administering to a subject in need of such
treatment or
prevention an effective amount of the anti-IL-23p19 antibody or agent, whereby
the
antibody decreases the activity of IL-23 associated with the disease state.
Immunological diseases that are characterized by inappropriate activation of
immune
cells and that can be treated or prevented by the methods described herein can
be
classified, for example, by the type(s) of hypersensitivity reaction(s) that
underlie the
disorder. These reactions are typically classified into four types:
anaphylactic reactions,
cytotoxic (cytolytic) reactions, immune complex reactions, or cell-mediated
immunity
(CMI) reactions (also referred to as delayed-type hypersensitivity (DTH)
reactions).
(See, e.g., Fundamental Immunology (William E. Paul ed., Raven Press, N.Y.,
3rd ed.
1993).) Immunological diseases include inflammatory diseases and autoimmune
diseases.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 114 -
Specific examples of immunological diseases include the following: rheumatoid
arthritis,
autoimmune demyelinative diseases (e.g., multiple sclerosis, allergic
encephalomyelitis),
endocrine opthalmopathy, uveoretinitis, systemic lupus erythematosus,
myasthenia
gravis, Grave's disease, glomerulonephritis, autoimmune hepatological
disorder,
inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis),
anaphylaxis,
allergic reaction, Sjogren's syndrome, type I diabetes mellitus, primary
biliary cirrhosis,
Wegener's granulomatosis, fibromyalgia, polymyositis, dermatomyositis,
inflammatory
myositis, multiple endocrine failure, Schmidt's syndrome, autoimmune uveitis,
Addison's
disease, adrenalitis, thyroiditis, Hashimoto's thyroiditis, autoimmune thyroid
disease,
pernicious anemia, gastric atrophy, chronic hepatitis, lupoid hepatitis,
atherosclerosis,
subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's
syndrome,
autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic
anemia,
pemphigus vulgaris, pemphigus, dermatitis herpetiformis, alopecia arcata,
pemphigoid.
scleroderma, progressive systemic sclerosis, CREST syndrome (calcinosis,
Raynaud's
phenomenon, esophageal dysmotility, sclerodactyl), and telangiectasia), male
and
female autoimmune infertility, ankylosing spondolytis, ulcerative colitis,
mixed
connective tissue disease, polyarteritis nedosa, systemic necrotizing
vasculitis, atopic
dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas' disease,
sarcoidosis,
rheumatic fever, asthma, recurrent abortion, anti-phospholipid syndrome,
farmer's lung,
erythema multiforme, post cardiotomy syndrome, Cushing's syndrome, autoimmune
chronic active hepatitis, bird-fancier's lung, toxic epidermal necrolysis,
Alport's
syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis, interstitial
lung disease,
erythema nodosum, pyoderma gangrenosum, transfusion reaction, Takayasu's
arteritis,
polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell
arteritis,
ascariasis, aspergillosis, Sampter's syndrome, eczema, lymphomatoid
granulomatosis,
Behcet's disease, Caplan's syndrome, Kawasaki's disease (also known as
Kawasaki
syndrome or Mucocutaneous Lymph Node Syndrome), dengue, encephalomyelitis,
endocarditis, endomyocardial fibrosis, endophthalmitis, erythema elevatum et
diutinum,
psoriasis, psoriatic arthritis, erythroblastosis fetalis, eosinophilic
faciitis, Shulman's
syndrome, Felty's syndrome, filariasis, cyclitis, chronic cyclitis,
heterochronic cyclitis,
Fuch's cyclitis, IgA nephropathy, Henoch-Schonlein purpura, graft versus host
disease,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 115 -
transplantation rejection, cardiomyopathy, Eaton-Lambert syndrome, relapsing
polychondritis, cryoglobulinemia, Waldenstrom's macroglobulemia, Evan's
syndrome,
acute respiratory distress syndrome, pulmonary inflammation, osteoporosis,
delayed
type hypersensitivity and autoimmune gonadal failure.
In one aspect, the immunological disease is psoriasis. Psoriasis is a chronic
inflammatory disease of the skin characterized by dysfunctional keratinocyte
differentiation and hyperproliferation and marked accumulation of inflammatory
T cells
and dendritic cells. For example, the immunological disease includes plaque
psoriasis,
for example chronic plaque psoriasis, for example moderate to severe chronic
plaque
psoriasis, for example in patients who are candidates for systemic therapy or
phototherapy. For example, the immunological disease includes palmar pustular
psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis or
erythodermic
psoriasis.
In a further aspect, the immunological disease is Crohn's disease. Crohn's
disease (CD)
is an inflammatory bowel disease characterized by chronic transmural
inflammatory
lesions in the gastrointestinal epithelial barrier and mucosa. CD can affect
any site within
the GI tract, most frequently the terminal ileum. CD typically follows a
relapsing and
remitting course, and causes substantial acute and long-term morbidity and
increased
mortality. Patients often develop local complications (e.g. fistulas,
abscesses), systemic
complications (e.g. uveitis, arthritis), or side effects of treatment, and may
require major
surgery. Roughly a third of patients fall into each of the categories of mild,
moderate,
and severe disease. Patients with moderate-to-severe Crohn's Disease have
debilitating
illness with clinical features such as abdominal pain, diarrhea, abscess
formation, and
fistulae.
In a further aspect, the immunological disease is spondyloarthritis. In a
further aspect,
the disease is ankylosing spondylitis (also called radiographic
spondyloarthritis).
Ankylosing spondylitis (AS; radiographic axial spondyloarthritis) is the
prototypical form
of the spondyloarthritides (SpA). It is a crippling insidious rheumatologic
disease that is
commoner in males than females and affects young individuals; in 80% of
patients the
onset of symptoms occurs at less than 30 years of age. It is characterized by
an
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 116 -
inflammatory component which contributes to the Ankylosing Spondylitis
Activity Score
(ASAS) that is used as a measure of improvement in treatment studies.
Additionally,
abnormal bone growth results in the formation of bony spurs (syndesmophytes)
visible
on plain radiographs accompanied by increased spinal rigidity, ultimately
leading to bony
ankylosis and vertebral deformities. In a further aspect, the immunological
disease is
non-radiographic axial Spondyloarthritis. Non-radiographic axial
Spondyloarthritis
(nrSpA), a more recently defined entity than AS, is considered to represent an
earlier
manifestation of the same pathologic processes as AS, although it is
increasingly
recognized that some patients (particularly females) may not progress to
radiographic
disease, and may therefore be considered to have a distinct subtype of this
disease. In a
further aspect, the disease is peripheral spondyloarthritis. Peripheral
spondyloarthritis
can be defined by the presence of arthritis, enthesitis, or dactylitis, with
either at least
one 'specific' SpA feature (psoriasis, inflammatory bowel disease, preceding
infection,
HLA-627, uveitis, sacroiliitis on imaging) or at least two of the remaining
SpA-features
(arthritis, enthesitis, dactylitis, inflammatory back pain in the past,
positive family history
for SpA). This definition is for example used by ASAS (Association
SpondyloArthritis
investigation Society), see also for example Carron P. et al. (Curr Opinion
Rheumatol
2012; 24: 370-4).
In some embodiments, the immunological disorder is a T cell-mediated
immunological
disorder and accordingly, the anti-IL-23p19 antibodies and agents as described
herein
are also useful for treating or preventing T cell-mediated immunological
disorders.
In one aspect, the anti-IL-23p19 antibodies or agents are useful for treating
or
preventing a respiratory disorder in which IL-23 is abnormally expressed.
Treatment or
prevention of the respiratory disorder, according to the methods described
herein, is
achieved by administering to a subject in need of such treatment or prevention
an
effective amount of the anti-IL-23p19 antibody or agent, whereby the antibody
decreases the activity of IL-23 associated with the disease state.These
include, but are
not limited to: respiratory complaints, obstructive pulmonary diseases of
various origins,
pulmonary emphysema of various origins, restrictive pulmonary diseases,
interstitial
pulmonary diseases, interstitial lung disease, cystic fibrosis, bronchitis of
various origins,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 117 -
bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of
pulmonary
oedema; obstructive pulmonary diseases selected from among CORD (chronic
obstructive pulmonary disease), asthma, bronchial asthma, paediatric asthma,
severe
asthma, acute asthma attacks and chronic bronchitis; pulmonary emphysema which
has
its origins in CORD (chronic obstructive pulmonary disease) or al -proteinase
inhibitor
deficiency; restrictive pulmonary diseases selected from among allergic
alveolitis,
restrictive pulmonary diseases triggered by work-related noxious substances,
such as
asbestosis or silicosis, and restriction caused by lung tumours, such as
lymphangiosis
carcinomatosa, bronchoalveolar carcinoma and lymphomas; pneumonia caused by
infections, such as for example infection by viruses, bacteria, fungi,
protozoa, helminths
or other pathogens, pneumonitis caused by various factors, such as for example
aspiration and left heart insufficiency, radiation-induced pneumonitis or
fibrosis,
collagenoses, such as for example lupus erythematosus, systemic scleroderma or
sarcoidosis, granulomatoses, such as for example Boeck's disease, idiopathic
interstitial
pneumonia or idiopathic pulmonary fibrosis (IPF); mucoviscidosis, bronchitis
caused by
bacterial or viral infection, allergic bronchitis and toxic bronchitis;
bronchiectasis;
pulmonary oedema, for example, toxic pulmonary oedema after aspiration or
inhalation
of toxic substances and foreign substances; rhinitis, arthritis and related
arthropathies,
psoriasis, myeloid leukemia, multiple sclerosis, Alzheimer's disease,
glomerulonephritis,
and chronic atopic dermatitis.
In another aspect, the anti-IL-23p19 antibodies and agents as described herein
are also
useful for treating cancers, in which IL-23 is abnormally expressed.
IL-23-expressing cancers that can be treated by the methods described herein
include,
for example, leukemia, such as acute leukemia, acute lymphocytic leukemia,
acute
myelocytic leukemia (e.g., myeloblastic, promyelocytic, myelomonocytic,
monocytic, or
erythroleukemia), chronic leukemia, chronic myelocytic (granulocytic)
leukemia, or
chronic lymphocytic leukemia; Polycythemia vera; Lymphoma (e.g., Hodgkin's
disease
or Non-Hodgkin's disease); multiple myeloma, Waldenstrom's macroglobulinemia;
heavy
chain disease; solid tumors such sarcomas and carcinomas (e.g., fibrosarcoma,
myxosarco ma, liposarcoma, chondrosarcoma, osteogenic sarcoma, osteosarcoma,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 118 -
chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma,
lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's
tumor,
leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, colorectal carcinoma,
pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous
cell
carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma,
sebaceous
gland carcinoma, papillary carcinoma, papillary adenocarcinomas,
cystadenocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma,
bile
duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor,
cervical cancer, uterine cancer, testicular tumor, lung carcinoma, small cell
lung
carcinoma, non small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma,
glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma,
pinealoma,
hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma,
neuroblastoma, retinoblastoma, nasopharyngeal carcinoma, or esophageal
carcinoma).
In another aspect, the anti-IL-23p19 antibodies and agents as described herein
are also
useful for treating discoid lupus, malaria, malignant melanoma, aplastic
anaemia,
Huntington's Disease, palmoplantar pustulosis, IgA nephritis, ANCA-Associated
Vasculitis, scleritis or sepsis.
Pharmaceutical Compositions and Administration Thereof
A composition comprising an IL-23p19 binding agent (e.g., an anti-IL-23p19
antibody)
can be administered to a subject haying or at risk of having an immunological
disorder,
respiratory disorder or a cancer_ The invention further provides for the use
of a IL-23p19
binding agent (e.g., an anti-IL-23p19 antibody) in the manufacture of a
medicament for
prevention or treatment of a cancer, respiratory disorder or immunological
disorder. The
term "subject" as used herein means any mammalian patient to which an IL-23p19
binding agent can be administered, including, e.g., humans and non-human
mammals,
such as primates, rodents, and dogs. Subjects specifically intended for
treatment using
the methods described herein include humans. The antibodies or agents can be
administered either alone or in combination with other compositions in the
prevention or
treatment of the immunological disorder, respiratory disorder or cancer. Such
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 119 -
compositions which can be administered in combination with the antibodies or
agents
include methotrexate (MTX) and immunomodulators, e.g. antibodies or small
molecules.
Examples of antibodies for use in such pharmaceutical compositions are those
that
comprise a humanized antibody or antibody fragment having the light chain
variable
region amino acid sequence of any of SEQ ID NO: 84, 86, 88, 90, 91, 93, 95,
97, 99,
101, 103, 105, 107, 109, 111, 113, 115, 117 or 119. Examples of antibodies for
use in
such pharmaceutical compositions are also those that comprise a humanized
antibody
or antibody fragment having the heavy chain variable region amino acid
sequence of
any of SEQ ID NO: 121, 123, 125, 127, 128, 130, 132, 134, 136, 138, 140, 142,
144,
146, 148, 150, 152, 154 or 156.
Further examples of antibodies for use in such pharmaceutical compositions are
also
those that comprise a humanized antibody or antibody fragment having the light
chain
variable region amino acid sequence of any of SEQ ID NO:158, 160, 162 or 164.
Preferred antibodies for use in such pharmaceutical compositions are also
those that
comprise a humanized antibody or antibody fragment having the heavy chain
variable
region amino acid sequence of any of SEQ ID NO:166, 168, 170 or 172.
Further examples of antibodies for use in such pharmaceutical compositions are
also
those that comprise a humanized antibody or antibody fragment having the light
chain
variable region and heavy chain variable region of any of SEQ ID NO: 160 and
166,
SEQ ID NO: 160 and 168, SEQ ID NO: 158 and 166 or SEQ ID NO: 158 and 168.
Further examples of antibodies for use in such pharmaceutical compositions are
also
those that comprise a humanized antibody having the light chain region amino
acid
sequence of any of SEQ ID NO:174 or 180. Preferred antibodies for use in such
pharmaceutical compositions are also those that comprise humanized antibody
having
the heavy chain variable region amino acid sequence of any of SEQ ID NO:176 or
178.
Further examples of antibodies for use in such pharmaceutical compositions are
also
those that comprise Antibody A, Antibody B, Antibody C or Antibody D.
Various delivery systems are known and can be used to administer the IL-23p19
binding
agent. Methods of introduction include but are not limited to intradermal,
intramuscular,
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 120 -
intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral
routes. The IL-
23p19 binding agent can be administered, for example by infusion, bolus or
injection,
and can be administered together with other biologically active agents such as
chemotherapeutic agents. Administration can be systemic or local.
In preferred
embodiments, the administration is by subcutaneous injection. Formulations for
such
injections may be prepared in for example prefilled syringes that may be
administered
once every other week.
In specific embodiments, the IL-23p19 binding agent composition is
administered by
injection, by means of a catheter, by means of a suppository, or by means of
an implant,
the implant being of a porous, non-porous, or gelatinous material, including a
membrane, such as a sialastic membrane, or a fiber. Typically, when
administering the
composition, materials to which the anti-IL-23p19 antibody or agent does not
absorb are
used.
In other embodiments, the anti-IL-23p19 antibody or agent is delivered in a
controlled
release system. In one embodiment, a pump may be used (see, e.g., Langer,
1990,
Science 249:1527-1533; Sefton, 1989, CRC Crit. Ref. Biomed. Eng. 14:201;
Buchwald
et al., 1980, Surgery 88:507; Saudek et al., 1989, N. Engl. J. Med. 321:574).
In another
embodiment, polymeric materials can be used. (See, e.g., Medical Applications
of
Controlled Release (Langer and Wise eds., CRC Press, Boca Raton, Fla., 1974);
Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen
and Ball
eds., Wiley, New York, 1984); Ranger and Peppas, 1983, Macromol. Sci. Rev.
Macromol. Chem. 23:61. See also Levy et al., 1985, Science 228:190; During et
al.,
1989, Ann. Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105.) Other
controlled
release systems are discussed, for example, in Langer, supra.
An IL-23p19 binding agent (e.g., an anti-IL-23p19 antibody) can be
administered as
pharmaceutical compositions comprising a therapeutically effective amount of
the
binding agent and one or more pharmaceutically compatible ingredients.
In typical embodiments, the pharmaceutical composition is formulated in
accordance
with routine procedures as a pharmaceutical composition adapted for
intravenous or
subcutaneous administration to human beings. Typically, compositions for
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
-121 -
administration by injection are solutions in sterile isotonic aqueous buffer.
Where
necessary, the pharmaceutical can also include a solubilizing agent and a
local
anesthetic such as lignocaine to ease pain at the site of the injection.
Generally, the
ingredients are supplied either separately or mixed together in unit dosage
form, for
example, as a dry lyophilized powder or water free concentrate in a
hermetically sealed
container such as an ampoule or sachette indicating the quantity of active
agent. Where
the pharmaceutical is to be administered by infusion, it can be dispensed with
an
infusion bottle containing sterile pharmaceutical grade water or saline. Where
the
pharmaceutical is administered by injection, an ampoule of sterile water for
injection or
saline can be provided so that the ingredients can be mixed prior to
administration.
Further, the pharmaceutical composition can be provided as a pharmaceutical
kit
comprising (a) a container containing a IL-23p19 binding agent (e.g., an anti-
IL-23p19
antibody) in lyophilized form and (b) a second container containing a
pharmaceutically
acceptable diluent (e.g., sterile water) for injection. The pharmaceutically
acceptable
diluent can be used for reconstitution or dilution of the lyophilized anti-IL-
23p19 antibody
or agent. Optionally associated with such container(s) can be a notice in the
form
prescribed by a governmental agency regulating the manufacture, use or sale of
pharmaceuticals or biological products, which notice reflects approval by the
agency of
manufacture, use or sale for human administration.
The amount of the IL-23p19 binding agent (e.g., anti-IL-23p19 antibody) that
is effective
in the treatment or prevention of an immunological disorder or cancer can be
determined
by standard clinical techniques. In addition, in vitro assays may optionally
be employed
to help identify optimal dosage ranges. The precise dose to be employed in the
formulation will also depend on the route of administration, and the stage of
immunological disorder or cancer, and should be decided according to the
judgment of
the practitioner and each patient's circumstances. Effective doses may be
extrapolated
from dose-response curves derived from in vitro or animal model test systems.
Generally, the dosage of an anti-IL-23p19 antibody or IL-23p19 binding agent
administered to a patient with an immunological disorder or IL-23p19-
expressing cancer
is typically about 0.1 mg/kg to about 100 mg/kg of the subject's body weight.
The
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 122 -
dosage administered to a subject is about 0.1 mg/kg to about 50 mg/kg, about 1
mg/kg
to about 30 mg/kg, about 1 mg/kg to about 20 mg/kg, about 1 mg/kg to about 15
mg/kg,
or about 1 mg/kg to about 10 mg/kg of the subject's body weight.
Exemplary doses include, but are not limited to, from 1 ng/kg to 100 mg/kg. In
some
embodiments, a dose is about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3
mg/kg,
about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg,
about 9
mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about
14
mg/kg, about 15 mg/kg or about 16 mg/kg. The dose can be administered, for
example,
daily, once per week (weekly), twice per week, thrice per week, four times per
week, five
times per week, six times per week, biweekly or monthly, every two months, or
every
three months. In specific embodiments, the dose is about 0.5 mg/kg/week, about
1
mg/kg/week, about 2 mg/kg/week, about 3 mg/kg/week, about 4 mg/kg/week, about
5
mg/kg/week, about 6 mg/kg/week, about 7 mg/kg/week, about 8 mg/kg/week, about
9
mg/kg/week, about 10 mg/kg/week, about 11 mg/kg/week, about 12 mg/kg/week,
about
13 mg/kg/week, about 14 mg/kg/week, about 15 mg/kg/week or about 16
mg/kg/week.
In some embodiments, the dose ranges from about 1 mg/kg/week to about 15
mg/kg/week.
In some embodiments, the pharmaceutical compositions comprising the IL-23p19
binding agent can further comprise a therapeutic agent, either conjugated or
unconjugated to the binding agent. The anti-IL-23p19 antibody or IL-23p19
binding
agent can be co-administered in combination with one or more therapeutic
agents for
the treatment or prevention of immunological disorders or cancers.
Such combination therapy administration can have an additive or synergistic
effect on
disease parameters (e.g., severity of a symptom, the number of symptoms, or
frequency
of relapse).
With respect to therapeutic regimens for combinatorial administration, in a
specific
embodiment, an anti-IL-23p19 antibody or IL-23p19 binding agent is
administered
concurrently with a therapeutic agent. In another specific embodiment, the
therapeutic
agent is administered prior or subsequent to administration of the anti-IL-
23p19 antibody
or IL-23p19 binding agent, by at least an hour and up to several months, for
example at
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 123 -
least an hour, five hours, 12 hours, a day, a week, a month, or three months,
prior or
subsequent to administration of the anti-IL-23p19 antibody or IL-23p19 binding
agent.
For example, a pharmaceutical composition of the present invention comprises
an
antibody molecule, for example an antibody molecule described herein, and
succinate
buffer. In one embodiment, the pharmaceutical composition comprises 50 mM or
less
succinate buffer.
In a further embodiment, a pharmaceutical composition of the present invention
comprises 1 to 40 mg/ml of an antibody molecule, for example an antibody
molecule as
described herein, and further comprises 5 to 50 mM succinate buffer and 50 to
200 mM
sodium chloride. In one further embodiment, the pH of the pharmaceutical
composition
is in the range of pH 6.0 to 7Ø In one further embodiment, the
pharmaceutical
composition comprises 2.5 to 30 mg/ml of the antibody molecule, in a further
embodiment 5 to 20 mg/ml of the antibody molecule. In a further embodiment,
the
pharmaceutical composition comprises 10 to 40 mM succinate buffer, in a
further
embodiment 20 to 30 mM succinate buffer. In a further embodiment, the
pharmaceutical
composition comprises 75 to 175 mM sodium chloride, in a further embodiment
100 to
150 mM sodium chloride. In a further embodiment, the pharmaceutical
composition
further comprises a detergent, for example polysorbate 20 (Tween 20), for
example at a
concentration of 0.20 g/I. In one aspect, the antibody molecule in the
pharmaceutical
composition is Antibody A, Antibody B, Antibody C or Antibody D.
In a further embodiment, a pharmaceutical composition of the present invention
comprises 10 mg/mlof an antibody molecule, 25mM succinate buffer, 125mM sodium
chloride and 0,02% Tween 20 at a pH of 6.0 to 7Ø In one aspect, the pH of
the
pharmaceutical composition is 6.5. In one aspect, the antibody molecule in the
pharmaceutical composition is Antibody A, Antibody B, Antibody C or Antibody
D.
In a further embodiment, the present invention provides a pharmaceutical
composition
comprising 70 to 100 mg/ml of an antibody molecule, for example an antibody
molecule
as described herein, and 100 to 300 mM sorbitol. In a further embodiment, the
pharmaceutical composition further comprises 25 mM or less succinate buffer.
In one
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 124 -
further embodiment, the pH of said pharmaceutical composition is in the range
of pH 5.5
to 6.5. In one aspect, the pH of the pharmaceutical composition is 5.5 to 6.1.
In one
further embodiment, the pharmaceutical composition comprises 80 to 95 mg/ml of
the
antibody molecule. In a further embodiment, the pharmaceutical composition
comprises
10 mM or less succinate buffer, in a further embodiment 5 mM or less succinate
buffer.
in a further embodiment at least 1 mM succinate buffer, in a further
embodiment at least
2.5 mM succinate buffer, in a further embodiment 1 to 10 mM succinate buffer,
in a
further embodiment, 2.5 to 5 mM, succinate buffer. In a further embodiment the
pharmaceutical composition comprises 150 to 300 mM sorbitol, in a further
embodiment
175 to 275 mM sorbitol, in a further embodiment 200 to 250 mM sorbitol. In a
further
embodiment, the pharmaceutical composition further comprises a detergent, for
example polysorbate 20 (Tween 20), for example at a concentration of 0.20 g/I.
In one
aspect, the antibody molecule in the pharmaceutical composition is Antibody A,
Antibody B, Antibody C or Antibody D.
In a further embodiment, a pharmaceutical composition of the present invention
comprises 90 mg/ml of an antibody molecule, 4.4mM succinate buffer, 225mM
sorbitol
and 0,02% Tween 20 at a pH of 5.5 to 6.5. In one aspect, the pH of the
pharmaceutical
composition is 5.5 to 6.1. In one aspect, the pH of the pharmaceutical
composition is
5.8. In one aspect, the antibody molecule in the pharmaceutical composition is
Antibody
A, Antibody B, Antibody C or Antibody D.
In a further embodiment, a pharmaceutical composition of the present invention
comprises 90 mg/ml of an antibody molecule, 240mM sorbitol and 0,02% Tween 20
at a
pH of 5.5 to 6.5. In one aspect, the pH of the pharmaceutical composition is
5.5 to 6.1.
In one aspect, the pH of the pharmaceutical composition is 5.8. In one aspect,
the
antibody molecule in the pharmaceutical composition is Antibody A, Antibody B,
Antibody C or Antibody D.
Pharmaceutical compositions according to the present invention are described
in further
details hereinbelow. In one aspect, the pharmaceutical compositions disclosed
herein
are physico-chemically stable and maintain the integrity of an antibody
comprised in said
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 125 -
pharmaceutical composition, for example when stored for 8 weeks at 40 C as
shown
hereinbelow.
Articles of Manufacture
In another aspect, an article of manufacture containing materials useful for
the treatment
of the disorders described above is included. The article of manufacture
comprises a
container and a label. Suitable containers include, for example, bottles,
vials, syringes,
and test tubes. The containers may be formed from a variety of materials such
as glass
or plastic. The container holds a composition that is effective for treating
the condition
and may have a sterile access port. For example, the container may be an
intravenous
solution bag or a vial having a stopper pierceable by a hypodermic injection
needle. The
active agent in the composition is the humanized anti-IL-23p19 antibody. The
label on or
associated with the container indicates that the composition is used for
treating the
condition of choice. The article of manufacture may further comprise a second
container
comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered
saline,
Ringer's solution, and dextrose solution. It may further include other
materials desirable
from a commercial and user standpoint, including other buffers, diluents,
filters, needles,
syringes, and package inserts with instructions for use.
The invention is further described in the following examples, which are not
intended to
limit the scope of the invention.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 126 -
Examples
Example 1: Production of Humanized Anti-IL-23p19 Antibodies
Mouse lead antibody 6B8 was converted to a chimeric antibody consisting of the
mouse
variable domain of 6B8 and a human constant IgG1K0 domain. Mouse antibody 6B8
is
shown in Tables 1 and 2 herein above. The IgG1K0 (knock out) has two
replacement
mutations (Leu234Ala and Leu235A1a) that eliminate ADCC and CDC activity by
reducing effector functions such as FayR and complement binding. The variable
domains of the mouse and chimeric antibodies are identical. Chimeric
antibodies are
generated to confirm the function of the antibody and to ensure the correct
sequence
has been obtained. The variable region of the antibody is then humanized
through a
design and screening process. A library was made where human and mouse
residues
were varied in such a way that in any given position there could be either a
human or
mouse residue. Such a library was made for those amino acids that were
different
between human germline and mouse antibody. Only the clones that retain the
function
of the parent mouse antibody were selected. Representative humanized variable
regions for antibody 6B8 are shown in Tables 5 and 6.
In this manner, Antibody A, Antibody B, Antibody C and Antibody D were
humanized
antibodies derived from mouse antibody 6B8 (cloned into a human IgG1-K0
(KO¨knock-out)/kappa backbone. Antibodies A, B, C and D are shown in Table 7.
Example 2: Binding of antibodies to recombinant IL-23 protein
A) Kinetics and affinity of mouse anti-IL-23p19 antibodies binding to
recombinant
human IL-23 are shown below (Table 9). Kinetics and binding affinities were
measured
using the Fortebio Octet (Fortebio, Menlo Park, CA) using material generated
from
hybridoma following single column purification. Since the Octet is not a
fluidics based
technology, this method does not provide precise determination of off-rate. In
some
cases, only a estimate of affinity can be obtained.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 127 -
Table 9
Antibody ka(1/Ms) kd(1/s) KD(pM)
18C4 3.84E+05 2.14E-06 5.57
18E 5 3.29E+05 2.61E-06 7.93
18D3 3.19E+05 2.16E-06 6.78
20 E8 4.21E+05 2.69E-04 638
22 E2 3.46E+05 3.53E-04 1024
24A5 2.02E+05 4.57E-06 22.6
15C11 4.11E+05 1.07E-05 26
43F5 1.72E+05 5.96E-06 34.6
27G8 1.57E+05 4.26E-06 27.2
31H9 2.99E+05 3.45E-06 11.5
2D1 < 1 e-6 <1
9012 < 1 e-6 <1
6B8 < 1 e-6 <1
73H10 5.29E+04 5.24E-06 99.2
74H3 3.06E+04 2.09E-06 68.3
35H8
26F7 4.76E+05 1.34E-05 28.1
34G3 9.18E+05 3.10E-05 32.8
34D9 3.44E+03 1.87E-06 544
B) Affinities were measured for humanized antibodies derived from mouse
antibody
6B8. Kinetic binding data, measured using the ProteON XPR36 (Biorad, Hercules,
CA)
and globally fit to a 1:1 binding model, demonstrated the interactions with
recombinant
IL-23 either with or without a 21 amino acid linker covalently joining the p19
and p40
subunits to be of high affinity, in the range of 1 pM - 100 pM (Table 10).
Antibody 6H12
(disclosed in WO 2007/027714), antibody QF20 (disclosed in WO 2007/024846) and
antibody C1273 (disclosed in WO 2007/005955) were also tested.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 128 -
Table 10
Antibody Human IL-23 with linker Human IL-23 no linker
ka (1/Ms) kd (1/s) KD ka (1/Ms) kd (1/s) KD
(PM) (PM)
Mouse 6B8 5.57E+05 1.38E-05 24.5
Antibody A 6.27E+05 < 1 e-6 <1 5.51E+05 <1e-6 <1
Antibody B 3.56E+05 < 1 e-6 < 1 5.17E+05 <1e-6 < 1
Antibody C 3.74E+05 1.19E-05 31.8 4.54E+05 1.65E-05 36.3
Antibody D 3.82E+05 4.07E-05 107 3.66E+05 4.93E-05 135
C-1273 3.60E+05 5.75E-06 15.8
6H12 4.99E+05 1.07E-04 214
QF20 2.03E+05 5.89E-06 2.91
C) Affinity and kinetic data for the anti-IL-23p19 antibodies binding to
cynomologous IL-
23 were measured on the ProteON XPR36, and globally fit to a 1:1 binding model
(Table
11). Antibody 6H12 (disclosed in WO 2007/027714), antibody QF20 (disclosed in
WO
2007/024846) and antibody C1273 (disclosed in WO 2007/005955) were also
tested.
Table 11
Antibody KD (pM) ka (1/Ms) kd (1/s)
Antibody A < 1 2.95E+06 < le-6
Antibody B < 1 2.99E+06 < 1 e-6
Antibody C 2.9 3.23E+06 9.36E-06
Antibody D 15.9 2.07E+06 3.29E-05
C-1273 >5,000 n/a n/a
6H12 157 9.91E+05 1.56E-04
0F20 1.2 3.90E+06 4.78E-06
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 129 -
D) Molecular Selectivity over human IL-12
The anti-IL-23p19 antibodies were also injected over a human IL-12 surface at
a
concentration of 100 nM. The binding signal for these antibodies measured
using the
Fortebio Octet is zero, which indicates that these antibodies selectively bind
to human
IL-23. The binding of the anti-IL-23p19 antibodies to IL-23 was also analyzed
in the
presence of 50% human serum and no significant effect of serum on binding on-
rate
was observed demonstrating high specificity.
Example 3: Competition binding assay of human IL-23 binding to human IL-23R/Fc
Human IL-23R-Fc was captured on the biosensor surface and 10 nM of human IL-23
was injected. The sensorgram indicates the specific binding between IL-23 and
the IL-23
receptor (Figure 2, top trace). Antibodies were then co-injected with 10 nM
human IL-23
to assess whether antibody binding to the IL-23 could inhibit the interaction
between IL-
23 and the IL-23 receptor. In this example, if the antibody binds to human IL-
23 and is
able to inhbit the interaction then reduced or no binding will be observed
(Figure 2,
bottom trace). In the example shown an equivalent molar concentration of
Antibody A
was co-injected with 10 nM recombinant human IL-23.
Example 4: Functional Cell Assays, Inhibition of IL-17 production from IL-23
stimulated mouse splenocytes
One functional cell assay for anti-IL-23p19 antibodies measures their ability
to inhibit IL-
23 stimulated IL-17 production from mononuclear cells isolated from mouse
spleens.
Human recombinant IL-23 protein is capable of stimulating IL-17 release from
mouse
splenocytes. In addition, a natural source of human IL-23 found in the
supernatant of
activated human monocytic THP-1 cells can be used to stimulate IL-17
production from
mouse mononuclear cells.
Human recombinant IL-23 or natural human IL-23 from activated THP-1 cells was
preincubated with titrated anti-IL-23p19 antibodies. The IL-23/antibody
combinations
were then added to freshly isolated murine splenocytes. Recombinant IL-23
alone was
used as a positive control. After two days in culture, cell supernatants were
collected
and assayed for IL-17 by ELISA (R&D Systems, Minneapolis, MN). Representative
IC50
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 130 -
values for anti-IL-23p19 antibodies are shown below. The tested antibodies are
mouse
antibodies derived from hybridomas (rows 1-19, see tables 1 and 2), chimeric
antibodies
(rows 20-23), and Antibodies A to D. Antibody 6H12 (disclosed in WO
2007/027714),
antibody QF20 (disclosed in WO 2007/024846) and antibody 01273 (disclosed in
WO
2007/005955) were also tested.
Table 12
Antibody IC50 Values (pM), IC50 Values (pM),
recombinant human IL- natural human IL-23
23
1804 471 100,413
18E5 not determined 9,9, 13
18D3 234 not determined
20E8 not determined 438, 561
22E2 61, 130 117,35
24A5 22, 37 85, 31
15011 126 232
43F5 250, 8000 8000
27G8 235 5000
31H9 960 2000
2D1 not determined 2336, 1911, 1597
9D12 59 281,138
6B8 13 8,2
73H10 1411 not determined
74H3 1352 not determined
36H8 not determined not determined
26F7 27 2, 8
34G3 336 27, 25
34D9 510 456
Chimeric 18E5 31 8, 36, 10, 9
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
-131 -
Chimeric 22E2 100 9,178
Chimeric 24A5 404 95,102
Chimeric 6B8 26, 37, 57 5, 2, 6, 3
Antibody A 5, 5, 5, 15 1, 1
Antibody B 13, 30, 54,42 9, 8
Antibody C 53, 71,162, 89 16,32
Antibody D 236, 225, 614, 458 133, 125
6H12 1600, 806, 1300 957, 4400, 1013, 439
QF20 not determined 7, 12
01273 not determined 93, 44
Example 5: Functional specificity testing against IL-12 in a human activated T
cell
assay
Anti-IL-23p19 antibodies were tested for functional inhibition of IL-12 in a
human
activated T cell assay. Human recombinant IL-12 (1 ng/ml) was preincubated
with 5
lag/mlanti-IL-23p19 antibodies. The IL-12/antibody combinations were then
added to
human PHA-derived T cell blasts. Recombinant IL-12 alone was used as a
positive
control. An anti-IL-12p70 antibody (Bender MedSystems, Vienna, Austria) was
used as
a control inhibitory antibody. After two days in culture, cell supernatants
were collected
and assayed for IFN-y by ELISA (R&D Systems). Samples were tested in
triplicate and
the average pg/ml of IFN-y was determined. Results (with standard deviations)
are
shown in the table below.
Table 13
Antibody Cytokine Stimulation Average
pg/ml IFN-y +/-
Standard Deviation
no antibody None 87 +/- 7
no antibody 1 ng/ml IL-12 532 +/- 51
chimeric 18E5 1 ng/ml IL-12 511 +1-3
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 132 -
chimeric 6B8 1 ng/ml IL-12 523 +/- 60
Antibody A 1 ng/ml IL-12 497 +/- 30
Antibody B 1 ng/ml IL-12 537 +/- 2
Antibody C 1 ng/ml IL-12 495 +/- 25
Antibody D 1 ng/ml IL-12 539 +/- 38
anti-IL-12p70 1 ng/ml IL-12 119 +/- 12
antibody
Example 6: Inhibition of IL-23 induced STAT3 phosphorylation in the human cell
line DB
The human cell line DB (ATCC, Manassas, VA) responds to IL-23 stimulation
through
an endogenous IL-23Rcomplex (IL-23R and IL-121=1[31) and phosphorylates STAT3
in an
IL-23 dose dependent manner. An assay was developed for testing anti-IL-23p19
antibody inhibition of IL-23 induced STAT3 phosphorylation. DB cells were
plated at
1x10e6 cells/well in a 96 well plate. Antibodies to be tested were serially
diluted and pre-
incubated with recombinant human IL-23 (10 ng/ml) for 1 hour at room
temperature.
The antibody/IL-23 mixture was then added to the cells for 30 minutes at 37 C.
Cells
were harvested by centrifugation at 4 C for 10 minutes and then lysed in ice
cold buffer
(Cell Signaling Technology, Beverly, MA). A portion of the lysate was run in a
phospho-
STAT3 ELISA (lnvitrogen). Antibody IC50 values were calculated as percent
inhibition of
STAT3 phosphorylation compared to control wells without antibody.
Representative IC50
values are shown in the table below.
Table 14
Antibody IC50 (PM)
Antibody A 25, 15, 38,
23, 13, 18
Antibody B 73, 84
Antibody C 132, 80
Antibody D 158
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 133 -
QF20 26, 26, 27
C-1273 163,438
Example 7: In vivo model of IL-23 induced cytokine production in the mouse ear
An in vivo model in the mouse was used. Recombinant human IL-23 is injected
into the
.. skin of the mouse ear for 4 consecutive days resulting in epidermal
thickening and up-
regulation of IL-17 and IL-22 protein. Anti-IL-23p19 antibodies were evaluated
in this
model. A single intraperitoneal injection of lmg/kg or 5 mg/kg antibody was
administered 1 hour prior to the initial IL-23 injection into the skin.
Recombinant human
IL-23 (with linker) was injected once daily for 3 additional days and tissue
was collected
for cytokine assessment. Inhibition of cytokine production was demonstrated
for the
antibodies. The results of three experiments are shown in the table below
(exp. 1: rows
1-7, exp. 2: rows 8-10, exp. 3: rows 11-14).
Table 15
Ear Tissue Ear Tissue Ear Tissue IL- Ear Tissue
IL-17 pg/ml IL-17 22 pg/ml IL-22
Mean +/- Percent Mean +/- Percent
SEM Inhibition SEM Inhibition
0.1% BSA + Citrate 3 +/- 1 NA 1 +/- 0 NA
Buffer i.p.
(Unstimulated
Control)
0.3ug IL-23 + Citrate 25 +/- 3 NA 274 +/- 30 NA
Buffer i.p.
(Vehicle Control)
0.3ug IL-23 + 1mg/kg 7 +/- 2 81 57 +/- 19 80
Antibody 6B8
0.3ug IL-23 + 1mg/kg 2 +/- 1 101 17 +/- 3 94
Antibody A
0.3ug IL-23 + lmg/kg 5 +/- 1 93 30 +/- 2 89
Antibody B
0.3ug IL-23 + 1mg/kg 11 +1-i 66 108 +/- 12 61
Antibody C
CA 02871985 2014-10-28
WO 2013/165791
PCT/US2013/038109
- 134 -
0.3ug IL-23 + 1mg/kg 10 +1-i 67 151 +/-12 45
Antibody D
0.1% BSA + Vehicle 14+!- 1 NA 1 +/- 1 NA
(Unstimulated
Control)
0.3ug IL-23 + Vehicle 31 +/- 4 NA 129 +/- 29 NA
0.3ug IL-23 + 5mg/kg 14+!- 1 102 10 +/- 5 93
24A5
0.1% BSA + mIgG 17 +/- 1 NA 4 +/- 1 NA
(Unstimulated
Control)
0.3ug IL-23 + mIgG 30 +/- 2 NA 208 +/- 40 NA
(Vehicle Control)
0.3ug IL-23 + 5mg/kg 16+!- 0 109 28 +/- 5 88
24A5
0.3ug IL-23 + 5mg/kg 21 +/- 2 70 53 +1-41 80
18E5
Example 8: Pharmacokinetic Studies in Cynomolgus Monkey
Humanized anti-IL-23p19 antibodies were administered by ten minute intravenous
infusion at a dose of 1.0 mg/kg to three cynomolgus monkeys. Serum samples
were
collected over a 6 week time course and free antibody concentrations were
measured
using a specific ELISA. The serum concentration-time profiles for the
antibodies and the
corresponding pharmacokinetic parameters are summarized in the Table 16 below.
Table 16
Antibody CL Vol (ml/kg) AUC 1-112 (days)
MRT (days)
(ml/d/kg) (nM=h/m1)
Antibody A 5.2 88 32262 12.1 17.2
Antibody B 6.0 87 27030 10.1 14.8
Antibody C 4.7 91 34642 14.1 19.6
Antibody D 3.4 67 47633 12.6 19.8
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 135 -
Example 9: Expression in NSO cells and biophysical data
Transfection of NSO cells and generation of stable pools:
NSO cells were grown in the presence of 1 /0 FBS before transfection. 40x10e6
cells
were collected and resuspended in 0.8m1 in media containing 2% FBS with 20ug
of
linearized DNA (heavy chain and light chain expression vectors) and then cells
were
incubated on ice for approximately 15 min before electroporation of the cells
at
750V/25uF (Bio-Rad Gene Pulser Xcell). Cells were recovered with 2% FBS for
approximately 48 hours at 37 C and 5% CO2 then plated in 96 well plates at
2x10e5
cells/ml containing G418 and mycophenolic acid for 14-21 days until formation
of
colonies.
Supernatant from 96 well plates with colonies were screened by ELISA. ELISA
plates
were coated with 1ug/m1 of goat anti-kappa (Southern Biotech, Birmingham, AL)
in PBS
and diluted supernatant were incubated and then detected with goat anti-human
IgG Fc-
HRP (from Jackson ImmunoResearch Laboratories, West Grove, PA). The positive
colonies were pooled for scale up. Titers for antibody production were
determined by
ForteBio using protein A tips according to manufacture protocol. The titers
for Antibody
A and Antibody D were between 250-350 mg/L, with more than 80% recovery from
protein purification, and more than 94% monomer after IEX purification.
Proteins were
resuspended in a final buffer containing 20mM Sodium Citrate and 115mM NaCI,
pH 6.0
and are stable at 4 C for at least 4 months and with solubility up to 100
mg/ml in this
buffer.
Table 17
Protein A Column !EX Column
Titer (mg/L) Yield (mg/L) Recovery Yield (mg/L) Recovery
Antibody A 345 275 80% 221 80%
Antibody D 248 225 90% 175 78%
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 136 -
Table 18
Quality Stability Solubility
AUC SEC AUC SEC AUC SEC
AUC at 100
fresh fresh 1month 1month 4months 4months
mg/ml (%M)
Nvo (0/0m) mivo (0/0m) (cyow (yom)
Antibody A 98 99 97 99 96 99 99
Antibody D 94 100 98 100 99 99 97
AUG: Analytical Ultracentrifugation as measured by the sedimentation velocity
method
at concentrations of 0.5 -1 mg/ml; SEC: Size exclusion chromatography; %M:
percent
monomer.
Example 10: Epitope mapping
Hydrogen/Deuterium Exchange Mass Spectrometry (HXMS) was employed to map the
epitope of Antibody A binding to human IL-23p19. This method determined the
susceptibility of the amide backbone hydrogens of I L-23p19 to exchange with
D20. The
experiment was conducted with IL-23 alone and IL-23 with added Antibody A.
Regions
of the IL-23p19 sequence showing significant protection from exchange due to
binding
of Antibody A were thus identified. Resolution of the method is determined by
the
peptides produced by digestion with pepsin or Protease XVIII. These IL-23p19
derived
peptides were identified by additional control experiments with unexchanged
samples
employing standard accurate mass and HPLC MS/MS technologies.
Recombinant human IL-23 was used. For the protein + antibody sample, 50u1 of
IL-23
(0.8mg/m1) was incubated with 10u1 of Antibody A (12.7mg/m1) for 15 minutes at
room
temperature. The final molar ratio Antibody A/IL-23 was 1.2:1.
For the exchange 5u1 of IL-23 protein was added to 50u1 deuterated buffer
(50mM PBS
in D20) and incubated for 100 seconds at room temperature. 50u1 of 2M
Urea/0.5M
TCEP was added and incubated for 60 seconds at room temperature. 5u1 pepsin or
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 137 -
Protease XVIII (4mg/m1 in 0.1% formic acid) was added and the sample was
immediately cooled to 4 C.
After 5 minutes 50u1 of sample was injected onto a Shimadzu HPLC system
(SCL10A
controller and two LC1OAD pumps) under the following conditions:
Mobile Phase A = 9911/0.1 (water/acetonitrile/formic acid).
Mobile Phase B = 95/5/0.1 (acetonitrile/water/formic acid).
Flow rate = 100u1/min.
Column = Phenomenex Jupiter C5, 5u, 50x1.0mm.
Mobile phase lines, column, injector loop are in ice baths.
Gradient = Time 0 (3%B), Time 2.2 (3%B), Time 10.1 (90%B), Time 12.0
(90%B), Time 12.1 (3%B).
Mass Spectrometry was carried out as follows:
Mass Spec = Thermo Orbitrap Velos (0900865).
Methods:
A. Fragmentation (to ID peptides): 12 minute acquisition time (3 minute
start delay), full-scan FTMS at 30,000 resolution, seven ion trap data
dependant scans (CID).
B. MS Runs: 12 minute acquisition time (3 minute start delay), full-scan
FTMS at 60,000 resolution_
Pepsin and Protease XVIII peptides were identified using fragmentation data
and the
program Proteome Discoverer (Thermoscientific, Waltham, MA). Identified
peptides
were visually compared (protein alone vs. protein with antibody present) using
Xcalibur
software (Thermoscientific). No significant shifts in exchange were observed
for IL-23
alone vs. IL-23 with Antibody A outside of the IL-23p19 region. For the p19
portion of
the protein, data was analyzed using the program PepMap (Thermoscientific).
This
program calculates the average mass for exchanged peptides. PepMap results
were
checked and those peptides that did not yield verified results were calculated
with the
aid of Microsoft Excel.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 138 -
The regions of the IL-23 sequence showing significant protection from exchange
due to
binding of Antibody A were identified as amino acid residues 108 to 126 of SEQ
ID
NO:181 and amino acid residues 137 to 151 of SEQ ID NO:181.
Example 11: Pharmaceutical compositions
Examples of formulations suitable for an antibody of the present invention are
shown
below. Antibodies used in the formulations below are for example Antibody A,
Antibody
B, Antibody C or Antibody D.
Formulation 1:
Components Concentration Concentration Nominal Amount
[mrnol/L] [g/I] [mg/vial]
V = 10.0 ml
Antibody 10.0 100.0
Succinic acid 0.7 0.083 0.8
Disodium
succinate 24.3 6.564 65.6
hexahydrate
Sodium chloride 125 7.305 73.1
Polysorbat 20 0.16 0.20 0.20
Water for
Ad 1L Ad 1mL
Injection
The pH of formulation 1 is typically in the range of pH 6.0 to 7.0, for
example pH 6.5.
This formulation is particularly suitable for intravenous administration.
Molecular weight (MW in g/mol) of used excipients: Disodium succinate
hexahydrate =
270.14 g/mol; Succinic acid = 118.09 g/mol; Sodium chloride = 58.44 g/mol.
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 139 -
The osmolarity of the formulation is 300 +/- 30 mOsmol/kg, as determined using
an
Osmomat 030 (Gonotec GmbH, Berlin, Germany). The density at 20 C of the
formulation is approximately 1.0089 g1cm3, as determined using a measuring
unit DMA
4500 (Anton Paar GmbH, Ostfildern-Scharnhausen, Germany).
Formulation 2:
Components Concentration Concentration Nominal Amount
[mmol/L] [g/I] [mg/syringe]
V = 1.0 ml
Antibody 0.6 90.0 90.0
Succinic acid 0.5 0.059 0.059
Disodium
succinate 3.9 1.054 1.054
hexahydrate
Sorbitol 225 41.00 41.00
Polysorbat 20 0.16 0.20 0.20
Water for
Ad 1L Ad 1mL
Injection
The pH of formulation 2 is typically in the range of pH 5.5 to 6.5, for
example 5.5 to 6.1,
for example the pH is 5.8. This formulation is particularly suitable for
subcutaneous
administration.
Molecular weight (MW in g/mol) of used excipients:
MW: Succinic acid (04H604)= 118.09 g/mol
MW: Disodium succinate hexahydrate (C404Na2H4 x 6H20) = 270.14 g/mol
MW: Sorbitol = 182.17 g/mol
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
- 140 -
MW: Polysorbate 20 = 1227.72 g/mol
The osmolarity of the formulation is 300 +/- 30 mOsmol/kg, as determined using
an
Osmomat 030 (Gonotec GmbH, Berlin, Germany). The density at 20 C of the
formulation is approximately 1.040 g/cm3, as determined using a measuring unit
DMA
4500 (Anton Paar GmbH, Ostfildern-Scharnhausen, Germany).
Formulation 3:
Components Concentration Concentration Nominal Amount
[mmol/L] [g/I] [mg/syringe]
V = 1.0 ml
Antibody 0.6 90.0 90.0
Sorbitol 240 43.733 43.733
Polysorbat 20 0.16 0.20 0.20
Water for
Ad 1L Ad 1mL
Injection
The pH of formulation 3 is typically in the range of pH 5.5 to 6.5, for
example 5.5 to 6.1,
for example the pH is 5.8. This formulation is particularly suitable for
subcutaneous
administration.
Molecular weight (MW in g/mol) of used excipients:
MW: Sorbitol = 182.17 g/mol
MW: Polysorbate 20 = 1227.72 g/mol.
The osmolarity of the formulation is 300 +/- 30 mOsmol/kg, as determined using
an
Osmomat 030 (Gonotec GmbH, Berlin, Germany).
CA 02871985 2014-10-28
WO 2013/165791 PCT/US2013/038109
-141 -
Example 12: Stability of pharmaceutical compositions
Pharmaceutical cornpositions are stored at 40 C for 8 weeks in a syringe in
the case of
formulations 2 and 3. Properties of the formulations are measured initially
and after 8
weeks in storage at 40 C and are shown below.
The turbidity is expressed in Formazin Nephelometric Unit (FNU), as measured
using
nephelometry. The % monomer is determined by High-Performance Size-Exclusion
Chromatography (HP-SEC).
Storage stability of formulations 2 and 3
Formulation 2 Formulation 3
(initial/after 8 weeks storage) (initial/after 8 weeks storage)
pH 5.7 / 5.8 5.6 / 5.7
Osmolarity 298 / 301 312 / 308
Turbidity (FNU) 7 / 8 2 / 3
Monomer % 99 / 97 99 / 97
